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Breast tumour kinase (Brk)/PTK6 is over-expressed in 80% of all breast cancers and has 
shown to be involved in tumour development and progression of breast cancer. There is a 
lack of development of breast tumour kinase (Brk) inhibitors and, therefore the clinical 
benefits associated with Brk inhibition are unknown. Due to Brk’s known role in proliferation 
and cell death, it was hypothesised that it may modulate responses to common breast cancer 
therapies.  ALT-PTK6 is an alternatively spliced isoform of Brk and may act as a competitive 
inhibitor of the full-length form. Little is known regarding ALT-PTK6’s role in breast cancer 
therapeutics. I hypothesised ALT-PTK6 may negatively regulate cell proliferation within breast 
cancer cell lines and thus reduce the oncogenic functions of the full-length form.  Initially, in 
vitro studies using multiple breast cancer cell showed survival at 2Gy radiation dose (SF2) 
correlated with Brk expression levels for some cell lines, with high SF2 survival there was 
also higher Brk expression. DNA repair kinetics and Brk interaction with ataxia telangiectasia 
mutated protein (ATM) showed no significant differences in relation to Brk expression.  Brk 
modulates response to: Paclitaxel (Taxol), Doxorubicin, Lapatinib, Tamoxifen and showed 
significant reduction in cell proliferation in combination with a novel Brk inhibitor (Compound 
4f) suggesting potential for a Brk targeted therapy.  It was hypothesised that due to the 
proposed role of ALT-PTK6 as a negative regulator of Brk, ALT-PTK6/PTK6 transcript ratios 
will be lower in breast cancer cells and tissues. There were increased ALT-PTK6 to PTK6 
transcript ratios in non-cancerous cell lines, hormone (ER/PR) positive and HER2 positive 
breast cancer cell lines compared to hormone negative cell lines.  ALT-PTK6/PTK6 ratios 
were increased in patients with improved overall survival. Thus, there is potential for ALT-
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1.1 Introduction  
Although there has been a decline in breast cancer mortality rates since the 1970s, the rate 
of breast cancer incidence has increased by 19% since the 1990s (Cancer Research UK, 
2014). It has been previously shown that breast cancer is the most common malignancy in 
the UK with over 356,000 cases of cancer diagnosis reported in the UK in 2014 with 55,222 
for breast cancer (Cancer research UK, 2014).  Breast cancer has been shown to be the 
second most common cause of cancer death for women in the UK, accounting for 11,400 
deaths in 2014 (Cancer Research UK, 2014).  The introduction of early diagnostic techniques 
as well as the development of improved and novel breast cancer therapies have attributed to 
the overall reduced mortality rates.  For example, the introduction of the NHS breast 
screening programme which screens women aged between 50-70 years old (and is currently 
trialling screening for women aged 47 onwards) for early detection of breast cancer and may 
explain the increase in incidence in the UK.  These diagnostic techniques may detect cancers 
that would have gone unnoticed until much later, thus allowing for early diagnosis of breast 
cancer at a more treatable or curable stage.  Nonetheless, there is still room for improvement. 
Furthermore, breast cancer therapies need to be effective, patient specific, relatively non-
toxic and increase patient overall survival.  There is also progress needed towards 
understanding recurrence, resistance and spread (Eccles et al., 2013).  
A closer look at breast cancer pathology, molecular biology, and progression may lead to a 
better understanding of the underlying factors involved in breast cancer tumorigenesis and 
metastasis. A particular interest has risen in breast tumour kinase (Brk) also known as PTK6 
(protein tyrosine kinase 6). Over a number of years, the Brk research field has grown and Brk 
has shown as being a desirable therapeutic target in relation to tyrosine kinase inhibition as 




1.1.1 Breast cancer pathological types  
 
Breast cancer malignancies constitute adenocarcinomas, accounting for over 95% of all 
breast cancers (Kumar et al. 2014).  Invasive or infiltrating breast cancer involves invasion of 
neoplastic cells through the duct wall and into the stoma, of which there are two types 
including infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).  The 
variation between these two types is based on the site they originate from (the ducts or the 
lobes).  Ductal carcinoma in situ (DCIS) describes a non-invasive proliferation of epithelial 
cells confined to the ducts, and its features consist of nuclear atypia, potential malignancy 
capacity and it is usually considered as a precursor for subsequent invasive breast carcinoma 
(Makki 2015).  Lobular carcinoma in situ (LCIS) describes growth of uniform cells originating 
from the terminal duct lobular unit (TDLU) that, under the microscope, show intact underlying 
architecture and lobules; however, in comparison to DCIS, there is rarely any pleomorphism, 
mitosis or necrosis (Hanby, Hughes 2008).  IDC constitutes a group of carcinomas which lack 
specific features to be histologically categorised and thus are known as IDC no specific type 
(NST) which make up 40-75% of all invasive ductal carcinomas (Moinfar 2007).  There is 
usually a range of morphological variations including pleomorphisms, variation in shape and 
size, and obvious nucleoli which show numerous mitosis (Hanby, Hughes 2008).  Tubular 
carcinoma is rare and defines a well differentiated IDC characterised by proliferation of 
elongated tubules with disorganised structure and a single layer of epithelium lining an open 
lumen with some invasion of the stroma and fat at the periphery of the tumour (Juan 2011).  
This subtype is more common amongst elderly females and is most likely associated with 
lymph node metastasis (Makki 2015).  Medullary carcinoma is common in patients with breast 
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cancer susceptibility gene 1 (BRCA1) mutations and is characterised by well circumscribed 
carcinoma, composed of poorly differentiated cells with scanty stroma and lymph infiltration, 
mucin secretion and no glandular differentiation (Armes, Venter 2002).  Invasive papillary 
carcinoma comprises 1-2% of all invasive breast carcinomas and is predominately an 
intraductal lesion (Juan 2011).   
1.1.2 Breast cancer molecular subtypes 
  
Before the advent of molecular profiling, breast cancers were mainly categorised according 
to histology, tumour grade, lymph node involvement and presence of predictive markers 
(Holliday and Speirs, 2011).  However due to the advent of high throughput assays, gene 
expression profiling is now possible.  This scientific advance has provided further insight into 
the molecular characteristics of breast cancer whereby tumour cell response has been shown 
to be dependent not on only pathological features, but also age and gender as prognostic 
factors (Weigelt, Baehner and Reis-Filho, 2010).  This allows for more specific categorisation 
of breast cancer, leading to improved diagnosis, more accurate prognosis as well as a better 
informed therapeutic decisions to provide the greatest clinical response for individual patients 
(Pusztai et al., 2008). 
It has become increasingly more evident which patients will respond better to treatments at 
the same time allowing clinicians to predict patient prognosis.  Due to these differences and 
the fact breast cancer is not a single disease, it has become difficult to find a treatment that 
is effective for all subtypes.  Since Brk is expressed in over 86% of breast cancers (J H 
Ostrander et al., 2007) and it’s expression is detectable in a range of breast cancer subtypes 
(Luminal A, B, HER2 positive and triple negative breast cancers), a potential Brk therapy 
could be beneficial for all types of breast cancers.  The characteristics of breast cancer 
subtypes are further discussed below. 
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1.1.2.1 Luminal A breast cancer cell lines 
 
Luminal A breast cancer is characterised by the presence of oestrogen (ER) and 
progesterone receptors (PR) but lacks human epidermal growth factor receptor 2 (HER2) 
expression.  Luminal A breast cancers are associated with more favourable outcomes (Juan, 
2011). The Luminal A subtype consists of tubular carcinoma, cribriform carcinoma and low 
grade infiltrating ductal carcinoma of no specific type (IDC NST) (Makki, 2015).  Luminal A 
subtypes exhibit a lower number of mutations and chromosomal changes in comparison to 
Luminal B cancers and have reduced number of mutations in their p53 gene and higher 
number of mutations in P1K3CA (Koboldt et al., 2012).  Oestrogen receptor (ER) is the most 
prevalent biomarker for categorising breast cancers and has a key role in carcinogenesis of 
breast cancer (reviewed in Dai et al., 2016).  ER positive tumours comprise over 75% of all 
breast cancer cases and are usually well differentiated histologically as well as being less 
aggressive in comparison to ER negative breast cancers (Dunnwald, Rossing and Li, 2007). 
An exact role for progesterone on its own is difficult to elucidate as breast cancers with PR 
isoforms, PR-A and PR-B can also express ER and require oestrogen for PR-A expression 
(Lange and Yee, 2008). Furthermore, expression of these isoforms are not induced unless 
other factors are present, including epidermal growth factor (EGF) (Ankrapp, Bennett and 
Haslam, 1998).   
T47D cells carry receptors for a variety of steroids and calcitonin. They express mutant 
tumour suppressor protein p53 protein. Under normal culturing conditions, they express 
progesterone receptor constitutively and are responsive to oestrogen. They can lose the ER 




1.1.2.2 Luminal B breast cancer cell lines 
 
Lumina B breast cancer cell lines express low levels of oestrogen receptor, may be 
progesterone receptor positive or negative as well as HER2 positive (reviewed in Eroles et 
al., 2012).  Although Luminal A and Luminal B are distinct subtypes, there are some molecular 
similarities.  Tumour cells from the Luminal B subtype have higher proliferation rates and 
more DNA amplifications than those from Luminal A.  Luminal B cancers are also 
characterised by higher levels of chromosomal aberrations than any other subtype and the 
‘wingless relating integrated site’ (WNT) and NOTCH signalling pathways are stimulated, 
which are involved in regulation of breast tumour initiating cells (TICs) (Sircoulomb et al., 
2011). This is of importance, as these TICs, also known as cancer stem cells (CSCs), have 
been proposed to be involved in de novo resistance of breast cancer treatments due to their 
ability to self-renew and develop new tumour cells which are clonogenically derived from the 
parental tumour (Wei and Lewis, 2015). The new tumour cells will be resistant to the type of 
therapy the parental tumour was exposed to therefore rendering the treatment ineffective.  
Clinically, Luminal B cancers are more aggressive with poorer prognostic outcomes than 
Luminal A cancers and show increased 5-year relapse rates after diagnosis as well as a 
metastatic dissemination time pattern similar to basal-like and HER2 subtypes of breast 
cancer (Ignatiadis et al., 2009).  In comparison to Luminal A tumours, Luminal B breast 
cancers have the tendency to metastasise to the bone more than other metastatic sites (Smid 
et al., 2008).  Neoadjuvant chemotherapy showed greater effect in reducing overall tumour 
volume in Luminal B cancers than Luminal A (Ades et al., 2014).  An example of a Luminal 
B cell line is BT474 (Kao et al., 2009).  Both Luminal A T47D and Luminal B BT474 cell lines 
form tight cohesive structures exhibiting robust cell-cell adhesions whereas HER2 positive 
cell line SKBR3 and triple negative cell lines MDA-MB 231 show loose cohesive grape-like 
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or stellate structures (Kato et al., 2009).  Morphologically, both Luminal A and Luminal B 
types of cells display a similar epithelial structure when viewed under a light microscope 
(Holliday and Speirs, 2011). 
 
1.1.2.3 Metastatic model cell line  
 
Xenotransplantation success rates of breast cancer into experimental animal models were 
previously relatively low (7-20%) and there was reportedly little evidence of metastatic growth 
(Hurst et al., 1993).  However, advancements in xenotransplantation over the years have 
contributed significantly to our understanding of breast tumorigenesis and progression as well 
as novel therapeutic strategies (Cariati, Marlow and Dontu, 2011).  The GI101 cell line is an 
oestrogen receptor-negative metastatic breast tumour cell line derived from an infiltrating 
ductal breast carcinoma xenograft.  When cells from a tumour derived from an infiltrating 
ductal adenocarcinoma were injected subcutaneously, the tumour grew slowly and 
metastasized to the lungs, lymph nodes and bone marrow of athymic murine (Hurst et al., 
1993).  The GI101 cell line is negative for c-erbB-2 oncogene, but positive for p53 protein and 
both the tumour implant and lung metastases were negative for ER and PR (Hurst et al., 
1993; Allen et al., 2011).   
 
1.1.2.4  HER2 positive breast cancer cell line 
 
Human epidermal growth factor receptor 2 (HER2) positive cancers are usually ER and PR 
negative and have elevated expression of a proliferation related gene called marker of 
proliferation of Ki-67 (MKI67) (Smith et al., 2017). The HER2 protein is membrane spanning 
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and 185 kDa in size, and encoded by the HER/neu oncogene on chromosome 17q21 
(Schechter et al., 1984). HER2 as a heterodimer with EGFR, is involved in various cancer 
promoting processes including cell proliferation (Lenferink et al., 2001), inhibition of cell death 
mechanisms, for example apoptosis (Yarden and Sliwkowski, 2001) as well as promotion of 
angiogenesis (Wen et al., 2006). A representative of HER2 positive cell line, SKBR3, is a 
mammalian breast cancer epithelial cell line that overexpresses the Her2 (Neu/ErbB-2) gene 
(Fogh, Fogh and Orfeo, 1977). This cell line can form poorly differentiated tumours in 
immune-compromised mice (van Slooten et al., 1995) and thus is used as a model to study 
therapeutic effects of drugs, for example, Herceptin that targets HER2 as well as to study 
therapeutic drug resistance mechanisms.  
 
1.1.2.5 Triple negative breast cancer cell lines  
 
Triple negative breast cancer (TNBC) or basal like breast cancers are characterised by 
reduced expression of luminal-related genes along with little or no HER2 expression and 
elevated levels of KMKI67 (Prat et al., 2015). These types of cancers are more difficult to 
treat in comparison to other subtypes of breast cancer due to the lack of receptor expression 
which means targeted therapy is not appropriate. Thus most of these cancers are treated 
with chemotherapy, although treatments are being evaluated as many basal-like cancers are 
inherently refractory to chemotherapy (Lachapelle and Foulkes, 2011).  Nonetheless, a small 
subset of these cancers show sensitivity to chemotherapy and have a good prognosis 
(Foulkes, Smith and Reis-Filho, 2010).  TNBC cancers account for approximately 10-15% of 
all breast tumours; they are more clinically aggressive than the other subtypes, and most are 
diagnosed at a higher tumour grade (Foulkes, Smith and Reis-Filho, 2010). Furthermore, 
9 
 
these tumours have a high number of mutations across the genome, hypomethylation and a 
high percentage of them are TP53 and BRCA1 mutated (Prat et al., 2014).  The 
characterisation of TNBC indicates distinct features including expression of genes linked with 
both basal epithelium and myoepithelium of the normal mammary gland (Reis-Filho and Tutt, 
2007).   Claudin low tumours were identified in 2007 as a distinct subtype of TNBC 
(Herschkowitz et al., 2007).  These were characterised by low gene expression of tight 
junction proteins claudin 3, 4 and 7 as well as E-cadherin, a calcium dependent cell to cell 
adhesion protein (Prat et al., 2014).  Claudin low tumour subtypes lack common epithelial cell 
features and are enriched with tumour initiating cell (TIC) features (Herschkowitz et al., 2007).    
Studies have further identified up to 6 molecular subtypes within the triple negative breast 
cancer including, basal like, immunomodulatory, mesenchymal, a mesenchymal stem like 
and a luminal androgen receptor subtype (LAR) which is HER2 enriched (Lehmann et al., 
2011).   Due to the presence of sub-categories of triple negative breast cancers, there is a 
lack in a unifying definition and there may still be a need to define and separate basal like 
and triple negative breast cancers, since they identify different risk factors.  Basal like and 
TNBCs tend to be mainly associated with high grade invasive ductal carcinomas (Lachapelle 
and Foulkes, 2011). Although this indicates the heterogeneity of TNBC subtype, there is a 
suggestion that subtyping within triple negative breast cancer may not have a clinical impact 
based on prognosis (Prat et al., 2015).  Treatment with chemotherapy has shown patients 
with TNBC tend to show greater response despite an overall poorer prognosis compared to 
other subtypes of breast cancer (Cortazar et al., 2014).  Anthracyclines and Taxanes indicate 
the most effective types of chemotherapy drugs (Henderson et al., 2003; Mazouni et al., 
2007).  Nonetheless, less than 30% of patients with metastatic breast cancer survive 5 years 





1.1.3 Breast cancer Risk Factors  
 
Risk factors that have been intensively examined and which actively contribute towards 
neoplastic transformation of breast cells include gender, age (where women over 40 are at 
increased risk of developing breast cancer), history of mammary gland diseases including 
family history of breast cancer, early menarche and late childbearing, menopause as well as 
race (reviewed in Bucholc et al. 2001).  A summary of breast cancer risk factors is shown in 
Table 1.1.  Interestingly most risk factors are only associated with 20-30% of newly diagnosed 
breast cancer whereas the 70-80% majority indicate no risk factors (reviewed in Kaminska et 




Table 1.1 Summary of breast cancer risk factors.  
Breast Cancer 
Risk Factor  
Description 
Gender Women are at an increased risk of developing breast cancer. Approximately 
only 390 cases of male breast cancer were diagnosed in the UK in 2014 
(Cancer Research UK).  Generally, male breast cancer rates are less than 1 
in 100,000 (Ly et al., 2013). 
Age Women over the age of 40 are at a higher risk of developing breast cancer.  
In the UK, 48% of breast cancer cases each year are diagnosed in women 
over the age of 65 (Cancer Research UK, 2014) 
Genetic  Breast cancer relative risk increases with increasing numbers of affected 
first degree relatives (Dossus and Benusiglio, 2015).  A number of breast 
cancer susceptibility genes have been identified including BRCA1 (Miki et 
al., 1994), BRCA2 (Wooster et al., 1994), TP53 (Børresen et al., 1992), ATM 
(Athma, Rappaport and Swift, 1996) and PTEN (Liaw et al., 1997).   
Ethnic 
background 
Frequency of breast cancer occurrence in Caucasian women is higher than 
in African American women.  In addition, African American women are twice 
as likely to develop triple negative breast cancer (TNBC) than Caucasian 






Breast cancer risk increases in early menarche (relative risk increased by a 
factor of 1.050 for every year younger at menarche) and late menopause 
(relative risk increased by a factor of 1.029 for every year older at 
menopause) (Collaborative Group on Hormonal Factors in Breast Cancer, 
2012).  
Diet  Certain dietary factors contribute towards the risk of breast cancer 
development, including high dietary fat intake (Wynder et al., 1997), 
although data are conflicting due to study bias, data discrepancy and other 




Intrinsic factors like race are linked with elevated breast cancer risk in studies which used 
data from Surveillance, Epidemiology and End Results (SEER) databases (Ban and 
Godellas, 2014).  These showed a frequency of occurrence of breast cancer in Caucasian 
women as approximately 127.4 in 100,000 people whereas the frequency of occurrence of 
breast cancer in African American women was approximately 121.4 in 100,000 people.   
Amongst African American women, breast cancer presents at a more advanced stage with 
more aggressive characteristics as well as a less favourable survival rate in comparison to 
Caucasian women (Danforth Jr, 2013).  Individuals with familial history of breast cancer are 
at an increased risk of developing the cancer themselves and this is one of the strongest risk 
factors.  Approximately 5-10% of all breast cancers are hereditary (Claus, Risch and 
Thompson, 1991).  Studies comparing cancer incidence in relatives of breast cancer patients 
shows increasing relative risk (RR) with increasing number of first-degree relatives that are 
affected with breast cancer (reviewed in Dossus and Benusiglio, 2015).  These include 
inheriting mutations in breast cancer susceptibility genes; BRCA1 and BRCA2.  BRCA1 acts 
as a tumour suppressor gene which encodes a nuclear phosphoprotein that functions mainly 
in maintaining genomic stability (Claus, Risch and Thompson, 1991).  BRAC2 functions more 
specifically in the homologous recombination (HR) pathway which is involved in the repair of 
double strand DNA breaks and is encoded by a large gene with 27 exons with potential 
mutations throughout the gene (Apostolou and Fostira, 2013).  Germline mutations in these 
genes, although rare, account for a high proportion of familial breast cancer.   Other genes, 
contributing to risk, include tumour protein 53 (TP53), which is a tumour suppressor gene that 
Martin and Weber, 2000).  Alcohol also increases relative risk of developing 
breast cancer (Hamajima et al., 2002).   
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encodes the protein p53 and is mutated in approximately half of all cancers including in 20-
30% breast cancers with more than 15,000 known mutations (Hainaut, 2013).   
Phosphatase and tensin homolog (PTEN) is located at the chromosome 10q23 region and 
encodes a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and is another tumour 
suppressor protein as it negatively regulates the AKT/P13K signalling pathway (Li et al., 
1997).  Germline mutations in the PTEN gene renders individuals with Cowden Syndrome, 
an autosomal dominant disease that is characterised by hamartomas,  at an increased risk 
of tumours of the thyroid, endometrium as well as breast (reviewed in Apostolou and Fostira, 
2013).  Most individuals with Cowden Syndrome have a 50% increased risk of developing 
breast cancer (reviewed in Apostolou and Fostira, 2013).   
Other extrinsic factors include dietary habits, although epidemiological data is conflicting for 
specific food groups.  Excess fat intake can contribute to the increase in occurrence of 
mammary tumours in animal models (Holmes and Willett, 2004).  However, large meta-
analysis studies also show weak association between polyunsaturated fat and the link to 
breast cancer (Kotepui, 2016).   
Alcohol consumption increases the relative risk of breast cancer by 7.1% for each additional 
10g per day intake of alcohol (Hamajima et al., 2002).  Alcohol consumption over the 
recommended amount, which is 14 units a week in the UK, is associated with a linear increase 
in incidence of breast cancer (Smith-Warner et al., 1998).  Alcohol metabolises to reactive 
oxygen species (ROS), including acetaldehyde, which are known to generate DNA 
modifications via various mechanisms including protein adducts and chromosomal 




1.2 Breast Tumour Kinase (Brk)/PTK6 
 
PTKs (protein tyrosine kinases) are products of a large multigene family and mainly function 
in signalling pathways to regulate cell differentiation, tumour growth, migration and survival 
(Easty et al., 1997).  Many function as oncogenes and are implicated in a large number of 
cancers.  Brk, also known as protein tyrosine kinase 6 (PTK6), was originally identified in a 
study involving human melanocytes (Mitchell et al., 1994) and was subsequently isolated 
from breast cancer cell lines in a study identifying novel kinases with therapeutic potential 
(Mitchell et al., 1994).  Brk expression in normal tissue has been indicated in differentiating 
cells in gastrointestinal tract, oral cavity, skin and prostate (Llor et al., 1999; Derry et al., 2003; 
Petro et al., 2004).  Originally it had been thought there were low or undetectable levels of 
Brk in normal mammary tissue, however more recently Brk expression has also been 
detected in the immortalised non-tumorigenic MCF10A human mammary gland epithelial cell 
line as well as in normal mammary gland tissues (Peng et al., 2014).  Since expression has 
only been more recently detected, this suggests there are relatively very low levels of Brk in 
normal mammary tissue.  Total activity of Brk is significantly higher in malignancy than in 
normal mammary tissue, and over-expression has been noted in 60-85% of invasive ductal 
breast tumours (Barker, Jackson and Crompton, 1997; J H Ostrander et al., 2007; Aubele et 
al., 2009; Harvey et al., 2009). 
Differing Brk protein expression levels have been detected in majority of breast cancer cell 
lines (Barker, Jackson and Crompton, 1997). Gene sequencing indicated similarities with the 
SRC-family of protein tyrosine kinases, however there are distinct differences such as the 
lack of N-terminal extension and consensus sequences for fatty acylation and membrane 
association (Mitchell et al., 1997). Furthermore, its genomic structure is quite distinct from the 
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SRC-family PTKs, which demonstrates an evolutionary divergence (Mitchell, Sara and 
Crompton, 2000).  Brk gene ptk6 has also been shown to have a significant degree of 
similarity with the Drosophila src related gene known as Dsrc41, with six out of seven of Brk’s 
exon boundaries conserved with the Dsrc41 gene which has 9 exons. This could indicate Brk 
is likely to share a common ancestor with Dsrc41. The ptk6 gene comprises 8 exons, 
encoding a 451 amino acid protein with FISH studies indicating localization to chromosome 
20q13.3 (Mitchell et al., 1997). The protein product has a predicted molecular weight of 
50kDa, which generally resolves to around 48kDa on an SDS-PAGE gel (reviewed in Harvey 
and Burmi, 2011). 
 
1.3 Short isoform - ALT-PTK6  
 
An alternatively spliced Brk transcript which was named originally as λm5 and much later 
coined as ALT-PTK6 was also identified (Mitchell et al., 1997; Brauer et al., 2011).  This short 
isoform is 15Kda and 134 amino acids long with a 122 base pair deletion at the 3’ end of the 
SH3 coding region thus it lacks a functional SH2 domain and tyrosine kinase domain but has 
a C-terminal proline rich sequence (Figure 1.1).  Thus far ALT-PTK6 expression has been 
shown in breast, colon and prostate cancer cells (Mitchell et al., 1997; Brauer et al., 2011; 
Peng et al., 2014).  Unlike the full-length form, its expression has not yet been reported in 
normal mammary tissue.  The protein expression of ALT-PTK6 has been shown in the T47D 
cell line along with the full length form (Mitchell et al., 1997).  There is still speculation on the 
role that this isoform plays in breast cancer, however, it is suggested that it could be a 
competitive inhibitor for the SH3 binding partners of the full length Brk  as both possess 
functional SH3 domains (Mitchell et al., 1997; Brauer et al., 2011)  
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The localisation of Brk may play an important role in development of cancer since Brk’s 
arrangement in the cellular environment may affect its role due to the variety of substrates 
available in nucleus and cytoplasm (Ie Kim and Lee, 2009). As it was shown adding a 
myristoylation sequence to Brk’s N-terminal resulted in enhanced oncogenic functions of Brk 
in cell proliferation, survival and migration whereas adding a synthetic nuclear localisation 
sequence (NLS) to trap Brk in the nucleus annulled these effects (Ie Kim and Lee, 2009).  
Also, the role of Brk in various tissue types has shown to be dramatically different. For 
example, in normal tissues it is involved in regulation of differentiation process (Wang et al., 
2005) whereas in tumour cells it promotes cell proliferation and survival (Kamalati et al., 1996; 
Harvey and Crompton, 2003; Julie Hanson Ostrander et al., 2007).  Therefore, Brk’s function 
will depend on the tissue it is expressed in, its intracellular location, and the substrate it 
interacts with along with its interactions with the shorter isoform.  The range of Brk functions 
dependent on its localisation and substrate/protein interactions are further explored in 
sections 1.5 and 1.6 below.  
The role of ALT-PTK6 has been more fully described within prostate cancer cells, where the 
full length Brk is expressed in normal and benign tissues as well as in cancerous cells (Brauer 
et al., 2011).  Initially, it was shown that β-catenin was a substrate of Brk (Palka-Hamblin et 
al., 2010) and now there is indication that the ALT-PTK6 isoform may also be involved in 
regulation of β-catenin/TCF transcription (Brauer et al., 2011).  ALT-PTK6 has been proposed 
to act as an inhibitor against the full-length form of Brk since there was reduced 
phosphorylation of tyrosine-phosphorylated proteins as well as phosphorylation of Brk in the 
presence of ALT-PTK6 which was further decreased with increasing levels of ALT-PTK6 
(Brauer et al., 2011). In co-transfection experiments with full length of Brk and ALT-PTK6, 
increased ALT-PK6 expression resulted in an increase of constitutively active form of Brk in 
the nucleus with a decreased proportion at the membrane (Brauer et al., 2011). There was 
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also reduced proliferation in ALT-PTK6 expressing prostate tumour cells compared to those 
without this short isoform. These data therefore suggest that ALT-PTK6 may contribute 
towards limiting Brk localisation to the nucleus and acting as a competitive inhibitor thus 
reducing the ability of Brk to interact with its substrates that promote tumour cell growth in the 
cytoplasm and plasma membrane.  Further clarification and confirmation is needed for 
specificity in breast cancer cell lines.  Also, PTK6 down regulation was shown to promote 
tumorigenicity and metastasis via an altered Akt/GSK3β/β-catenin signalling pathway; thus, 
a closer look at the interaction between ALT-PTK6, PTK6 and β-catenin in different tissue 
types and cell lines may give a more accurate overview of its role.  Furthermore, it should be 
noted Brk’s substrates include RNA binding proteins sam68, SLM1 and SLM2 (Derry et al., 
2003; Haegebarth et al., 2004) which have reported roles in RNA splicing (Paronetto et al., 
2007) thus it is possible that Brk may regulate alternative splicing.  In addition, sam68 
contains at least five proline rich splicing motifs which interact with SH3 domain of Src (Taylor 
and Shalloway, 1994), which shares homology with Brk.  More specifically, via  a Glutathione 
S-transferase (GST) pull down approach, it was determined the GST-P3 proline motif of 
sam68 was the main polypeptide that mediated interaction with Brk SH3 domain (Derry et al., 
2000).  This suggests sam68 may also interact with ALT-PTK6 via the SH3 domain and thus 






Figure 1.1 Full length BRK/PTK6 and short isoform ALT-PTK6 structure Indicating: the cDNA 
structure of both isoforms, with each box indicating each exon (total of 8 exons).  ALT-PTK6 has 
deletion at exon 2 and lacks SH2 domain due to shift in open reading frame, which gives a proline rich 
sequence at exon 3 instead of a SH3 domain.  Underneath, the protein structure shows SH3 domain 
in green, SH2 domain in orange and a tyrosine kinase domain for Brk/PTK6 or proline rich sequence 




1.3.1 Brk and ALT-PTK6 structure 
 
As discussed above in Section 1.3, Brk consists of SH2, SH3 a linker region and catalytic 
domains (Figure 1.1).  SH3 domains are small protein domains made up of β-sheets that 
allow the assembly of specific protein complexes via proline-rich peptide binding, (reviewed 
in Mayer, 2001).  Brk’s SH2 and SH3 domains are used for substrate recognition (Hong et 
al., 2001; Qiu and Miller, 2004). The Brk SH3 domain has been known to undergo 
conformational changes due to pH fluctuations indicating that its structure could determine 
substrate and protein interaction. The SH3 domain may also have a role in enzyme 
regulation, as a proline rich peptide that binds to the SH3 domain of the Src family of kinases 
was able to activate wild type Brk (Qiu and Miller, 2002).  The importance of the SH3 domain 
in enzyme regulation of Src kinases has been well documented previously (reviewed in 
Engen et al., 2008)  suggesting similarly the SH3 domain of Brk may also play a role in 
enzyme regulation (Qiu and Miller, 2002). In addition, The SH2 domain contains α/β folds 
and a phosphotyrosine binding surface with two α-helices opposite a central β-sheet made 
up of four anti-parallel strands (Hong E et al 2004). This domain plays a role in protein-protein 
interactions and is important for regulation of catalytic activity (Hong et al., 2001). Due to the 
lack of myristoylation and a nuclear localization sequence (NLS), Brk’s regulation is difficult 
to determine which allows for more flexibility with its subcellular localization, (reviewed in 
Harvey and Burmi, 2011). It has been proposed that Brk can ‘piggy back’ onto other protein 
complexes and thus is able to travel to and from the nucleus or it may simply diffuse from one 
cellular localisation to another (reviewed in Harvey and Burmi, 2011). 
 
1.4 Brk Expression in different tissues 
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Brk activity is increased in malignant melanomas which may be due to upregulation of normal 
melanocytic kinases or due to expression of additional PTKs (McArdle et al., 2001).   ptk6 
expression has been shown in metastatic melanomas but not in primary melanomas or 
normal melanocytes (Easty et al., 1997).  Brk protein expression was also reported in the 
normal gastrointestinal tract, oesophagus, stomach, and duodenum (Llor et al., 1999).  More 
specifically, within the small intestine, Brk is present in the non-dividing villus epithelium and 
has shown to be involved in negatively regulating Akt, resulting in growth inhibition and 
increased villus heights as seen in ptk6 null mice (Haegebarth et al., 2006) . Brk expression 
has also shown to be downregulated in over 93% of oesophageal squamous cell carcinoma 
(ESCC) compared to non-tumorous oesophageal tissue (Ma et al., 2012). 
Brk expression has been detected in normal luminal prostate epithelial cells as well as in 
secretory epithelial cells of prostate adenocarcinomas (Brauer et al., 2011).  Brk expression 
has also been detected in normal oral epithelial cells and oral squamous cell carcinoma.  In 
normal ovarian surface epithelium Brk expression is undetectable but overexpressed in high 
grade serous ovarian tumours (Schmandt et al., 2006).   
Brk expression was detected in normal T cells and malignant T cells, where it was expressed 
in a constitutively active form suggesting a role for Brk in pathogenesis of lymphomas 
(Kasprzycka et al., 2006) . Most malignant T cell lines expressed Brk at higher levels and 
there was also Brk expression in normal B lymphocytes and malignant B cell lymphomas.  
Brk expression in head and neck cancers was first described in 2004 (Lin et al., 2004), where 
over 37% of head and neck squamous cell carcinomas overexpressed Brk.   Furthermore, 
up-regulation of Brk  in thyroid tumours relative to normal thyroid tissue was noted (Cho et 
al., 2012).  
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In non-small cell lung cancer (NSCLC), Brk was first identified in a study investigating 
oncogenic kinases in lung cancer and was shown to be over phosphorylated (Rikova et al., 
2007).  Brk levels were higher in the cytoplasm of NSCLC compared to nuclear localisation.  
High expression levels did not associate with differentiation of NSCLC but rather with 
increased tumour size in NSCLC suggesting a role for Brk in tumour growth.   
Unlike melanocytes, Brk expression was shown in normal colon and adenocarcinomas of the 
colon.  There was a moderate increase in Brk expression levels in adenocarcinomas of the 
colon (Llor et al., 1999).  Chromosome 20q13, to which the ptk6 gene is localised, is over 
amplified in not only breast tumours but also in gastro-oesophageal tumours (El-Rifai et al., 
1998) and colon tumours (Schlegel et al., 1995).  Within the context of colon tumours, the 
increase in expression was not enough to indicate gene amplification as the cause for 
overexpression. Brk is found in both the nucleus and cytoplasm (Llor et al., 1999). 
In terms of localisation, Brk in oesophageal squamous cell carcinoma (ESCC) is detected in 
the nucleus and the cytoplasm  (Ma et al., 2012).  In normal luminal prostate epithelial it is 
highly localised to the nucleus and in secretory epithelial cells in prostate adenocarcinomas 
its localisation is altered (Derry et al., 2003).  It was noticed there was lower nuclear 
expression in high grade regions and higher nuclear expression in low grade regions of 
prostate tumours. Brk localised to the nucleus in normal prostate cells and the cytoplasm in 
prostate tumours.  Knock down of Brk, which was mostly confined to the cytoplasm in prostate 
cancer cell lines, resulted in decreased cell proliferation (Brauer et al., 2011). It is localised 
to both the nucleus and cytoplasm in normal oral epithelium and oral squamous cell 
carcinoma (Petro et al., 2004).  However; as with prostate tumours, in oral squamous cell 
carcinomas Brk nuclear levels are decreased with tumours that are poorly differentiated 
compared to those that are well differentiated (Petro et al., 2004).   In ovarian cancer cells, 
Brk is localised to the cytoplasm however in some ovarian tumour cells Brk was also detected 
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in the nucleus (Schmandt et al., 2006).  Brk was localised in the nucleus of lymphocytes 
within both T and B cell malignant lymphoma cell lines (Kasprzycka et al., 2006).  
Furthermore, Brk expression in normal and in non-small cell lung cancer (NSCLC) has been 
indicated in both the nucleus and cytoplasm (Fan et al., 2011).   
Overall, this shows the range of tissues Brk expression is detected, suggesting a potential 
Brk targeted therapy may be beneficial in a range of cancers.  This also shows the impact of 
localisation considering cytoplasmic Brk mainly shows oncogenic functions for Brk as higher 
Brk levels are detected in cytoplasm compared to nuclear Brk in tumour cells. This is further 
supported by Kim and Lee studies which showed adding a myristoylation sequence to Brk’s 
N-terminal resulted in enhanced oncogenic functions of Brk in proliferation, survival and 
migration of tumour cells whereas adding a synthetic nuclear localisation sequence (NLS) to 
trap Brk in the nucleus negated these effects (Ie Kim and Lee, 2009).   
 
1.5 Brk substrates and protein interactions   
It has been previously reported there were over 30 Brk interacting proteins that have been 
identified (reviewed in Harvey and Burmi, 2011), however, a number of additional interactions 
have since been identified including; hypoxia inducible factor 1-alpha (Regan Anderson et 
al., 2013) as a regulator of Brk, identification of Brk as a novel substrate of phosphatase and 
tensin homolog (PTEN) (Wozniak et al., 2017), induction of Brk expression by glucocorticoid 
receptor (GR) in triple negative breast cancers (Regan Anderson et al., 2016), 
downregulation of tumour suppressor Dok1 by Brk (Miah et al., 2014) and inhibition of calpain 
1 activity via  HER2 increasing Brk stability and upregulating calpastatin (Ai et al., 2013)  
Table 1.2 shows a summary of Brk substrates and interacting proteins. This is an indication 
of the wide variety of pathways Brk is involved in.   Although Brk is capable of phosphorylating 
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some of these and others may bind directly with Brk, there is still speculation on how the other 




























Table 1.2 Summary of known Brk substrates and interacting proteins, adapted from (Harvey and 
Burmi, 2011). Proteins marked with (*) show Brk substrates. 
Brk substrate/interacting Protein Localisation 
EGFR Membrane 
HER2 Membrane 











Insulin Receptor Substrate-1 Cytoplasmic/Membrane-associated 
















*p190 Rho GAP Cytoplasmic 
23KDa Cytoplasmic 
100kDa Cytoplasmic  
HIF-1α Nuclear 
Glucocorticoid receptor (GR) Nuclear 
Dok1 Cytoplasmic/Nuclear 













Of the many interacting proteins, ARAP1 is a membrane associated protein.  ARAP1 (also 
known as Arf-GAP, Rho-GAP, ankyrin repeat and pleckstrin homology (PH) domain 
containing protein 1) protein displays RHO-GAP and phosphatidylinositol (3,4,5) 
trisphosphate (PIP3)-dependent ARF-GAP activity.  The encoded protein is thought to be 
involved in cell specific trafficking of a receptor protein involved in apoptosis. Co-
immunoprecipitation assays of proteins interacting with Brk revealed ARAP1 as an interacting 
protein (Kang et al., 2010).  Upon further investigation, it was shown binding of ARAP1 with 
Brk decreased in serum-depleted conditions showing there was some growth factor 
involvement.  EGFR has shown to interact with Brk suggesting it may be involved in 
stimulating ARAP1 binding to Brk (Kamalati et al., 1996).  When using a EGFR inhibitor, the 
association between Brk and ARAP1 was blocked (Kang et al., 2010).  Furthermore, Brk’s 
catalytic activity was needed for full interaction with ARAP1, in some cases Brk’s catalytic 
activity is required for binding whereas at other times it is not required as with the sam68 
protein (Derry et al., 2000).   This is important due to Brk having kinase independent functions 
suggesting that inhibiting the catalytic domain may not always be enough to inhibit Brk’s 
oncogenic role. 
Sam68, SLM1 and SLM2 are members of the signal transducers and activators family which 
are involved in regulation of RNA metabolism.  Sam68 (Src-associated protein in mitosis of 
68 kDa) functions in regulation of transcription as well as post-transcriptional alterations 
including alternative splicing resulting in mRNA variability (reviewed in Sánchez-Jiménez and 
Sánchez-Margalet, 2013).  SLM1 and SLM2 are sam68 mammalian like proteins with 
approximately 70% sequence homology, with SLM1 interacting with many of the same 
proteins as sam68 (Chen et al., 1999) and SLM2 interacting with RNA binding motifs (UA rich 
sequences) (Feracci et al., 2016) thus both proteins are involved in post transcriptional 
regulation of gene expression, similar to sam68. Furthermore, both proteins are involved in 
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regulation of alternative splicing sites transcripts encoded by CD44 minigene (Stoss et al., 
2001, 2004).  SLM1 and SLM2 proteins have been shown to be substrates of Brk 
(Haegebarth et al., 2004). With increasing expression of Brk, there is increased 
phosphorylation of SLM1 and SLM2 and nuclear retention of Brk which indicates Brk 
localisation plays a role in the varying functions of Brk.  SLM1 shows much similarity with 
sam68 including interacting with the same proteins and SLM2 showed the ability to interact 
with RNA-binding motif (UAAA), since sam68 was identified as a substrate, these two were 
predicted to also interact with Brk (Haegebarth et al., 2004).  Brk showed significant degree 
of specificity when binding to sam68, SLM1 and SLM2 along with selectively phosphorylating 
these proteins as opposed to other KH -domain containing proteins (Haegebarth et al., 2004).  
Upon closer investigation with RNA -binding studies involving activated Brk and vector, there 
was a clear indication of Brk negatively regulating the RNA binding abilities of sam69 and the 
sam68 -like mammalian proteins.  
Brk has shown binding with the ADAM family of proteins.  These are transmembrane proteins 
containing disintegrin and metalloprotease domains thus allowing for cell adhesion and 
protease functions.  There are over 25 variants within the human family, some still without a 
clear function, but most are involved in cell adhesion, cell fusion, proteolysis as well as 
intracellular signalling (reviewed in Giebeler and Zigrino, 2016).  Brk associates specifically 
with ADAM-15 which is mainly involved in cell adhesion and cell to cell interactions.  These 
functions of ADAM-15 may have significance in cancer progression due to its association with 
tumour cell invasion, migration and metastasis (Zhong et al., 2008).  In relation to breast 
cancer, it has been shown that ADAM-15 may be an indicator of disease free survival for 
patients with breast cancer, there was a clear link between poor survival in node negative 
patients and ADAM-15 expression (Zhong et al., 2008). Brk showed strong binding to the 
ADAM-15A and ADAM-15B variants and no association with ADAM-15C, and patients 
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associated with poor relapse-free survival showed high expression of ADAM-15A and ADAM-
15B whereas patients with favourable outcomes had high expression of ADAM-15C. 
Another interesting substrate of Brk is Akt, which Brk has shown to influence indirectly via 
regulation of ErbB3 which results in potentiated activation of Akt (Kamalati et al., 2000). Akt 
is involved in cell proliferation, and phosphorylation of various substrates and alterations 
within the P13K and Akt proteins or components in the pathway are involved in cancer 
progression and development (Osaki, Oshimura and Ito, 2004).  Further investigations 
revealed that Brk directly interacts with Akt as immunoprecipitation studies showed Akt and 
Brk associations (Zhang et al., 2005).  More interestingly for breast cancer cell lines, Brk-Akt 
complexes did not dissociate upon EGF stimulation whereas the alternative is true in 
keratinocytes and fibroblast-like cell lines derived from monkey kidney tissue known as COS-
1 cells (Zhang et al., 2005).   
STAT3 and STAT5 are also recognised as substrates of Brk and are involved in cellular 
processes leading to cell proliferation, migration and survival (Liu et al., 2006; Weaver and 
Silva, 2007; Gierut et al., 2011). STAT3 is regarded as an oncogene, with tyrosine 
phosphorylation of STAT3 connected to breast cancer development as discussed in (Gierut 
et al., 2011). Activation of STAT3 by Brk may contribute towards cell transformation and 
uncontrolled growth in initial stages of breast cancer. Brk also mediates STAT3 regulation in 
established tumours (Liu et al., 2006), and constitutive activation of Brk accelerated cell 
migration and tumour growth in vivo (Miah, Martin and Lukong, 2012).  More specifically in 
breast cancer, Brk suppression in HER2 positive and negative breast cancer cell lines 
resulted in reduced cell migration indicating a role for Brk in cell migration in a EGFR-family 
independent manner (Miah, Martin and Lukong, 2012).  This study suggests that Brk’s 
promotion of cell migration may require the full activation of Brk. 
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1.5.1 Brk and Her2 interactions  
 
In cancer cells, alterations in HER receptors or in their downstream signalling components 
are known to occur; HER2 is a negative prognostic factor, the presence of which indicates 
aggressive phenotype and reduced overall survival rate reviewed in (Montemurro and 
Scaltriti, 2013), although it should be noted that survival rates for HER2 positive cancers are 
improving due to the introduction of targeted therapies (Rugo et al., 2012). 
HER2 is overexpressed in approximately 20-30% of breast cancers (Hayes and Thor, 2002) 
and it has been suggested that Brk may be involved in regulation of signal transduction from 
HER tyrosine kinases. Several studies have shown a link between HER2/neu expression and 
PTK6 (Zhao et al., 2003; Born et al., 2005; Aubele et al., 2007; Xiang et al., 2008). 
This is of interest because HER2 targeted therapy, although clinically proven to be effective, 
does pose some restrictions such as lack of effect in some HER2/neu positive cancers as 
well as resistance. Therefore, a Brk targeted therapy maybe of clinical benefit especially when 
used in combination with existing HER2/neu targeted therapy. Due to the strong correlation 
between Brk and HER2, there is evidence suggesting that it may also be linked with prognosis 
thus indicating a role for Brk as a prognostic factor in breast cancer. Brk expression studied 
in 426 breast cancer cases further supports its potential as an independent prognostic factor 
regardless of morphological and molecular markers such as lymph node involvement, tumour 
size and HER2 status (Aubele et al., 2008).  Co-expression of Brk and HER2 has been linked 
to co-amplification of both the ErbB2 and ptk6 genes (Xiang et al., 2008), although this is not 
a consistent finding in other patient studies (Irie et al., 2010). It is worth noting that although 
HER2 is over expressed in 20-30% of breast cancers (Hayes and Thor, 2002), Brk is over 
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expressed in up to 86% of breast cancers (Harvey et al., 2009), which indicates that in the 
majority of breast cancers Brk is over expressed independently of HER2 status. 
At a protein level, Aubele and colleagues showed that Brk forms protein complexes with 
HER2 using paraffin-embedded tissues from invasive breast carcinomas (Aubele et al., 
2010). The effect of simultaneous knockdown of Brk and HER2 was analysed in the 
Herceptin-resistant cell line JIMT-1 (Ludyga et al., 2013). The results indicated significant 
reduction in phosphorylation of important signalling intermediates, namely, ERK and 
p38MAPK and PTEN, which are involved in regulating tumorigenesis. More specifically for 
PTEN, which is a tumour suppressor, phosphorylation at Ser380/Thr382/383 reduces its 
activity as a tumour suppressor (Vazquez et al., 2000). Furthermore, there was reduced 
migration and invasion of JIMT-1 cells when expression of both proteins was suppressed. 
HER2 may also be involved in elevating Brk levels via upregulating calpastatin and inhibiting 
calpain-1 activity in breast cancer cells (Ai et al., 2013). 
These combined data further support the study of dual inhibition of Brk and HER2, firstly for 
a greater clinical effect and secondly to overcome anti-HER2 therapeutic resistance. 
 
1.5.2 Brk and EGFR interactions 
 
ErbB signalling in breast tumour progression has been extensively documented. EGFR 
tyrosine kinases have been involved in regulation of normal and abnormal cellular 
proliferation and survival reviewed in (Kim and Muller, 1999). Both EGFR and HER2 are 
intrinsically linked; HER2 potentiates EGFR signalling by enhancing binding ability of EGF 
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and reducing its degradation and studies have indicated that HER2 signalling is reduced via 
EGFR-specific inhibitors (Moasser et al., 2001).  
The EGF receptor family are linked to the tumorigenic transformation of breast epithelial cells. 
When Brk-transfected mammary epithelial cell lines, MCF10A and Hb4a, were treated with 
human growth factors (EGF), mitogenic activity of Brk was observed. This reveals Brk’s role 
in sensitizing human mammary epithelial cells to growth factors such as EGF (Kamalati et 
al., 1996). Furthermore, Brk association with the EGF receptor has also been detected, even 
in the absence of EGF, leading to proliferation of epithelial cells. EGFR expression also plays 
a role in keratinocyte differentiation (Tran et al., 2012), a process in which Brk is involved 
(Tupper, Crompton and Harvey, 2011). Inhibition of EGFR signalling during differentiation 
induces growth arrest; however, Brk’s promotion of EGFR signalling suggests that one of its 
roles may involve promoting cell survival during early differentiation. 
EGF stimulation results in rapid phosphorylation of Brk indicating the involvement of Brk in 
the EGF signalling complex (Kamalati et al., 2000). EGF binding to its receptor, EGFR, not 
only induces its phosphorylation but also the phosphorylation of other EGFR family members 
(HER2, 3 and 4). The expression of Brk therefore not only increases phosphorylation of 
EGFR and HER2 but also of HER3 (erbB3) in breast cell lines (Kamalati et al., 2000).  It may 
do this via direct interaction with an erbB3-containing complex in response to EGF 
stimulation. Brk’s ability to enhance EGFR signalling could be mediated by inhibition of EGFR 
downregulation (Li et al., 2012), which is achieved by phosphorylation of either ARAP-1 (Kang 
et al., 2010) or c-Cbl (Kang and Lee, 2013), thereby prolonging EGFR signalling. 
Expression of Brk enhances EGF-induced ErbB3 phosphorylation and recruitment of P13K 
to ErbB3 thus inducing P13K activity (Kamalati et al., 2000). Since the P13K pathway is 
implicated in breast cancer and is linked with resistance to HER2 targeted therapies, its 
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interaction with Brk may give a wider overview of the mechanisms involved in developing 
resistance. P13K has been a desirable therapeutic target of its own and current therapies 
focus on anti-mTOR agents, tyrosine kinase inhibitors and P13K inhibitors reviewed in 
(Baselga, 2011). However, to create a greater clinical effect, combinations of these 
treatments including a potential Brk tyrosine kinase inhibitor maybe more useful and reduce 
the activation of compensatory feedback loops which could decrease efficacy of single 
agents. Since Akt is a known substrate of Brk, and Brk negatively regulates its 
phosphorylation in epithelial cells, the potential consequences of this therapy may need to be 
fully assessed (Haegebarth et al., 2006). Nonetheless, due to most of the normal cells that 
express Brk being outside the proliferative areas of the tissues, Brk targeted therapy may still 
be highly specific reviewed in (Harvey and Crompton, 2004). 
Overall Brk prolongs EGFR signalling, sensitises tumour cells to EGF stimulation, inhibits the 
degradation of EGFR and reduces the sensitivity of EGFR inhibitors in Brk overexpressing 
cells. This suggests Brk inhibition could reduce tumour proliferation and growth via reduced 
EGFR signalling and increase EGFR inhibitor sensitivity.  
 
 
1.5.3 Brk and IGF interactions 
 
Insulin receptor substrate 4 (IRS-4) is part of the insulin receptor substrate family, which also 
contains IRS-1, IRS-2 and IRS-3. Their function includes a variety of biological effects such 
as cell proliferation, growth, survival and differentiation downstream of insulin and insulin-like 
growth factor 1 (IGF-1) receptors (reviewed in Sachdev, 2008). IRS-4, upon IGF-1 
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stimulation, is phosphorylated which leads it to binding to P13K activating the MAPK pathway. 
The link between insulin-like growth factor (IGF) and breast cancer has been well 
documented; the IGF-1 receptor is significantly overexpressed in tumour cell lines compared 
to normal breast cancer epithelial tissue and benign tumours reviewed in (Zeng and Yee, 
2007) and there is also a clear correlation between poor breast cancer prognosis and 
overexpression of IGF-1R (Klinakis et al., 2009). In the MCF-7 breast carcinoma cell line, IGF 
stimulation results in Akt activation leading to cell proliferation through phosphorylation of Raf 
kinase. Along with this, IGF stimulation leads to resistance to anoikis (Irie et al., 2010), a 
process whereby epithelial cells undergo apoptosis due to loss of interaction with 
neighbouring cells and the basement membrane (Frisch and Francis, 1994). Overexpression 
of IGF-1R is also implicated in resistance against breast cancer therapy, especially against 
Herceptin (reviewed in Fink and Chipuk, 2013). 
Immunoprecipitation and mass spectrometry have shown IRS-4 substrate interaction with Brk 
in co-transfected HEK 293 cells (Qiu et al., 2005). In addition to this interaction with IRS-4, 
Brk also co-precipitates with IRS-1 and IGF-IR (Irie et al., 2010). The interaction of Brk with 
IGF-IR as well as EGFR and HER2 gives an indication of the range of Brk activity in regulating 
signalling. EGFR, HER2 and IGF-1R are overexpressed in different subsets of breast cancers 
whereas Brk is overexpressed in majority of breast cancers and has a role in each of these 
signalling pathways, thus making it an attractive therapeutic target for disrupting signalling 
cross-talk. Since Brk interacts with IGF-1R, disrupting this association may also reduce the 
chance of developing resistance against current breast cancer therapies such as Herceptin, 
through HER2-IGF-R1 heterodimer formation resulting in phosphorylation and activation of 
HER2 (reviewed in Bender and Nahta, 2008).  Figure 1.2 shows the summary of Brk 
interactions with HER2, EGFR and IGF as well as some other substrates or interacting 
proteins involved in the complex signalling pathways that lead to the activation of signalling 
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intermediates resulting in increased cell proliferation, migration and reduced cancer cell death 





Figure 1.2 Summary of Brk interactions in the signalling pathways leading to increased breast cancer 
cell proliferation, migration and reduced cell death .  Brk interacts with IRS-4 (Qiu et al., 2005) and co-
precipitates with IGF-1R (Irie et al., 2010).  IRS-4, upon IGF-1 stimulation, is phosphorylated which leads it 
to binding to P13K activating the MAPK pathway and resulting in increased cell proliferation.  EGF stimulation 
results in rapid phosphorylation of Brk (Kamalati et al., 2000) and leads to HER3 phosphorylation and 
recruitment of P13K to HER3 thus inducing P13K activity.  EGF stimulation also results in Brk phosphorylation 
of paxillin leading to increased cell migration and invasion (Chen et al., 2004). Brk forms protei n complexes 
with HER2 (Aubele et al., 2010). Simultaneous knockdown of Brk and HER2 results in reduced 
phosphorylation of important signalling intermediates such as ERK and p38MAPK as well as reduced cancer 
cell migration and invasion (Ludyga et al., 2013).  Brk overexpression increases ERK1/2 activity (Ono, Basson 
and Ito, 2014). Activation of STAT3 by Brk contributes toward cell transformation and uncontrolled growth 
(Liu et al., 2006).  P13/AKT activation leads to Akt phosphorylation and inhibition of pro-apoptotic Bcl-2 family 
members thus reducing apoptosis of cancer cells.  Furthermore, Brk oncogenic functions include protecting 





1.6 Brk and Differentiation 
 
One of the major roles of Brk within normal tissues is inducing cellular differentiation as 
indicated in tissues of skin and intestine (Llor et al., 1999; Wang et al., 2005).  Keratins are 
fundamental components of cytoskeleton and have roles in integrity as well as mechanical 
stability (reviewed in Moll, Divo and Langbein, 2008) and changes in keratin expression in 
the epidermis are particularly important.  For example, during wound healing or other 
hyperproliferative conditions such as cancer, epidermal expression of some keratins 
including keratin 10 is significantly reduced (Santos et al., 2002).  Keratin 10, a type I keratin, 
is expressed in post-mitotic suprabasal keratinocytes of the skin and is involved in 
suppressing cell proliferation and tumour formation in skin cells (Chen et al., 2006). Brk has 
been detected within the epidermis of the skin mainly in differentiating layers in the 
suprabasal keratinocytes (Wang et al., 2005).  This was shown in immortalized non-
tumorigenic HaCaT cell lines which closely resemblance differentiation pattern of primary 
keratinocytes.  It was hardly detected in basal layer and was more abundant in the 
differentiating layer. It has been indicated Brk expression is more intense in well differentiated 
squamous cell carcinoma (Wang et al., 2005).  Indirect immunofluorescence indicated an 
increased up-regulation of Brk during keratinocytes differentiation; calcium addition was 
shown within this study to enhance Brk kinase activity.  After transfection of Brk, there was 
increased expression of Keratin10, indicating Brk is involved in regulation of keratinocyte 
differentiation in some way.  Brk also been shown to be involved in enterocyte differentiation 
within colon cells (Haegebarth et al., 2006).  Earlier studies indicated enhanced expression 
of the epidermal differentiation marker, filaggrin, within differentiating cells (Vasioukhin and 
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Tyner, 1997). This further suggests a role for Brk in epithelial cell differentiation.  There is 
some speculation that inhibition of Akt may be involved in the differentiation process as 
inhibiting Akt may allow for efficient cell cycle exit and differentiation (Haegebarth et al., 
2006).  Further to this, Brk protein levels in normal adult human keratinocytes decreased as 
cells became more terminally differentiated in vitro (Tupper, Crompton and Harvey, 2011).   
Brk suppression resulted in increased number of cells incorporating trypan blue which is an 
indication of early keratinocyte differentiation.  It was proposed Brk may promote survival in 
early keratinocyte differentiation and the subsequent decrease may be a result of the 
requirement of the differentiation process of primary cells.   
 
1.7 Brk in cell proliferation and cell cycle progression 
 
It has been shown that Brk can increase breast cancer cell proliferation as well as anchorage 
independent growth (Harvey and Crompton, 2003; Harvey et al., 2009; Chan and Nimnual, 
2010) as well as sensitize mammary epithelial cells to growth factors such as epidermal 
growth factor  (EGF) (Kamalati et al., 1996).  Since Brk has shown to phosphorylate Akt on 
the tyrosine, which results in inhibition of Akt within COS-1 cells, there is some evidence that 
it may be involved in negative regulation of growth (Haegebarth et al., 2006).  However, this 
role may be dependent on the tissue type and substrate or protein interactions as Brk has 
largely cell proliferating and cell growth roles in various tumour cell lines including breast 
tumour cells (Kamalati et al., 1996).  Furthermore, Brk’s localisation within the cellular 
compartments may also contribute towards its function in cell proliferation as it has been 
reported that Brk’s interaction with Akt resulted in promotion of cell growth and cell 
proliferation (Zheng and Tyner, 2013).  Studies have indicated knockdown or suppression of 
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Brk in Brk-expressing cell lines such as SKBR3 (a HER2 positive cell line), T47D (ER positive 
cell line) and MDA-MB-231 (triple negative cell line) resulted in decreased cell proliferation of 
up to a 60% decrease in cell population (Chan and Nimnual, 2010).  
To some extent, Brk’s role in cell proliferation and its ability to promote cell cycle progression 
may contribute towards breast cancer development.  Cell cycle deregulation has been known 
to contribute towards neoplasia, progression to mitosis is tightly controlled by cyclins and 
cyclin dependent kinases (Chan and Nimnual, 2010).  The kinase activity of these CDKs is 
inhibited by CDK inhibitors such as CDK1 (p27) which is deregulated in cancers.   Brk has 
shown to down regulate p27, which leads to a disruption in the cell cycle progression and 
cells enter S phase in a growth factor independent manner (Chan and Nimnual, 2010).  
Previously, Brk suppression has shown a significant reduction in DNA synthesis which 
indicated that cells were progressing through S-phase at a slower rate (Harvey and 
Crompton, 2003).  It has been shown that Brk may downregulate p27 expression as 
suppression of endogenous Brk showed an increase in p27 levels in MDA-MB 231 breast 
cancer cells and this is mediated by nuclear exclusion of the transcriptional factor proteins 
called FoxO which are involved in regulation of p27. Brk-transfected cells showed FoxO3a 
was localised mainly in the cytoplasm compared to control cells which have nuclear FoxO3a 
(Chan and Nimnual, 2010).  Along with the substrates and interacting proteins, as well as the 
type of tissue Brk is expressed in, Brk’s cellular localisation also determines its function.  As 
previously described, Brk’s localisation varies widely within different tissue types.  In addition, 
in the presence of Brk, polypyrimidine tract-binding protein- (PTB) associated splicing factor 
(PSF), which is involved in mammalian spliceosomes (Chanas-Sacré et al., 1999) 
compromised cell cycle progression by arresting cells in the S-phase (Lukong, Huot and 
Richard, 2009).  PTB associated splicing factor (PSF) has been identified as a novel 
peroxisome proliferator activated receptor gamma (PPARγ) interacting protein (Tsukahara, 
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Haniu and Matsuda, 2013).  PPARγ is a nuclear receptor involved in regulation of cell 
proliferation and apoptosis and its expression is increased in a number of cancers including 
colon, lung and breast (Tsukahara, Haniu and Matsuda, 2013).  Suppression of PSF by 
siRNA significantly suppressed the proliferation of colon cancer cells and induced apoptosis 
in DLD-1 human adenocarcinoma cells (Tsukahara, Haniu and Matsuda, 2013). 
  
1.8 Brk in cell migration and metastasis 
 
To a large extent Brk is involved in breast cancer cell proliferation, however it is also involved 
in cell migration (Shin et al., 2017). A reduced ability for T47D and JIMT-1 breast cancer cell 
migration was observed in response to Brk suppression (Ludyga et al., 2013). Paxillin is a 
multidomain protein that is recruited to edges of the cell once migration is initiated, (as 
reviewed in (Deakin and Turner, 2008), and Brk has been recognised as a novel paxillin 
tyrosine kinase that binds to, as well as phosphorylates, paxillin (Chen et al., 2004).  Brk also 
acts a mediator of EGF-induced paxillin phosphorylation, thus promoting activation of Rac1 
and stimulating cell migration and invasion. KAP3A is a subunit of the kinesin-2 heterotrimeric 
complex and binds microtubule-based subunits KIF3A/3B to various cargo proteins, which 
enable membrane morphogenesis (Yamazaki et al., 1996). KAP3A has also been identified 
as a substrate of Brk and is phosphorylated at its C-terminus, a process required for Brk-
induced cell migration (Lukong and Richard, 2008). Another study revealed that, upon Met 
receptor activation, Brk acts upstream of ERK5 activation which mediates cell migration 
(Castro and Lange, 2010). It appears that Brk’s kinase activity was not required for Brk/ERK5 
interaction or induction of migration within breast cancer cell lines.  ERK5 has recently been 
indicated to be elevated in invasive breast cancers (Liu, Zhang and Song, 2017) indicating 
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disrupting Brk/ERK5 interaction may reduce cell migration and cell proliferation. Met 
signalling pathways increase tumour cell migration and disease progression by promoting 
tumour vasculature and increasing volume, thus a Brk-targeted therapy potentially could 
prevent spread and progression of tumours (Castro and Lange, 2010).  Along with this, p190, 
another substrate of Brk, once phosphorylated is associated with p120 leading to Rho 
inactivation and Ras activation (Shen et al., 2008).  p190 also known as p190RhoGAP-A, is 
an inhibitor of RhoA signalling and associated with p120RasGAP (p120), and both these 
GTPase-activating proteins (GAP) mediate cross-talks between Rho and Ras (Bernards and 
Settleman, 2005).  Migratory effects of Brk are greatly impaired in cells lacking p190. These 
interactions indicate an important function of Brk in regulating tumour cell migration via 
various systems, thus a Brk-targeted therapy could potentially cause disruption in these 
processes.  
Angiogenesis has been recognised as an essential process in survival of cancerous cells in 
vivo; it is involved in tumour growth, progression and metastasis (Otrock et al., 2007). One of 
the main pro-angiogenic factors involved in promoting tumour angiogenesis is vascular 
endothelial factor (VEGF) reviewed in (Niu and Chen, 2010). Osteopontin is a secreted non-
collagenous chemokine-like protein that regulates VEGF expression via a Brk/nuclear factor-
kappa B (NF-κB)/ ATF-4 signalling cascades (Chakraborty, Jain and Kundu, 2008).  Briefly, 
osteopontin induced VEGF regulation of tumour angiogenesis is mediated through autocrine, 
paracrine and juxtracrine mechanism as highlighted in Figure 1.3 (Chakraborty, Jain and 
Kundu, 2008).  Osteopontin was shown to enhance VEGF and Neuropilin 1 (NRP-1), a  
transmembrane glycoprotein and VEGF-specific receptor (Herzog et al., 2011), interactions 
in breast cancer cells and there was enhanced osteopontin induced wound migration in cells 
transfected with wild type Brk compared to kinase mutant Brk suggesting osteopontin 
regulation of VEGF dependent wound migration through NRP-1 mediated autocrine 
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mechanism (Chakraborty, Jain and Kundu, 2008).  Furthermore, VEGF interaction with 
endothelial cell surface VEGF receptor -2 (KDR) induces phosphorylation of KDR which has 
shown to lead to tumour angiogenesis (Cross et al., 2003), thus osteopontin induced VEGF 
regulation of KDR phosphorylation via paracrine loop was assessed in MDA-MB 231 breast 
cancer.  In addition, osteopontin induced VEGF showed to act as a link between NRP-1 which 
is expressed in tumour cells and KDR which is expressed in endothelial cells through the 
juxtracrine mechanism (Chakraborty, Jain and Kundu, 2008). In all these signalling pathways, 
osteopontin was shown to stimulate Brk phosphorylation and Brk mediated NF-κB-
dependent/independent ATF-4 activation which leads to VEGF expression and enhanced 
angiogenesis (Chakraborty, Jain and Kundu, 2008).  Furthermore, higher levels of expression 
of Brk, NF-κB and ATF-4 correlated with higher tumour grades. As osteopontin is secreted 
from the bone and expressed in brain (Oldberg, Franzen and Heinegard, 1986; Saitoh et al., 
1995), which are frequent sites for breast cancer metastasis (reviewed in Irvin Jr, Muss and 
Mayer, 2011), this study provides a mechanism whereby Brk could be involved in the 
formation of metastases. 
Overall Brk’s ability to promote cell migration and metastasis via various mechanisms may 
indicate that targeting Brk via tyrosine kinase inhibitors and disrupting its protein-protein 











Figure 1.3 Brk/nuclear factor-kappa B (NF-κB)/ ATF-4 signalling cascades involved in osteopontin 
induced VEGF expression.   Osteopontin induced Brk/ nuclear factor-kappa B (NF-κB)/ATF-4 mediated 
signalling results in VEGF expression leading to tumour migration, growth and angiogenesis via autocrine, 
paracrine and juxtacrine pathways (Chakraborty, Jain and Kundu, 2008).   
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1.9 Brk and cell death 
 
Brk’s role in cell death has thus far shown to be contradictory, in certain cellular environments 
Brk tends to promote apoptosis and cell death whereas in other cases it protects cells from 
cell death.     
Brk’s proliferative ability when coupled with its ability to protect cancerous cells from cell death 
promotes tumour cell survival. Brk has shown association with the P13-K/Akt pathway which 
is not only involved in cell proliferation but in apoptosis; thus activation of this pathway may 
reduce the ability of cells to undergo apoptosis (Kamalati et al., 2000). Furthermore, Brk can 
protect breast cancer cells from autophagy; reduced expression of Brk coupled with 
suspension of culture increased the number of dead cells compared to controls (Harvey et 
al., 2009).  Brk also increases phosphorylation of p38 MAPK which is associated with pro-
survival cell phenotypes in breast cancer (Lofgren et al., 2011).  Brk’s ability to protect cancer 
cells from cell death is further enhanced due to its ability to protect cells from DNA damage-
induced apoptosis in colon cancer cells.  Knockdown of Brk in HCT116 cells led to increased 
apoptosis following γ-irradiation (Gierut et al., 2012). In addition, p53 was recognised as a 
possible positive regulator of Brk activity in response to DNA damage (Gierut et al., 2012). 
Reduced expression of p21 and STAT3 were also noticed in Brk-suppressed cells, leading 
to increased apoptosis and decreased survival (Gierut et al., 2012). This gives indication for 
Brk inhibitors reducing tumour cell growth and survival.  
Brk suppression in breast cancer cells suspended in culture resulted in increased the rate of 
cell death via autophagy compared to controls whereas Brk expression in Brk negative cancer 
cells resulted in increased cell survival, showing a role for Brk in protecting cancer cells from 
cell death (Harvey et al., 2009).   Brk also protected cells from anoikis via IGF-I signalling (Irie 
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et al., 2010). Further to this, Brk was shown to protect cells from anoikis via direct 
phosphorylation of focal adhesion kinase (FAK) and activating Akt (Zheng et al., 2013).  
Knockdown of Brk in PC3 prostate cancer cell line disrupted FAK and Akt activation which in 
consequence promoted anoikis thus indicating an important protective role for Brk in 
anchorage independent survival (Harvey et al., 2009).   
Within a different cellular context such as the non-transformed rat fibroblasts, Brk has shown 
a role contradictory to that seen in breast cancer since it sensitises cells to apoptosis 
(Haegebarth, Nunez and Tyner, 2005).  Furthermore, it also promotes apoptosis in crypt 
epithelial cells in response to DNA damage (Haegebarth et al., 2009). This may show a role 
for Brk as a damage sensor that promotes apoptosis in response to cellular stress in normal 
tissue. These differences in Brk’s role may again depend on its cellular localisation, 
substrates and protein interactions. 
1.10 Brk and Hypoxia  
 
Hypoxia refers to low oxygen levels (below the normal physiological tissue level).  Hypoxia 
has shown to be a characteristic of malignancy and an important survival feature of the 
tumour microenvironment (reviewed in Challapalli, Carroll and Aboagye, 2017).  Hypoxia 
arises due to high metabolic demand for oxygen as a consequence of rapid tumour growth 
and  ineffectiveness of the tumour vasculature (Brown and Giaccia, 1998).  Hypoxia inducible 
factors are mediators of transcriptional responses to hypoxia and are involved in many 
cellular functions within cancer cells leading to progression and metastasis (Semenza, 2010). 
HIFα subunits are overexpressed in breast cancers especially in triple negative breast 
cancers  and indicate higher risk of metastasis (Dales et al., 2005; Yamamoto et al., 2008).  
Brk/PTK6 has shown to be induced in hypoxic conditions in a HIF-dependent manner (Regan 
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Anderson et al., 2013).  In contrast, Hammond and colleagues showed Brk is rapidly 
stabilised in hypoxic conditions in a HIF-1α independent manner (Pires et al., 2014).  Brk was 
induced rapidly in response to hypoxia and Brk induction occurred prior to HIF-1α stabilization 
in breast and colorectal cancer cell lines.  In addition, it was shown that in response to 
hypoxia, Brk ubiquitylation was reduced and proteasomal-mediated degradation was 
decreased compared to normoxia (Pires et al., 2014).  This may be regulated via E3 ligases 
such as c-Cbl independently of HIF, however Brk has shown to promote the degradation of 
c-Cbl itself and thus may be involved in a reciprocal feedback loop with Brk (Kang and Lee, 
2013; Pires et al., 2014). Furthermore, the study showed Brk regulates cellular invasion and 
migration through relocalisation to the cellular membrane, a process which is important for 
Brk’s oncogenic functions (Pires et al., 2014).  This suggests a Brk targeted therapy may 
have potential to reduce tumour metastasis which may be particularly important for triple 
negative breast cancers.   
 
1.11 Issues with current breast cancer treatments 
 
Chemotherapy and radiotherapy have been recognized to target normal rapidly dividing cells 
such as bone marrow, gastrointestinal tract or hair follicles; the range and intensity of adverse 
effects reduces the specificity and increases toxicity of these therapies. Both these types of 
treatments therefore have a limited therapeutic index and can often be palliative in use as 
reviewed by Arora (Arora and Scholar, 2005).  Hormonal therapies have also been in use; for 
example Tamoxifen, which has been used for early stage and metastatic breast cancer since 
its license in 1972 (Smith, 2012). Although proven to be effective against pre-menopausal 
breast cancer, especially those that are oestrogen receptor positive, there are still many 
46 
 
issues that need to be overcome for maximum effect of the drug to be achieved, whether by 
itself or as combination therapy. These include the diverse adverse toxicities such as 
thrombosis, strokes and development of secondary cancers. Other issues include resistance 
against Tamoxifen and subsequent disease recurrence in some patients (Chang, 2012; 
Mayor, 2017). Furthermore, this drug is only effective against oestrogen or progesterone 
receptor positive breast cancers thus making it unsuitable for other types of breast cancer 
such as HER2 positive/ER/PR negative and triple negative breast cancers (den Hollander, 
Savage and Brown, 2013). However, there are treatments available for HER2 positive 
cancers such as Herceptin, a monoclonal antibody that binds to HER2 thus negatively 
affecting receptor function, as well as a number of kinase inhibitors. Unfortunately the more 
advanced stages of breast cancer do not always respond to Herceptin therapy and those that 
do, often progress in 12 months from the start of the treatment (Fink and Chipuk, 2013). In 
addition resistance may occur due to the involvement of a number of signalling pathway 
molecules such as activation of the PI3K/AKT pathway, loss of PTEN and activation of 
PIK3CA (reviewed in Brauer and Tyner, 2010). Brk is expressed in a wide range of cancer 
types including in hormone positive ( ER/PR/HER2) and negative breast cancers, thus 
making it an ideal candidate for therapeutic intervention (Barker, Jackson and Crompton, 
1997;, reviewed in Brauer and Tyner, 2010). 
 
1.12 Tyrosine kinase inhibition 
 
The potential for a Brk tyrosine kinase targeted therapy was investigated in this thesis, 
therefore a brief introduction to targeted therapy is needed. Targeted therapy is largely 
directed specifically towards tumour cells thus reducing many side effects and providing a 
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wider therapeutic window. They can also be used in combination with traditional 
chemotherapy or radiotherapy to enhance anticancer effects. Further patient benefit includes 
convenience with oral consumption rather than intravenous administration as is the case for 
many chemotherapy drugs.  
Tyrosine kinases have been implicated in a range of cancers; they are involved in cellular 
signalling and play a significant role in growth factor signalling. In their active form tyrosine 
kinases can promote tumour cell proliferation, growth and induce anti-apoptotic effects, as 
well as promote angiogenesis and tumour cell metastasis. Since most of these cellular events 
contribute to tumour progression and decreased patient prognosis, tyrosine kinases are 
considered ideal candidates for targeted therapy. 
There are two main types of kinases; these can be categorized as receptor protein kinases 
that are generally membrane spanning, or non-receptor protein kinases that relay intracellular 
signals from the receptors, of which, Brk is one example.  Briefly, when ligands bind to their 
cognate receptors, they stimulate receptor dimerization followed by autophosphorylation and 
activation of tyrosine kinase activity. As a result, multiple signalling pathways are activated 
and intracellular mediators in these pathways transduce signals from membrane receptors 
through the cytosol and into the nucleus which ultimately alters DNA synthesis and cell 
division as well as a wide range of biological processes (Arora and Scholar, 2005). Protein 
tyrosine kinase activity within breast tumour tissues has been reported to be significantly 
higher in comparison to benign or normal breast tissues (Romain et al., 1994). For example, 
the tyrosine kinase activity of the product of c-src proto-oncogene has been found to be 
elevated in human breast tumours (Ottenhoff-Kalff et al., 1992), and several tyrosine kinase 
receptors with links to Brk have also been implicated in breast cancer development and 
progression for example , epidermal growth factor receptor (EGFR) and HER2/neu 
transmembrane tyrosine kinase receptor, as well as receptors for insulin like growth factors 
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(IGF) such as IGF-1R (Meric et al., 2002; Nielsen et al., 2004). Others include fibroblast 
growth factor receptor (Fearon, Gould and Grose, 2013) and met receptor tyrosine kinase 
reviewed in (Ponzo and Park, 2010). 
 
41.13 Breast cancer radiation sensitivity 
 
Radiation therapy after breast conserving surgery has been indicated to be more beneficial 
to patients than initially thought.  A wide variety of breast cancer patients show increased 
survival rate and reduced chance of recurrence as well as reduced metastasis in a 10 and 
15-year study (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al., 2011). 
BRCA1 and BRCA2 are genes that, once mutated, cause a higher chance of cancer forming 
and indicate a reduced ability for DNA repair. Approximately 19% of all triple negative breast 
cancers have BRCA gene mutations and thus are known to have defective DNA repair 
mechanisms (Wong-Brown et al., 2015). The BRCA genes are tumour suppressors and the 
proteins encoded by them are involved in homologous recombination, a double strand DNA 
break repair mechanism (Welcsh and King, 2001).  This would suggest this subtype of breast 
cancers with defective DNA repair mechanisms would be more susceptible to radiotherapy 
and chemotherapy.  However, the opposite is true, triple negative breast cancers with BRCA 
mutations, are more radio-resistant and patients with these tumours have a higher overall 
mortality rate when treated with radiotherapy compared to hormone receptor and HER2 
positive breast cancers (Kyndi et al., 2008).  This contradiction may be due to enhanced DNA 
repair mechanisms compensating for the defects in the BRCA genes meaning cells are forced 
to repair damage via other repair mechanisms such as non-homologous end joining (NHEJ) 
(Langlands et al., 2013). The cell cycle phase is an important factor in determining the radio-
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sensitivity/resistance as cells in the G2 phase are most sensitive to radiation, less sensitive 
in the G1 phase and least sensitive in the late S phase (Pawlik and Keyomarsi, 2004). The 
NHEJ repair pathway has shown to be predominantly active in the G1 phase whereas HR in 
comparison, is active in the G2 phase of the cell cycle (Mao et al., 2008) thus suggesting the 
alternative NHEJ repair pathway may reduce the sensitivity of radiotherapy.  
 
1.14 Brk and breast cancer chemotherapy  
 
Despite improvements in treatment of breast cancer with adjuvant chemotherapy; there is still 
a need for novel breast cancer therapies.  Treatment of the majority of invasive and higher 
grade/stage cancers is heavily chemotherapy based (Lee and Newman, 2007; Roche and 
Vahdat, 2011) thus the significance of how Brk may influence breast cancer cell sensitivity to 
chemotherapy agents as well as other drug-based treatments needs to be understood.  
Previous studies have shown that Brk may contribute towards influencing chemotherapeutic 
sensitivity in breast cancer (Burmi et al., 2009; Harvey et al., 2009).  The mechanism 
proposed involves Brk altering the ratios of anti and pro-apoptotic proteins; Bcl-XL and Bcl-XS 
respectively, in respect of Bcl-XL.  Suppression of Brk in T47D breast cancer cells, which are 
representative of Luminal A breast cancer subtype, significantly increased sensitivity to 
chemotherapeutic drugs paclitaxel and doxorubicin, however this was not studied in triple 
negative breast cancers (Burmi et al., 2009).   The anti-apoptotic protein Bcl-XL is associated 
with chemotherapeutic resistance (Gul, Basaga and Kutuk, 2008) and reduced levels of Brk 
protein resulted in reduced levels of Bcl-XL protein and thus increased sensitivity to 
chemotherapy (Harvey et al., 2009).  Furthermore, breast cancer cells treated with 
methotrexate and 5-flurouracil showed decreased apoptosis due the inhibition by Bcl-XL in 
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vitro and in vivo.  Based on these studies, it is expected a Brk targeted therapy would 
modulate chemotherapeutic drug response.    
 
1.15 Aims and Objectives    
 
Considering the extensive research on breast tumour kinase (Brk)’s oncogenic role in breast 
cancer including cancer cell proliferation and protection against cell death to migration and 
metastasis (reviewed in Hussain and Harvey, 2014); little is known of the role Brk plays in 
breast cancer therapeutics.  The main aims of this thesis were; to investigate if Brk influences 
radio-sensitivity of breast cancer cell lines as well as to determine the potential mechanism 
that mediates the radio-sensitivity, to determine the potential of a novel Brk targeted therapy 
as a monotherapy and in combination with other breast cancer therapies, and to determine 
the ratios of mRNA levels of PTK6 and ALT-PTK6 transcripts in response to Brk inhibition 
and other breast cancer therapies as well as the potential of ALT-PTK6/PTK6 expression 
ratios as prognostic factors for overall and disease free survival in breast cancer.   
The objectives were to: 
 To determine the radio-sensitivity of different breast cancer cell lines to γ-radiation 
through clonogenic survival in relation to Brk protein expression.  
 Investigate the role of Brk in the DDR response pathway through γ-H2AX DNA repair 
assays. 
 Examine whether there is a functional link between Brk and ATM signalling through 
analysis of total and phosphorylated protein levels of ATM in breast cancer cell lines. 
 To investigate the effect on cell viability of breast cancer cells using the novel Brk 
inhibitor known as Compound 4f (Mahmoud et al., 2014) through MTT assays as a 
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monotherapy as well as in combination with breast cancer therapies; Taxol, Doxorubicin, 
Lapatinib and Tamoxifen. 
 To investigate the effect on Brk activity including the activity of its downstream signalling 
molecule STAT3, as well as determine levels of ALT-PTK6 protein in response to 
Compound 4f treatment over a 48-hour time period in breast cancer cell lines.   
 To determine expression of both full length PTK6 transcript and the short splice 
variant; ALT-PTK6 in breast cancer cell lines using Real Time-PCR. 
 To quantify the relative mRNA expression and ratios of both PTK6 transcripts in breast 
cancer cell lines at basal levels and before and after treatment with compound 4f as 
well as in response to standard breast cancer treatments: Taxol, Doxorubicin, 
Lapatinib as well as Tamoxifen. 
 To determine ALT-PTK6 to PTK6 mRNA expression ratios in normal and tumour 
breast tissue samples in relation to overall and disease-free survival.  
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2. 1 Materials  
2.1.1 Equipment  
 
Table 2.1 List of Equipment  
Equipment  Supplier  Address  
60Cobalt source  Puridec Technologies Ltd  REVISS Services (UK) Ltd, 179 Brook Drive, 
Milton Park, Abingdon, Oxon, England 
OX14 4SD 
Fisher Scientific Power pack 
300  
Fisher Scientific  Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gel Doc™ XR+ Gel and blot 
imaging System 
Bio Rad Bio-Rad Laboratories Ltd. The Junction, 
Station Road, Watford, Hertfordshire, 
WD17 1ET 
Imagestream Amnis® Imaging 
Flow Cytometer 
Amnis® - part of 
Millipore  
Millipore UK Limited, Suite 21, Building 6, 
Croxley Green Business Park Watford 
Hertfordshire WD18 8YHUnited Kingdom 
Incubator Hera Cell 240  Heraeus  Heraeus Noblelight Ltd. Cambridge Science 
Park, Milton Road, Cambridge, CB4 0GQ 
Laminar Flow Cell Culture 
Hood Hera Safe  
Heraeus   Heraeus Noblelight Ltd. Cambridge Science 
Park, Milton Road, Cambridge, CB4 0GQ 
Microplate reader  BioTek Papermakers House, Rivenhall Road, 
Swindon SN5 7BD, United Kingdom 
Pipettes, P10, P20, P200, 
P1000 
Gilson  Gilson Scientific UK, 3B Humphrys Road, 
Woodside Estate, Dunstable 
Bedfordshire, LU5 4TP 
QuantStudio 7 Flex Real-Time 
PCR System 
Applied Biosystems Stafford House, 1 Boundary Park, Hemel 
Hempstead HP2 7GE 
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Sorvall Legend T Benchtop 
Centrifuge 
Fisher Scientific  Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Spectrophotometer Nanodrop 
2000c 
Thermo Fisher Scientific  Stafford House, 1 Boundary Park, Hemel 
Hempstead HP2 7GE 
Thermo cycler DNA engine 
Tetrad 2 
Bio Rad  Bio-Rad Laboratories Ltd. The Junction, 
Station Road, Watford, Hertfordshire, 
WD17 1ET 
Olympus CK400 Light 
Microscope  
Olympus  KeyMed House 
Stock Road 




2.1.2 Consumables  
 
Consumables Supplier Address 
BioLite Multidishes and Microwell 
plate (6 wells, 12 wells, 24 wells, 
96 wells) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
Falcon™ 50mL/15mL Conical 
Centrifuge Tubes 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
Fisherbrand™ Eppendorf 
Microcentrifuge Tubes (1.5ml, 
0.5ml, 200µl) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 




Pipet Tips and Filter Tips (0.5-
10µl, 1-200µl, 200-1000µl)  
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
Fisherbrand™ Sterile Polystyrene 
Disposable Serological Pipets 
(10ml, 5ml, 25ml) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
GE Healthcare Amersham™ 
Hyperfilm™ MP 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
MicroAmp® Fast Optical 96-Well 
Reaction Plate, 0.1 mL  
Applied Biosystems 
by Life Technologies 
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
MicroAmp® Optical Adhesive Film 
(100 covers) 
Applied Biosystems 
by Life Technologies 
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
MicroAmp® Splash-Free 96-Well 
Base 
Applied Biosystems 
by Life Technologies 
3 Fountain Drive, Inchinnan Business 
Park, Paisley PA4 9RF, UK 
Nalgene™ Cryogenic Vials (1.5ml) Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
Nunc™ EasYFlask™ Cell Culture 
Flasks (T25/T75) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
Sterilin™ Standard 90mm Petri 
Dishes 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 




Thermo Scientific™ Sterile White 
Top 5ml Vials   
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG 
 
2.1.3 Reagents  
 
Reagents /Chemicals Supplier  Address  
10% SDS Solution Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
100ML Ethanol, Absolute (200 
Proof), Mol Biology Grade, 
DNase, RNase & Protease-Free 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
1Kb Plus DNA Ladder 
(Invitrogen) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
250ng Random Primers  Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Accumax Solution Sigma-Aldrich  Sigma-Aldrich Company Ltd. The Old 




Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Acetic acid glacial  Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Table 2.3 List of main reagents and chemicals. 
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Acetone  Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Agarose 50g  Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Ammonium Persulfate powder 
25g 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Bovine Serum Albumin (BSA) 
powder 100g 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Brilliant Blue (Coomassie) 25g Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 




et al., 2014) 
Institute of Pharmacy, Martin-Luther 
University Halle-Wittenberg, Wolfgang-
Langenbeck-Str. 4, 06120 Halle, Germany 
Coumaric Acid powder 5g Sigma-Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Dimethyl sulfoxide (DMSO) Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
dNTP set: dATP, dTTP, dCTP, 
and dGTP (100mM each) 
(Invitrogen) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Doxorubicin powder (100mg/ml 
DMSO) 
Sigma- Aldrich  Sigma-Aldrich Company Ltd. The Old 




Kodak Developer and Fixer (1 
gal each)  
Sigma- Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
DRAQ 5 Staining solution 
5.0mM 
Biostatus  56A Charnwood Road, Shepshed, 
Leicestershire, LE12 9NP, United Kingdom 
G418 (Invitrogen) Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ DMEM/F-12, HEPES, No 
Phenol Red 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ Foetal Bovine Serum Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ Foetal Bovine Serum, 
charcoal stripped  
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ L-Glutamine 200mM Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ Penicillin-Streptomycin 
(5,000 U/mL) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ Rabbit Serum 500ml Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ RPMI 1640 Medium, no 
glutamine 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ RPMI 1640 Medium, No 
Phenol Red 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Gibco™ TrypleExpress Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
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Glycine powder 5kg Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Hydrogen Peroxide 30% in 
water (w/w) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Isopropanol, Molecular Biology 
Grade 500ml 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Lapatinib powder (20mg/ml 
DMSO) 
Sigma- Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Luminol powder 2g Sigma-Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Methanol Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Methylene Blue 100g Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
MTT reagent A 50mg/vial (5 
vials) 
Millipore  Suite 21, Building 6, Croxley Green Business 
Park Watford Hertfordshire WD18 8YHUnited 
Kingdom 
Non-fat skimmed milk powder   Marvel  Premier House, Centrium House, Centrium 
Business Park, Griffiths Way, St Albans AL1 
2RE 
Paclitaxel powder (50mg/ml 
DMSO) 
Sigma- Aldrich  Sigma-Aldrich Company Ltd. The Old 




Phosphate Buffered Saline (PBS) 
no magnesium and calcium 1x 
Lonza Lonza, Unit 5, Brunel Drive, Stretton Business 
Park, Stretton, Burton on Trent  
Staffordshire DE13OBY 
Phosphate Buffered Saline (PBS) 
1 x pH 7.4 
Severn Biotech Severn Biotech Limited, Unit 2, Park Lane, 
Kidderminster, Worcestershire, DY11 6TJ 
PrecisionPLUS™ 2X qPCR 
Mastermix with SYBR Green, 
low ROX 
Primerdesign  Primerdesign, The Mill Yard, Nursing Street 
Southampton SO16 0AJ 
Prestained Protein Ladder 10-
250kDa 
 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
REDTaq® ReadyMix™ PCR 
Reaction Mix (20mM Tris-HCl, 
pH 8.3, with 100 mM KCl, 3 mM 
MgCl2, 0.002 % gelatin, 0.4 mM 
dNTP mix (dATP, dCTP, dGTP, 
TTP), stabilizers, and 0.06 
unit/mL of Taq DNA 
Polymerase) 
Sigma-Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
RNase, DNase Free Water Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
RNaseOUT™ Recombinant 
Ribonuclease Inhibitor -40 
units/μL (Invitrogen) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
RNeasy Plus Mini Spin Kit (50 
columns) 




Sodium Chloride powder 1kg Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Sodium Dodecyl Sulphate (SDS) 
White Powder 500g 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
SuperScript II Reverse 
Transcriptase Kit (10,000 units 
200U/µL). Also contains:5X First 
Strand buffer (250mM Tris-HCl 
(pH 8.3), 375mM KCl, 15mM 
MgCl2) and 100mM DTT 
(Invitrogen)  
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Sybr Safe DNA gel stain-10,000x 
concentrate in 
DMSO(Invitrogen)  
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Tamoxifen powder (2mg/ml 
DMSO)  
Sigma- Aldrich  Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Tris Base powder 5kg Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Triton X-100 (density 
1.067g/cm³) 100ml 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Tween 20 Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
Tri-Reagent  Sigma-Aldrich Sigma-Aldrich Company Ltd. The Old 




LB Broth Sigma-Aldrich Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Oxoid™ Agar Bacteriological Fisher Scientific Fisher Scientific, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG 
QIAprep Spin Miniprep Kit (50) Qiagen Skelton House, Lloyd St N, Manchester M15 
6SH 
Ampicillin (5g) Sigma-Aldrich Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Polyethylenimine (PEI) 250ml Sigma-Aldrich Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 
4XT 
Gibco™ Opti-MEM medium 
(100ml) 
Fisher Scientific Fisher Scientific, Bishop Meadow Road, 






Table 2.4 Primary and corresponding secondary antibodies used for western blot and 
immunocytochemistry.  *Antibody diluted in 5% BSA/TBST, ** Antibody diluted in 5% milk/TBST, *** 
Antibody diluted in blocking buffer (100µl TritonX-100, 95ml PBS and 5ml rabbit serum).  All 
secondary antibodies were diluted in the corresponding diluent used for primary antibodies.  
Primary Antibody Protein 
Size(kDa) 
Final Concentration  Secondary 
Antibody 
 Dilution  
*Brk (ICR100-Kamalati 
et al 1996) 
52 1 µg/ml Anti-Rat (Dako)  1:100 
**Anti-GAPDH 
(Abcam) 



























(Abcam) for ALT-PTK6. 




histone H2A∙X (Serine 
139) monoclonal 
antibody. (Millipore) 























receptor A/B (Cell 
Signaling Technology) 
























Abcam 330 Cambridge Science Park Rd, Milton, Cambridge CB4 0FL 
Cell Signaling 
Technologies 
New England Biolabs (UK) Ltd. 75-77 Knowl Piece Wilbury Way 
Hitchin, Hertfordshire SG4 0TY 
ECM Biosciences EMELCA Bioscience – Belgium, Kapucinessenstraat 30 B-2000 
Antwerpen, Belgium 
Millipore Suite 21, Building 6, Croxley Green Business Park Watford 
Hertfordshire WD18 8YHUnited Kingdom 
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2.1.5 Primers  
Gene Name (Final 
Concentration) 
Strand   Primer Sequence (5’-3’) 
PTK6 (1µM) Forward ATGAAGAAGCTGCGGCACAA 
Reverse CCGAAACGGGCAGGACTT 
β actin (1µM) Forward AAGAGAGGCATCCTCACCCT 
Reverse TACATGGCTGGGGTGTTGAA 
Gene Name (Final 
Concentration) 
Strand  Primer Sequence (5’-3’) 
RPL13A (400nM) Forward CCTGGTCTGAGCCCAATAAA 
Reverse CTTGCTCCCAGCTTCCTATG 
SDHA (400nM) Forward TGGGAACAAGAGGGCATCTG 
Reverse CCACCACTGCATCAAATTCATG 
PTK6 (300nM) Forward GGTGGAGTCGGAACCGTGG 
Reverse GTAGTCGGCACTCGGCTTC 




Table 2.5 PCR primer sequences.  Primer sequences were verified using the primer BLAST -NCBI 
tool. 
Table 2.6 qPCR primer sequences for reference genes (RPL13A and SDHA) and genes of interest 
(PTK6 and ALT-PTK6).  Primer sequences were verified using the primer BLAST -NCBI tool. 
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2.1.6 Recipes  
2.1.6.1 Immunocytochemistry Recipes  
Buffer Triton X-100 
volume (µl) 
PBS volume (ml) Rabbit Serum 
volume (ml) 
Permeabilization Buffer 500 99.5 0 
Blocking Buffer  100 95.0 5 
Wash Buffer 100 99.9 0 
 
2.1.6.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE), Western 
blotting and Coomassie staining recipes 
 
 10x SDS PAGE Running Buffer: 30.2g Tris base, 188g Glycine and 100ml 10% 
SDS dissolved in 1L H2O 
 1x SDS PAGE Running Buffer: 100ml 10x SDS PAGE running buffer and 900ml 
H2O 
 10x Towbin (Transfer) Buffer: 30g Tris base, 144g Glycine and 1L H2O 
 1x Transfer Buffer: 100ml of 10x Transfer buffer, 800ml H2O and 100ml of 
methanol 
 10x Tris buffered saline (TBS): 60.5g Tris base and 87.6g sodium chloride, pH 
7.6 and 1L H2O 
 1 x TBS Tween 20 (TBST):  100ml 10x TBS, 900ml H2O and 1ml Tween 20 
(Fisher Scientific). 
Table 2.7 Recipe for buffers used in immunocytochemistry (final concentrations). 
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 5 % Blocking Buffer: 2.5g non-fat skimmed milk powder (Marvel) and 50ml 1x 
TBST  
 Antibody diluent: 
o 0.5g Bovine Serum Albumin (BSA) (Fisher Scientific) and 10ml 1x TBST. 
o 0.5g non-fat skimmed milk powder (Marvel) and 10ml 1x TBST. 
 Enhanced Chemiluminescence (ECL) solution: 
o 100Mm Tris:  1.214g Tris base in 100ml H2O. 
o Coumaric Acid (Sigma Aldrich): 0.0148g in 1ml Dimethyl Sulfoxide (DMSO). 
o Luminol (Sigma Aldrich): 0.0443g in 1ml DMSO. 
o Solution A:  22µl coumaric acid and 55µl luminol in 3ml 100mM Tris pH8. 
o Solution B:  3µl hydrogen peroxide (Fisher Scientific) in 3ml 100mM Tris pH8.  
 10 % SDS: 10g SDS and 100ml H2O. 
 10% Ammonium Persulfate (APS): 0.5g APS in 5ml H2O. 
 Coomassie Blue: 300ml H2O, 150ml methanol (Fisher Scientific), 50ml Acetic 
acid (Fisher Scientific) and small drops of Brilliant Blue for colourisation. 
 Destain: 450ml H2O, 450ml methanol and 100ml Acetic acid. 
 1M Tris: 30.29g Tris base and 250ml H2O, pH 6.8. 




Table 2.8 2x SDSPAGE Loading buffer recipe. 
Reagent  Volume (ml) 
Glycerol  2 
1M Tris-HCL Ph 6.7 1 
Β-mercaptoethanol (Fisher Scientific) 0.5 
10% SDS 4 
HPLC pure water 2.5 





2.2.1 Breast cancer cell lines  
The immortalized non-transformed (non-tumorigenic) cell line MCF10A was used as a close 
representative of normal mammary epithelial cells.  The MCF10A cell line was derived from 
human fibrocystic mammary tissue and lacks expression of typical breast cancer receptors, 
for example, oestrogen receptor (ER) (Soule et al., 1990).   
T47D cell line was derived from pleural effusion obtained from a 54-year-old female patient 
with infiltrating ductal carcinoma and is representative of Luminal A subtype of breast cancer 
(Keydar et al., 1979).  GI101 is ER negative and derived from an infiltrating ductal breast 
carcinoma xenograft and representative of a metastatic model for breast cancer (Daoud, 
Table 2.9 SDS-PAGE resolving gel recipe with total volume 10ml. 
Reagent Volume for 10% gel  Volume for 12% gel Volume for 15% 
gel 
dH2O 4ml 3.3ml 2.3ml 
30% acrylamide 3.3ml 4ml 5.0ml 
1.5M Tris pH 8.8 2.5ml 2.5ml 2.5ml 
10% SDS 100µl 100µl 100µl 
10% Ammonium Persulfate (APS) 100µl 100µl 100µl 
Tetramethylethylenediamine 
(TEMED) 
4µl 4µl 4µl 
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Leathers and Hurst, 2002).  SKBR3 cell line is ER negative and progesterone receptor (PR) 
negative but overexpresses human epidermal growth factor receptor 2 (HER2) and was 
established from the pleural effusion of a 43-year-old Caucasian female with malignant 
adenocarcinoma (Fogh and Trempe, 1975; Fogh, Fogh and Orfeo, 1977).  BT474 cell line is 
derived from a 60-year-old female patient with invasive ductal carcinoma and is 
representative of Lumina B type as well as HER2 positive breast cancer (Lasfargues, 
Coutinho and Redfield, 1978).  MDA-MB 231 was derived from a pleural effusion of a 51-
year-old patient with adenocarcinoma (Cailleau et al., 1974).  MDA-MB 436 cell line was 
derived from the pleural effusion of a 43-year-old female patient with infiltrating ductal 
carcinoma (Cailleau, Olivé and Cruciger, 1978).  MDA-MB 157 cell line was derived from 
pleural effusion of a 44-year-old female patient with metaplastic carcinoma (Langbois et al., 
1979) whereas the MDA-MB 468 cell line was derived from pleural effusion of a 51-year-old 
female patient with adenocarcinoma (Cailleau, Olivé and Cruciger, 1978).  All the MDA-MB 
cell lines used in my studies are representative of triple negative or basal like breast cancer 
subtype.  All cell lines were originally purchased from American Type Culture Collection 
(ATCC).  Table 2.10 shows summary of breast cancer cell lines corresponding to their breast 
cancer subtype and their characteristics.  Fresh stocks of each cell line were used.  Cell lines 
were verified after culturing through morphology check by microscope and cell growth curves 
compared to literature.  Cell lines were routinely checked for mycoplasma contaminations by 









2.2.2 Transfected Cell lines 
The triple negative, Brk negative cell lines; MDA-MB 468 and MDA-MB 157 were originally 
purchased from ATCC and had previously been transfected with the pRc/CMV empty vector 
(Vector) or vector containing the cDNA for wild type Brk (Brk-WT) or kinase inactive Brk (Brk-
KM) as previously described (Harvey et al, 2009).  Briefly cells had been transfected at 3:1 
ratio with Fugene (Roche) and DNA.  Cells were incubated for 48 hours before sub-culturing 
into fresh medium containing 400µg/ml G418 (Invitrogen).   
 
2.2.3 Cell culturing protocol 
 
Tissue culture was performed in a designated tissue culture laboratory within a sterilized and 
Table 2.10 Breast cancer subtypes and corresponding cell lines.  ER= oestrogen receptor, 
PR= progesterone receptor, HER2= human epidermal growth factor receptor 2.  
Breast Cancer 
Subtype  
Characteristics  Cell line Supplier  
Luminal A ER+, PR+/- and HER2- T47D,  American type 
culture collection 
(ATCC) 
LGC Standards  






Luminal B ER+, PR+/- and HER2+ BT474 
Basal Like ER-, PR- and HER- MDA-MB 157, MDA-
MB 468, MDA-MB 
231 and MDA-MB 
436 
HER2 positive  ER-, PR- and HER+ SKBR3, BT474 
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filtered LaminAir Class II tissue culture hood.  The hood was maintained weekly by thorough 
cleaning with Trigene (Distel) and 70% industrial methylated spirit (IMS).  All materials and 
reagents were sterile before being used and all equipment was cleaned with 70% IMS before 
use within the laminar flow hood.  MCF10A cells were grown in 1:1 HamsF12: Dulbecco’s 
Modified Eagle’s medium (DMEM) (Fisher Scientific) and supplemented with the following:  
100 Uml-1 Penicillin-Streptomycin (Fisher Scientific), 10% foetal bovine serum (FBS) 
containing high content of embryonic growth promoting factors (Fisher Scientific), 2.0 mM L-
Glutamine, 5ng/ml epidermal growth factor (EGF), 1 µl/ml hydrocortisone and 5 µg/ml insulin 
(Fisher Scientific).  The MCF10A cell line was sub-cultured once a week, once confluent.  The 
GI101 cell line was cultured with Roswell Park Memorial Institute (RPMI) 1640 medium 
(Fisher Scientific) supplemented with 10% FBS, 2.0 mM L-Glutamine, 100 Uml-1Penicillin-
Streptomycin and 5µg/ml insulin.   The remainder of the cell lines (T47D, SKBR3, BT474, 
MDA-MB 231, MDA-MB 436, MDA-MB 157 and MDA-MB 468) were cultured in RPMI 1640 
medium supplemented with 10% FBS, 100 Uml-1 Penicillin-Streptomycin and 2.0 mM L-
Glutamine.  The MDA-MB 468 and MDA-MB 157 transfected cell lines were additionally 
supplemented with 400 µg/ml G418 (Invitrogen), an aminoglycoside antibiotic. All these 
breast cancer cell lines were sub-cultured at least twice a week depending on them reaching 
70-80% confluency.  Cell lines were grown in either a T25 or T75 tissue culture flask (Fisher 
Scientific) and cultured at 37˚C and 5% carbon dioxide (CO2) in a humidified incubator.  To 
subculture, cells were washed with 1x phosphate buffered saline (PBS) (Severn Biotech) 
twice before detaching cells from the flask with TrypleExpress (Fisher Scientific) and 
incubated at 37˚C, 5% CO2 for 2-5 minutes.  Cells were resuspended in the appropriate 
medium at ratio of 1:5 TrypleExpress/medium.  The cell mixture was then mixed thoroughly 




2.2.4 Cell cryopreservation and thawing  
 
In order to maintain cells and for long-term storage of cells, cryopreservation was performed.  
To preserve cells, cells were grown to 80% confluency in two or more T75 flasks.  The 
medium was removed, and cells were washed with 1x PBS; trypsinisation with  TrypleExpress 
was carried out as before and incubation at 37˚C and 5% CO2 for 2-5 minutes.  Once cells 
were detached, they were resuspended in fresh 8ml of the appropriate medium.  The 
suspension from each flask was then pipetted into a sterile 50ml Falcon tube (Fisher 
Scientific) before being centrifuged at 1500 revolutions per minute (rpm) for 5 minutes.  The 
supernatant was removed, and cell pellet resuspended with 10% dimethyl sulfoxide (DMSO) 
(Fisher Scientific) in the appropriate medium and mixed thoroughly. Approximately 1ml of the 
mixture was added to a 1.5ml cryovial (Fisher Scientific- Nalgene Cryogenic Vials) and placed 
in a cryovial rack within a liquid nitrogen dewar to begin slow freezing of the cells for 2 hours 
before placing the rack deeper in the dewar overnight and finally submerging the cryovials 
into the liquid nitrogen completely within a cryovial box.   
To thaw cells from cryopreservation, the appropriate culturing medium was left to warm in a 
water bath set to 37˚C before pipetting into a T25 flask.  A vial of cells from cryopreservation 
were taken out of liquid nitrogen and thawed within the water bath before being sprayed with 
70% IMS and placed inside the tissue culture hood.  The cells were diluted in the appropriate 
medium (1:10) and centrifuged (1000rpm for 4 mins) to remove DMSO before decanting the 
supernatant and adding l fresh medium and placed in an incubator at 37˚C and 5% CO2 for 
24 hours before removing the medium and adding fresh medium in order to remove any 
remaining DMSO.   
74 
 
2.2.5 Cell counting and cell growth curves 
 
Cells were trypsinised as described in above and the cell suspension pipetted into a 50ml 
Falcon tube.   The tube was centrifuged at 1500 rpm for 5 minutes.  Meanwhile, the 
haemocytometer was prepared with the coverslip placed tightly onto the surface.  The 
medium was removed from the tube carefully so as not to disturb the cell pellet and cells 
suspended in fresh medium.   A 10µl aliquot  was pipetted into the haemocytometer chamber 
for cell counting.  The middle 5x5 square was counted.   The number of cells counted was 
used to obtain the appropriate volume of cell suspension needed and the rest of the volume 
was made up by adding the appropriate amount of medium. For cell proliferation curves, 
0.04x106 cells/cm2 were seeded in a 24 well plate.  The 24 well plate was incubated, and 
cell numbers determined by haemocytometer counting daily for 6 consecutive days in order 
to determine cell numbers.  Medium was aspirated out of 4 wells, cells were washed with 
PBS and detached with 200µl of TrypleExpress from each well before adding 200µl of fresh 
medium.  Cells were counted using a haemocytometer.  To determine total number of cells, 
the number of cells counted in the middle square of the haemocytometer was multiplied by 
104 and the dilution factor (0.4).  Growth curves were generated to show growth rate of each 
cell line.  
2.2.6 Radiation Treatments 
 
2.2.6.1 Clonogenic Assays 
 
Cells were harvested, counted as before and diluted to 1000 cells per ml (for 0Gy and 2Gy 
γ-radiation doses), 1500 cells per ml (for 4Gy dose) and 2000 cells per ml (for 6Gy and 8Gy 
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doses) in medium and pipetted into sterile 10cm petri dishes (Fisher Scientific).  Cells were 
subjected to γ-irradiation using the high energy 60Cobalt source (Puridec Technologies Ltd) 
at 2,4,6 and 8Gy.  The exposure time for the 2Gy dose was determined by the distance from 
the radiation source (25cm) and the known current emission rate.  Once the 2Gy exposure 
time was complete the petri dishes with 2Gy dose were removed and the rest of the petri 
dishes exposed to a further 2Gy dose for the 4Gy dose.  This continued until the desired 
accumulative doses were reached. After irradiation, 1ml of each cell suspension was pipetted 
into each of three petri dishes per dose.  The petri dishes were kept in the incubator at 37ºC 
and 5% CO2 for up to two weeks to allow for formation of colonies.  
 
2.2.6.2  Fixing and staining cells for clonogenic assays 
 
To fix and stain cells, IMS and methylene blue solution (0.01% w/v in distilled water) were 
used.  Medium was decanted, and cells were washed with 1x PBS and then fixed in 100% 
IMS for 20 minutes inside the sterile tissue culture hood.  Once fixed, the IMS was removed 
and petri dish briefly rinsed under running tap water.  Methylene blue solution was then added 
to the petri dish at sufficient volume to cover the surface of the petri dish and left overnight to 
stain the cells.  The methylene blue solution was then removed, and the petri dishes washed 
with H2O to remove the excess stain before being left to air dry. Once the dishes were dry, 
the number of blue dots representing colonies were counted. Approximately 50 cells 
constituted one colony formation.   Survival curves were plotted as percentage of control in 
semi-log form as follows: 
Control - 0Gy (100%). 
Radiation dose 2Gy - (number of colonies at 2Gy / (number of colonies at 0Gy)) x 100 
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Radiation dose 4Gy - (number of colonies at 4Gy/ (number of colonies at 0Gy x1.5)) x 100 
Radiation dose 6 and 8Gy - (no colonies at 6 or 8Gy/ (no of colonies at 0Gy x 2)) x 100 
 
2.2.6.3  γ-H2AX DNA Repair Assay 
 
γ-H2AX DNA repair assays were carried out to investigate levels of DNA repair occurring 
using γ-H2AX as a DNA repair marker.  2x106 cells were seeded into petri dishes for each 
time point (30 minutes, 3 hours, 5 hours and 24 hours) along with control and compensation 
samples.  Compensation samples were needed to compensate for the overlap between two 
channels of the Imagestream machine due to fluorescence leakage from nearby channels.  
Cells were then irradiated with 2Gy gamma radiation as previously described (section 2.2.6).  
Cells were processed and fixed at 30 mins, 3 hours, 5 hours and 24 hours post radiation. The 
Alexaflour 488 (AF) and Draq5 (D5) compensation plates were exposed to radiation and fixed 
at the 30 minutes time point.  The fixing procedure for 30 minutes, AF and D5 compensation 
samples was started immediately on return to the laboratory.  Control un-irradiated samples 
were fixed prior to radiation.  To fix, the medium was decanted, the cells were washed with 
1x PBS, trypsinised with TrypleExpress as previously described and resuspended in fresh 
media.   The cell suspension was transferred to a sterile 50ml Flacon tube and centrifuged at 
1500rpm for 5 minutes before being washed with ice cold 1x PBS (Severn Biotech).  The 
cells were then fixed by resuspension in methanol/acetone solution (50:50 v/v) and 
transferred to a 1.5ml microcentrifuge tube. Fixed cells were then stored at -20°C until ready 
to process for the next step.   
 




The fixed cells were centrifuged at 3000 rpm for 3 minutes and the methanol/acetone solution 
removed by aspiration.  Cell pellets were rehydrated by resuspending in 1x PBS and placed 
on the rotary mixer for 5 minutes at 25rpm (at room temperature).  Tubes were centrifuged 
as before, and PBS removed.  Permeabilizing buffer (0.5% Triton X-100 solution (Sigma-
Aldrich) in 1x PBS) was added to each of the tubes and mixed thoroughly (but gently), placed 
on the rotary mixer for 5 minutes before centrifuged at 3000 rpm for 3 minutes.  The 
permeabilizing buffer was then removed by centrifugation and aspiration and the cells 
resuspended in blocking buffer (5% rabbit serum (Biosera) and 0.1% Triton X-100 in 1x PBS) 
and then placed on the rotary mixer for 1 hour at 25rpm. The samples were then removed 
from the rotary mixer and centrifuged at 3000 rpm for 3 minutes before the blocking buffer 
was removed by aspiration.  Primary antibody; anti-phospho-histone H2AX (Serine 139) 
monoclonal antibody (Millipore) was diluted in blocking buffer (1:10000 dilution), and 500µl 
added to each tube. The cells were then incubated overnight at 4°C with rotation at 25rpm 
using the rotary mixer.    
The following day, the cells were centrifuged at 3000rpm for 3 minutes and the primary 
antibody removed.   The cell pellet was then resuspended in wash buffer (0.1% Triton X-100 
in PBS) and incubated for 5 minutes with 25rpm rotation.  The cells were resuspended in 
fresh wash buffer and incubated with rotation as before. Once the wash buffer was removed, 
the secondary antibody, Alexa Fluor 488 rabbit anti-mouse IgG antibody (Invitrogen) was 
prepared as a 2 mg/ml dilution and 500µl was added to each sample except for the D5 
compensation samples which were resuspended in blocking buffer without antibody.   The 
samples were covered in foil and left to incubate at room temperature on the rotary mixer 
(25rpm) for 1 hour.  Table 2.7 (Section 2.1.6) lists all the buffers and their composition.  
Samples were removed from the rotary mixer and centrifuged at 3000rpm for 3 minutes 
78 
 
before aspirating the secondary antibody.  Then wash buffer was added to each tube and 
rotated on a tube rotator for 5 minutes at 25rpm.  The samples were centrifuged as before, 
and the wash buffer removed by aspiration.  The cells were washed with the wash buffer a 
second time before they were resuspended with 100µl of Accumax solution.  All samples 
were stored at 4°C overnight covered in foil if not processed immediately. 
 
2.2.6.5  Imagestream Analysis 
Samples were removed from the rotary mixer and centrifuged at 3000rpm for 3 minutes 
before aspirating the secondary antibody.  .  The cells were washed with the wash buffer 
twice before they were resuspended with 100µl of Accumax solution.  All samples were stored 
at 4°C overnight covered in foil if not processed immediately.  The samples were then stained 
with Draq 5 (D5) staining solution (1:100 D5/Accumax ratio) except for the Alexa Fluor (AF) 
compensation samples and ready for analysis with the Imagestream IDEAS software 
(Amins).    Table 2.11 indicates the parameters used for my experiments for all Imagestream 
analysis.  For each time point a minimum of 10,000 events or cells were captured for analysis.  
Cell classifiers identified the size of object to be collected by the Imagestream for analysis,  
Channel 1 showed Brightfield images of cells which showed a live image of the cell as it was 
collected and processed by the Imagestream (Figure 2.1).  Channel 2 was used to show 
staining of the primary antibody (anti-phospho-histone H2AX (Serine 139) monoclonal 
antibody) with Alex Fluor 488 as secondary antibody.  This was shown as a green colour 
representative of induction of γ-H2AX foci.  Channel 5 indicated nuclear staining of the cell 
using D5 which is represented as a blue colour.  After acquisition of cells, the IDEAS software 
was used to analyse the cells.  The cell population was first narrowed to include only single 
cell population thus eliminating any clusters of cells.  This was done by manual examination 
of objects collected and ‘gating’ of the cell population to only include single cells. Only cells 
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in focus were used for analysis and these were selected by determining gradient of cells 
based on image focus and the normalized frequency.  Cell population was further selected 
by determining best stained cells and the cells that were negative for γ-H2AX staining in order 
to additionally ‘gate’ cells based on staining intensity of the primary antibody.  The spot 
counting analysis wizard prompted the selection of low and high number of foci which were 
user determined.  The images were selected based on range of features including, size, 
shape, fluorescence intensity and number of foci for each selection of the low and high truth 
populations . These truth populations were used to create masks in order to determine γ-
H2AX foci enumeration in each cell.  The nuclear morphology mask was created first using 
the DRAQ 5 channel and then the spot mask for channel 2 (Figure 2.2).  Using both masks, 
a combined mask was created in order to determine the number of foci within the nuclear 
region of the cell.  The number of foci in cells were counted using the ‘Features’ option in the 
IDEAS analysis software and a histogram was plotted of normalised frequency of foci against 
the foci number.  This template was saved and applied to all time points for each cell line.  











Figure 2.1 Images captured by the Imagestream .  Channel 1 shows the live image of the cell 
(Brightfield).  Channel 2 shows the primary antibody staining of the cells in green and channel 5 





Figure 2.2 Masking of γ-H2AX foci for enumeration.  Masking identified region of interest and 
Nuclear morphology using channel 5 was created.  The spot mask was generated based on the 
selection of ‘truth population’ whereby a range of images were selected  with foci ranging from zero 
to 30 or more.  The spot mask was generated for ch02 with the γ-H2AX staining. The two masks 
were combined to create a new mask which identified number of foci within a specific nuclear 
















2.2.6.7  Image Compensation 
Image compensation involves compensating for the overlap between two channels of the 
Imagestream machine due to fluorescence leakage from nearby channels.  Along with the 
samples prepared to be fixed at 0. 0.5, 3, 5 and 24 hours, two extra samples were fixed at 30 
minutes for image compensation.   Images were captured of cells at 488nm wavelength only 
and no Brightfield illumination.  Cells with AF and D5 only staining were used for the 
compensation matrix. The Imagestream software compensation wizard (IDEAS software 
from Amins) provides a table of coefficients and the produced light placed into the correct 
channel, with channel 2 for the antibody and channel 5 for Draq 5 only. After normalization, 
any calculated compensation was automatically applied to rest of the samples. 
Table 2.11 Imagestream parameters for analysis.  
Imagestream Parameters 
Channels  Channel 1: Brightfield 
 Channel 2: Alex Fluor 488 stain 
 Channel 5: Draq 5 stain 
 Channel 6: Side Scatter 
Target Total Number of 
Events (cells) to be acquired 
 Dose samples: 10,000 events 
 Compensation samples: 1000 events 
Lasers  Brightfield laser intensity approximately at 
800 
 Excitation laser 488nm = 60.0Mw 
 Excitation laser 785nm =1.00mW 
Fluidics  Diameter = 10 microns 
 Core Velocity approximately 60mm/sec 
 Percent beads =7 
Cell Classifier Used for channels 1,2 and 5. 
 Lower limit = 50 
 Upper limit = 250 
Channel Colours and Gain 
values 
 Channel 1: White, Gain Value=3 
 Channel 2: Green, Gain Value = 6 




2.2.6.6  Determination of total and phosphorylated ATM protein levels 
 
Breast cancer cell lines; MDA-MB 468 Brk WT, Brk KM, vector a well as cell lines; MDA-MB 
157 Brk WT, Brk KM were exposed to 2Gy gamma radiation as described in section 2.2.6.1.  
The method for γ-H2AX DNA repair assay (section 2.2.6.3) was followed but with total ATM 
and phospho-ATM antibodies (section 2.1.4, Table 2.4).  .  For detection of total and 
phosphorylated ATM protein levels, cells were labelled with primary antibody (1.500) diluted 
in blocking buffer and incubated foe 24 hours at 4˚C with gentle agitation.  Mouse monoclonal 
antibody ATM for C-terminal region (ECM Biosciences) was used for total ATM detection and 
rabbit polyclonal for phosphorylated serine794 of the ATM protein (ECM Biosciences) to 
detect phosphorylated ATM. Following washes as described in section 2.2.6.4, cells (except 
D5 compensation cells) were stained with rabbit anti-mouse or goat anti-rabbit secondary 
antibody solutions containing Alexa Fluor488 IgG (diluted to 1:1000 in blocking buffer) to 
detect total and phosphorylated ATM levels respectively.  Cells were incubated for 1 hour at 
room temperature, washed with wash buffer and left overnight at 4˚C in Accumax solution.  
D5 solution was added to each sample except Alexa Fluor488 compensation cells and cells 
were analysed as described previously (section 2.2.6.5).  Analysis of total and phospho-ATM 
protein in control un-irradiated and irradiated cells involved identification of the nuclear region 
of the cells using masking feature of the Ideas Software and the fluorescent intensity of the 
cells calculated by determining the intensity of channel 2 (Alex Fluor488) within the nucleus 
and the mean levels of antibody staining were recorded to represent ATM protein levels in 
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the cells.     
 
2.2.7 Drug Treatments  
 
At the time of the studies there were no commercially available Brk inhibitors.  However after 
the discovery of 4-anilino α-carbolines as novel Brk inhibitors, compound 4f was identified as 
the most potent and selective Brk inhibitor (Mahmoud et al., 2014).  Thus, compound 4f was 
obtained from Hilgeroth and group for the experiments.    Compound 4f was weighed and 
dissolved in DMSO (5.506mg/ml) and filter sterilized to give a stock concentrations of 20mM, 
and stored in -80˚C.   Paclitaxel/Taxol (50mg/ml in DMSO), Doxorubicin (100mg/ml in 
DMSO), Lapatinib (20mg/ml in DMSO) and Tamoxifen (2mg/ml in DMSO) were purchased 
from Sigma-Aldrich, dissolved in DMSO at stock concentrations of 10 or 20mM, filter sterilized 
and stored at -20˚C.  
For each drug, serial dilutions were performed in vehicle (DMSO) to produce 1000-fold stock 
solutions; the drugs were diluted 1:1000 in appropriate culture medium and added to the 96 
well plate. The final concentrations used for compound 4f treatment were: 0.625µM, 1.25µM, 
2.5µM, 5µM, 10µM, 20µM with DMSO as a control.   The final concentrations used for Taxol 
or Doxorubicin single agent treatments and in combination with compound 4f (5µM) were: 
0.15µM, 0.3125µM, 0.625µM, 1.25, 2.5µM and 5µM along with DMSO control.  Final 
concentrations for lapatinib as single or combination treatment with compound 4f (5µM) were: 
0.3125µM, 0.625µM, 1.25µM, 2.5µM, 5µM, 10µM and DMSO as control.  Final concentrations 
for Tamoxifen as single or combination treatment with compound 4f (5µM) were: 0.3125µM, 
0.625µM, 1.25µM, 2.5µM, 5µM, 10µM and DMSO as control.  For Tamoxifen treatments, due 
to the presence of oestrogen in growth serum and phenol red being a weak oestrogen 
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(Berthois, Katzenellenbogen and Katzenellenbogen, 1986); cells were cultured and seeded 
as normal but medium  was changed to RPMI 1640 Medium, No Phenol Red (Fisher 
Scientific) and supplemented with 10% charcoal stripped foetal bovine serum (Fisher 
Scientific), 2.0 mM L-Glutamine and 100 Uml-1Penicillin-Streptomycin before addition of the 
drug. 1:1000 dilution of DMSO was used as control for all treatments. For each drug 6 wells 
were used per concentration for single treatments.  For combination treatments, half the 96 
well plate was used for the anticancer agent as a single treatment and the other half for 
combination with compound 4f.  . The 96 well plate layout is shown in Figure 2.2.6 
For analysis of PTK6 and ALT-PTK6 transcripts in response to compound 4f treatment or the 
anticancer drugs mentioned above, cells were seeded in 6 well plate at density of 2x105.  
Cells were incubated (37˚C, 5% CO2) over night before the appropriate drug concentration 
was added in each well.  5µM was used for compound 4f, Taxol, Doxorubicin or Tamoxifen 
treatment whereas 2.5µM (this was the IC50 dose in combination treatment with compound 
4f) was used for Lapatinib treatments.  .   Along with a treated 6 well plate, an untreated 
control plate was prepared.  RNA lysates using RNeasy Mini Spin Column extraction kit 
(Qiagen) as shown in section 2.2.15.3, were collected at the following time points for each 
cell line or treatment: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  cDNA and qPCR 
were performed as previously described (Chapter 2, sections 2.2.17 and 2.2.20).   
For analysis of protein expression and activity of Brk isoforms, Brk substrate STAT3 and 
breast molecular markers (HER2/ER) in response to Brk inhibition (5µM of compound 4f), 
cells were seeded in a 6 well plate or T25 flask at density of 3-7x105 (depending on confluency 
and proliferation rate of cell line).   Protein lysates were taken at the following time points after 
treatment along with control lysate: 4 hours, 6 hours, 24 hours and 48 hours.  Western blots 




2.2.8 MTT assay protocol 
. 
Cells were harvested by trypsinisation and 5x103 cells were counted as described in section 
2.2.5 and seeded per well in a 96 well plate.  The 96 well plate was incubated overnight at 
37°C and 5% CO2 before addition of the appropriate drug/s.     
The 96 well plates were then incubated at 37˚C, 5% CO2 for 7 days with fresh medium and 
drug added every 2/3 days.  MTT reagent (50mg per vial) was purchased from Millipore and 
diluted to stock concentrations of 5mg/ml with 1x PBS and stored at -20˚C.  After incubation, 
the medium and drug mixture was removed.  The MTT reagent was further diluted in 1:10 
with the appropriate medium. The 96 well plate was incubated at 37˚C, 5% CO2 for 2 hours.  
After which the mixture was poured out and the formazan was dissolved by addition of 100µl 
0.04M HCI isopropanol (Fisher Scientific) per well before absorbance was read using a 
multiplate reader at wavelengths 570nm for MTT and 630nm for background.  Background 
absorbance was subtracted from absorbance for MTT (570nm-630nm) and the average of 
each concentration from 6 wells calculated.  Cell viability was determined as percentage of 
control for all MTT assays.  Graphs were plotted as average of n=3 repeats per treatment 
with standard deviation as error bars.  
 
2.2.9 Cell lysis  
 
To obtain protein lysates, cells were washed with 1x PBS twice, detached from the flask with 
TrypleExpress and resuspended in fresh medium.  Cells were centrifuged at 1500 rpm for 5 
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minutes before being resuspended in PBS. Cells were counted using a haemocytometer, 
centrifuged and the resulting cell pellet lysed with 100µl of hot 2x SDS-PAGE loading buffer 
per 1 million cells.  The 2x SDS-PAGE loading buffer recipe is shown in Table 2.8 (section 
2.1.6) and was preheated to 90˚C on a heat block within a fume cupboard.  The loading buffer 
and cell pellet were mixed together, and samples heated at 90˚C for denaturation of protein 
before snap cooling on ice.  Protein lysates were then briefly centrifuged using a table top 
microcentrifuge to collect contents and stored at -20˚C.   
 
2.2.10 Coomassie Staining 
 
For the Coomassie blue staining, the appropriate percentage of SDS PAGE resolving gel 
was prepared as shown in Table 2.9 (section 2.1.6).  Resolving gels were overlaid with 
ethanol which was removed once the gel had polymerised. A stacking gel was prepared 
using: 2.1mls of dH2O, 500µl of 30% acrylamide, 380µl of 1M Tris pH 6.8 for a total volume 
of 3ml per gel.  Gel electrophoresis was performed with 1X SDS-PAGE buffer and BioRad 
power pack was used to run the gel at 300 volts and 40mAps for 45 minutes.  Once the 
proteins had separated, the gel was stained with Coomassie blue (recipe: 300ml H2O, 150ml 
methanol (Fisher Scientific), 50ml Acetic acid (Fisher Scientific) and small drops of Brilliant 
Blue for colourisation) and left to incubate at room temperature on a shaker for 30 minutes.  
The Coomassie blue was drained off and the gel destained (450ml H2O, 450ml methanol 
and 100ml Acetic acid) with two 10-minute washes using destain before a final wash for 30 
minutes on an orbital shaker 
.     




Protein lysates were prepared as described above (section 2.2.13) and gel electrophoresis 
performed as described in section 2.2.14.  The proteins were then electro-blotted onto 
nitrocellulose membrane in 1x transfer buffer (100ml of 10x Transfer buffer, 800ml H2O and 
100ml of methanol) for 1 hour at 300 volts and 400mAps.  The membranes were then blocked 
in 5% non-fat skimmed milk/TBS-T (2.5g non-fat skimmed milk powder (Marvel) and 50ml 1x 
TBST) for another hour and incubated overnight at 4°C in primary antibodies. Primary 
antibodies were either diluted in 5% BSA/TBST (0.5g Bovine Serum Albumin (BSA) (Fisher 
Scientific) and 10ml 1x TBST) or 5% Milk/TBST (Table 2.4, section 2.1.4).   The membranes 
were washed in 1X TBST (100ml 10x TBS, 900ml H2O and 1ml Tween 20 (Fisher Scientific)) 
for three 15-minute washes before incubating for 1 hour with appropriate secondary 
antibodies (HRP-Conjugated Dako), diluted in 5% BSA/TBST or 5% milk/TBST (Table 2.4, 
section 2.1.4).  Membranes were washed as before with 1x TBST.  For detection and 
visualisation of protein bands, membranes were transferred to the dark room with red filter 
light and chemiluminescent substrate containing 0.0148g/ml of Coumaric acid and 
0.0443g/ml of luminol (solution A) and 1:1000 dilution of H2O2 (solution B) in 100mM Tris pH 
7.0, were added directly onto each membrane and incubated for 1 minute.  Substrates were 
drained off the membrane before placing between two pieces of clingfilm/saran wrap or 
plastic bag and gently smoothed to remove air bubbles.  The appropriate size of 
autoradiography film (Amersham Hyperfilm GE Healthcare) was added on top of the 
membrane and the cassette closed.  Exposure time was initially for 1 minute for each 
experiment before adjusting for optimum exposure time. Kodak Developer  mixed with  H2O 
(1:4 dilution) was used to develop the film for 1 minute before rinsing in water and fixed using 
Kodak Fixer mixed with approximately of H2O (1:4 dilution).  Membranes were then rinsed 




2.2.12 RNA extraction  
 
Cells for RNA extraction were prepared first by aspiration of the culture medium from the 
flask, washing with 1x phosphate buffered saline (PBS, Severn Biotech Ltd) then adding 
TrypleExpress (Fisher Scientific)and incubating at 37°C 5% CO2 for 2-5 minutes. Cells were 
resuspended in fresh medium before centrifugation at 5,000rpm for 5 minutes.   Cells were 
washed with 1x PBS (Severn Biotech Ltd) and cell pellets collected after centrifugation at 
5,000rpm for 5 minutes.  All RNA samples not processed immediately after extraction were 
stored at -80°C.  RNase Away or 70% IMS were utilized throughout RNA extraction, cDNA 
synthesis, RT-PCR and qPCR processing for prevention of RNase contamination and filtered 
tips were also used. RNA extraction was carried out using the following two methods. 
 
2.2.12.1 Tri Reagent RNA extraction  
 
For Tri-reagent (Sigma-Aldrich) RNA extraction, lysates were prepared by resuspending cell 
pellet in Tri-reagent (1ml per 5 x 106 cells) and stored at -80˚C until ready for processing.  The 
RNA extraction involved thawing the RNA lysate in ice at room temperature.  Once completely 
thawed, the homogenate was transferred to a smaller tube (1.5ml) and 200µl of chloroform 
(Fisher Scientific) was added per ml of lysate.   Chloroform causes the denaturing of the 
proteins within the cells thus making them soluble in the organic phase whilst the nucleic 
acids remain in the aqueous phase.  The tube was then shaken vigorously for 15 seconds 
and allowed to stand for 5 minutes at room temperature.   The mixture was then centrifuged 
at 12000 rpm for 15 minutes after which, the aqueous phase was carefully isolated and 
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pipetted into another pre-labelled tube.  1:2 ratio of  2-propanol to TRI reagent) (Fisher 
Scientific) was subsequently added to the tube with the aqueous phase and mixed. The 
mixture was allowed to stand at room temperature for 5 minutes then centrifuged at 12000 
rpm for 10 minutes.   The RNA precipitate formed a pellet at the side and bottom of the tube.  
The supernatant was then pipetted out carefully to avoid disturbing the pellet.  The RNA pellet 
was then washed with 1ml of 70% Ethanol.  The sample was vortexed and centrifuged at 
7500 rpm for 5 minutes.   Once the supernatant was removed, the RNA pellet was air dried 
at room temperature for 5-10 minutes avoiding drying it completely as it would decrease the 
solubility.   The final preparation of RNA was diluted in 50µL of sterile DNase/RNase free 
water.    
 
2.2.12.2 RNeasy Mini Spin Column Extraction (Qiagen) 
 
For quantitative-PCR, RNA was prepared using RNeasy mini Kit from Qiagen.  This is a 
commercially available kit that uses silica-membrane RNeasy spin columns to extract high 
quality purified RNA. The kit contains: RLT, RPE and RW1 buffers with RNase free water, 
RNeasy spin columns, 2ml and 1.5ml collection tubes.  Cell pellets were prepared as above 
for RNA extraction.  Lysates were prepared by adding 350µl of RLT buffer provided with the 
kit.  This is a denaturing buffer containing guanidine-thiocyanate which inactivates RNases 
to ensure purity of sample.  70% Ethanol was added at an equal volume to ensure appropriate 
binding conditions to the silica membrane.  Up to 700µl of the mixture was added to the 
RNeasy Mini spin column placed in a 2ml collection tube before centrifugation at ≥ 10,000rpm 
for 15 seconds. The flow–through was discarded before washing the RNeasy Mini spin 
column with 700µl of buffer RW1.  The column was centrifuged for 15 seconds at ≥ 10,000rpm 
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and flow-through discarded.  The spin column membrane was further washed with 500µl 
buffer RPE.  Buffer RPE was supplied as concentrate and a working solution was prepared 
by adding 4 volumes of 100% ethanol.  The mini spin column was then centrifuged for 15 
seconds at ≥ 10,000rpm before a second wash with 500µl of RPE buffer and centrifugation 
for 2 minutes at ≥ 10,000rpm.  This allowed the column membrane to dry ensuring no ethanol 
remains in the RNA elution process.  The RNeasy spin column was then placed in a new 2ml 
collection tube and centrifuged at full speed for 1 minute to ensure total elimination of the 
Buffer RPE.  The RNeasy spin column was then placed in a pre-labelled 1.5ml collection tube 
before adding 50µl of RNase-free water directly onto the spin column membrane.  The tube 
was then centrifuged for 1 minute at ≥ 10,000rpm to elute the RNA. 
 
2.2.12.3 RNA quantification and purity 
 
The RNA was diluted 1:4 in sterile DNase/RNase free water and 1µl of sample was placed 
onto the nanodrop machine (Spectrophotometer Nanodrop 2000c) and read for concentration 
of RNA at 260nm.  The results were presented in ng/µl.  Purity was determined by calculating 
absorbance ratio at 260nm and 280nm.  A ratio between 1.8-2.0 is generally determined to 
show pure RNA and free of DNA and protein contamination. 
 
2.2.13 Complementary DNA (cDNA) Synthesis 
 
Complementary DNA was synthesised using SuperScript II Reverse Transcriptase 
(Invitrogen) kit.  To begin with, RNA samples were defrosted on ice.  Once defrosted, 1µl of 
random primers (100ng) and 1µl of dNTP Mix (10mM each) were added to the appropriate 
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volume of RNA used for each sample.  The volume of RNA to use was calculated by: desired 
RNA concentration for cDNA synthesis (250ng/ul) /RNA concentration as determined by 
nanodrop reading (ng/µl).  Sterile distilled water was added for a total volume of 12µl.  The 
mixture was then centrifuged and placed on the heat block at 65˚C for 5 minutes.  Once 
incubated, the samples were placed on ice immediately and centrifuged to collect the 
contents.  5X First-Strand Buffer (250mM Tris-HCI) was then added (4µl) along with 1µl of 
RNaseOUT (40 units/uL) and 2µl of 0.1 M DTT to the RNA mixture.  The contents were mixed 
gently, and tubes incubated for 25˚C for 2 minutes.  SuperScript II RT was added (1µl) to the 
tube and pipetted up and down to mix together.  The mixture was then incubated on a heat 
block with the following parameters:  10 minutes at 25˚C, then 50 minutes at 42 ˚C and finally 
at 70˚C for 15 minutes to inactivate the reaction. The cDNA was stored at -20˚C until further 
processing. 
 
2.2.14 Polymerase Chain Reaction (PCR) 
 
Primers for PTK6 were designed as described in (Harvey et al., 2009).  The primer sequences 
of PTK6 and β actin (Sigma) are shown in Table 2.5 (section 2.1.5).  Primers were provided 
at concentration of 100µM and diluted to 1µM using sterilised water.  The cDNA was defrosted 
on ice along with the reagents required for this procedure.  The master mix was prepared 
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with (per sample) for total of 25µl: 
 1x of REDTaq Readymix PCR Reaction Mix with MgCI2 (Sigma-Aldrich)  
 Sterile distilled water  
 Forward Primer (1µM) 
 Reverse Primer (1µM) 
 cDNA (250ng/µl). 
Master mix was pipetted into each tube and the cDNA was carefully pipetted into the lid of 
each tube and the lid closed tightly.  The contents were mixed together by centrifuging briefly 
to collect them at the bottom of the tube.  The tubes were then incubated in the thermal cycle 
with the following parameters.  
For the reaction with β actin primers: 
 35 cycles of denaturing at 95˚C for 30 seconds 
 Primer annealing at 58˚C for 30 seconds and extensions at 72˚C for 45 seconds.   
 The final step was at 72˚C for 10 minutes.   
For the reaction with PTK6 primers: 
 35 cycles of denaturing at 95˚C for 30 seconds  
 Primer annealing at 63˚C 30 seconds and extensions at 72˚C for 45 seconds 
 The final step was at 72˚C for 10 minutes.   
 
 
2.2.15 Gel Electrophoresis  
 
Once the PCR reaction was completed, the PCR product validity was determined by gel 
electrophoresis.  A 50x stock solution of TAE (Tris-acetate-EDTA) was prepared with 242g 
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Tris base, 57.1ml acetic acid and 500ml of 500Mm EDTA pH 8.0 with final volume of 1L made 
up with water.  1g of agarose (Fisher Scientific) was dissolved in 100ml of 1x TAE buffer.  
The mixture was carefully heated in a microwave until all the agarose had completely 
dissolved.  The mixture was cooled before adding 5µl of SYBR Safe, a DNA gel stain 
(Invitrogen) and poured onto a sealed tray with a comb and left to set for approximately 20 
minutes.  The gel was then placed onto a tank containing 1x TAE buffer.  15µl of the PCR 
product was loaded into the wells along with 5µl of a 1Kb DNA Hyperladder (Fisher Scientific).  
The gel was run at 100V and 400mAps for approximately 45 minutes.  Once the PCR product 
had migrated through the gel, it was visualised using Gel Doc Imaging System (BioRad).   
 
2.2.16 Quantitative PCR (qPCR) 
 
2.2.16.1 geNORM Analysis  
Before quantitative PCR experiments, geNORM analysis was performed to determine the 
appropriate reference genes to use as control for stably expressed genes in the cell lines as 
well as determining the number of reference genes to use.  The Primer Design geNORM 
analysis kit for 12 genes was used for this and protocol carried out according to the 
manufacturer’s guidelines.  The genes used for geNORM analysis are shown in Table 2.12.  
Upon receipt of the primers, they were briefly centrifuged and resuspended in RNase/DNase 
free water (220µl).  The master mix for each reference gene was made as shown in Table 
2.13.  15µl of the master mix for each gene was pipetted in duplicate into a 96 well plate along 
with 5µl of cDNA (5ng/µl) or water as negative control.  The plates were then sealed using 
MicroAmp Clear Adhesive Film (Applied Biosystems) to prevent evaporation and well-to-well 
contamination.  The amplification conditions are outlined in Table 2.14.  The experiments 
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were carried out using the QuantStudio 7 Flex Real Time PCR system.  The geNORM 
analysis was carried out using duplicate wells for each gene and repeated twice using 
QuantStudio 7 Flexi Real-Time PCR system (Applied Biosystems) for all experimental 
conditions and average values taken to determine the reference genes to use.  geNORM 











Gene Full Name 
ACTB Beta actin 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
UBC Ubiquitin C 
B2M Beta-2-microglobulin  
YWHAZ Phospholipase A2 
RPL13A Ribosomal protein L13A 
18S 18S RNA 
CYC1 Cytochrome C1 
EIF4A2 Eukaryotic translation initiation factor 4A 
isoform 2  
SDHA Succinate dehydrogenase complex 
TOP1 Topoisomerase DNA 1 
ATP5B ATP synthase subunit  
Table 2.12 The 12 reference genes in geNORM analysis (Primer Design).  
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2.2.16.2 Quantitative PCR (qPCR) protocol for detection of PTK6 
transcripts 
 
qPCR was carried out to detect and quantify relative gene expression.  Primers for RPL13A, 
SDHA, PTK6 and ALT-PTK6 transcripts are shown in Table 2.6 (section 2.1.5).  Primers for 
PTK6 and ALT-PTK6 were custom made by Primer Design and the primer sequences 
provided by them.  For RPL13A and SDHA, which were used as endogenous controls, Primer 
Design do not provide the sequences, so to comply with MIQE guidelines (Bustin et al., 2009) 
new primers were designed and produced by Sigma Aldrich.  These primers were shipped 
lyophilised and resuspended in RNase/DNase free water (100µM) and further diluted to 1µM 
to use as stock.  Final concentration used was same as template primers. For custom made 
primers by Primer Design, the manufacturers protocol was used.  The primers were provided 
lyophilised and were centrifuged to collect the contents before mixing with RNase/DNase free 
water to 300nM concentration.   The master mix was prepared with Primer Design primers 
as indicated in Table 2.13 and the experimental parameters used are shown in Table 2.14.  
For negative control, water was substituted for cDNA instead.  The appropriate volume was 
first pipetted into each of the wells in a MicroAmp Optical 96 well reaction plate (Applied 
Biosystems) and then 5µl of cDNA/water added.  Each experiment was carried in triplicate 
using duplicate wells. The plates were then covered with MicroAmp® optical adhesive film 
(Applied Biosystems) and briefly centrifuged, and qPCRs were carried out using QuantStudio 
7 Flex Real-Time PCR system (Applied Biosystems) and results analysed using the 
accompanying QuantStudio™ Software V1.3—for QuantStudio™ 6 and 7 Flex and ViiA™ 7 
















qPCR analysis was carried out using the average CT (Cycle Threshold) values obtained after 
each run.  This value is determined as the number of cycles required for the fluorescent signal 
to exceed the background (threshold) levels and is proportional to amount of target gene 
expressed in the sample.   Using this CT value, the relative quantification (RQ) value was 
obtained.  This indicates the amplification of the target gene relative to the untreated control 
samples which are used as endogenous control for all experimental conditions. The most 
common way to analyse relative quantification qPCR data is by using delta (Δ)Cq or ΔΔCq 
method (Livak and Schmittgen, 2001).  To obtain the RQ value, the following steps were 
Components  Volume for 1 Reaction (µl) 
PrecisionPLUS MasterMix with ROX at a lower level 
premixed with SYBRgreen 
10 
Primer Mix 1 







Step Time Temperature (°C) 
Enzyme Activation 2 minutes 95 
Denaturation 10 seconds 95 
Data Collection 60 seconds 60 
Table 2.13 Mastermix volumes used for qPCR experiments with PrecisionPLUS Mastermix with 
ROX at lower level premised with SYBRgreen. 
 




1. Normalization of Gene of Interest (GOI) to reference gene: 
a. Average CT value of GOI – Average CT value of Reference gene 1(RPL13A) 
b. Average CT value of GOI – Average CT value of Reference gene 2 (SDHA) 
2. The average was obtained for both reference genes which gives the delta Cq value 
(ΔCq) and normalised to untreated control samples. 
3.  The RQ value was obtained using the following equation: RQ=2-ΔΔCq 
 
 
2.2.17 PTK6 and ALT-PTK6  expression in breast cancer tissue 
 
The experimental procedures for determining the expression of PTK6 and ALT-PTK6 mRNA 
transcripts in breast cancer tissue samples was performed by the clinical collaborators; 
Professor Wen Jiang (Cardiff University) and Professor Kefah Mokbel (The Princess Grace 
Hospital).  Tissue samples with informed consent and ethical approval for the experiments 
were obtained as stated in (Wazir et al., 2013).  Breast cancer tissues (n=127) and normal 
background tissue (n=33) were collected and stored in -80˚C until commencement of study.  
The patient cohort has been part of a number of completed and on-going studies and the 
clinicopathological data describing the patient cohort is further described in (Wazir et al., 
2013).  The Kaplan Meier survival graphs and statistical analysis were performed by the 
collaborators.  Statistical analysis was determined at multiple levels using a number of 
statistical tests including Logrank (Mantel Cox) for significant difference between high and 
low PTK6 expression in relation to overall survival at later time points with Breslow 
(generalized Wilcoxon) test showing significant difference at the earlier time points.  The 
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Tarone-Ware test was used to further assess distribution of overall survival with assumptions 
that there is identical distribution as well as equal variance. 
 
2.2.18 Statistical Analysis 
 
Statistical analysis was performed to assess any changes that were observed for my 
experiments.  Students unpaired t-test using Excel was used to assess differences in means 
between two independent samples. The IC50 (IC50 indicates dose at which 50% of cell death 
occurs) values were determined using Excel.  Correlation analysis was performed using 
Graphpad Prism Software, Spearman rho correlation coefficient and P values were 
determined.  To determine whether there are any statistically significant differences between 
the means of three or more independent groups, one-way Analysis of Variance (ANOVA) test 
was used.  This test was performed using GraphPad Prism Software (GraphPad Software). 
The results of the ANOVA test are reported as, for example, ANOVA (F (2,27) = 4.467, 
P= .021).   
The first F value (2 as shown in the example) shows the degree of freedom (variation) 
between samples. The second F value (27 as shown in the example) shows the degree of 
freedom (variation) within the samples. The F value is the ratio of variance (e.g. the value 
4.467 is the F statistic ratio as shown in the example above).  It is calculated as: variation 
between samples/variation within samples. The P value is shown as P = (e.g. the value 
P=.021 in the example above). Statistical difference (P<0.05) is denoted by an asterisk (*) on 




3.0 Chapter 3: Investigating the role of 
Brk in radio-sensitivity and the 
DNA DSB damage response 





3.1 Introduction  
 
Since the discovery of X-rays in 1895 by German physicist W.C. Roentgen, radiotherapy (RT) 
has evolved to become a major therapy for cancer patients.  With the advancement of 
technology and our understanding of cancer, radiotherapy has proven to be an effective 
mode of treatment whether as a stand-alone therapy or in combination with surgery, 
chemotherapy and other targeted treatments.  Approximately, over 27% of patients 
diagnosed with cancer received radiotherapy during 2013-2014 in England and 63% of breast 
cancer patients received palliative or curative radiotherapy (NCRAS, 2017).  The studies in 
this chapter utilised the 60Cobalt radiation source (Puridec Technologies Ltd) which was first 
applied for patient treatment in 1948 and allowed for radiation doses of up to 60 Gy to be 
delivered to deep-rooted tumours without exceeding their tolerance dose (reviewed in Thariat 
et al., 2013).  The exact method of cell death induced by radiation is not entirely clear although 
it is mostly due to mitotic cell death. Radiation is known to effectively induce DNA double 
strand breaks which, if not repaired efficiently or correctly may lead to loss of reproductive 
and replicative ability. Eventual cell death can be via programmed cell death or through 
mitotic catastrophe; a process whereby cells improperly enter mitosis resulting in aberrant 
chromosome segregation and cell division with formation of abnormally sizes cells displaying 
improper nuclear morphology (Eriksson and Stigbrand, 2010).   The clinical significance of 
RT was seen early on especially in breast cancer patients, where randomised studies showed 
RT combined with ‘quadrantectomy’ and axillary dissection was just as effective as radical 
mastectomy (Veronesi et al., 1981).  This proved to be a clinical breakthrough, allowing for 
treatment of breast cancer patients with an alternative method that did not involve such 
radical mastectomies. The benefits of radiotherapy extended to increase patient overall 
survival and local control, and the combination of radiotherapy and adjuvant chemotherapy 
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led to better survival outcomes compared to chemotherapy alone (Ragaz et al., 2005).  
Advances in radiotherapy treatment modalities have led to better delivery of dose to the 
cancerous sites aided by computational models and 3D imaging.  With the advent of 
computerised tomography (CT), planning of radiation doses and shaping of the radiation field 
around the tumour volume has made it possible to deliver the radiation dose more accurately 
thus avoiding any non-cancerous organs at risk of being exposed.  Intensity modulated 
radiotherapy (IMRT) enables further modulation of multiple  beams, again ensuring better 
conformity around the cancer and surrounding organs (reviewed in (Thariat et al., 2013)).   
Further improvements are involving 4-D radiotherapy using image guided radiotherapy 
(IGRT), a technique that considers the movement and position of the patient, tumour or organ 
(Bucci, Bevan and Roach, 2005).  This technique is useful to account for changes in breathing 
patterns during treatment in patients with lung cancer or changes to the position of the 
prostate due to bladder filling or air within the rectum (Ling, Yorke and Fuks, 2006).  
Accordingly, new technologies are paving the way for high dose radiotherapy treatments 
targeting cancerous tissues while minimizing surrounding organs and reducing any adverse 
toxicities.   
 
3.1.1 Radiotherapy and signalling pathways 
 
Exposure of carcinoma cells to radiation causes DNA damage by direct ionisation of the 
macromolecules as well as by generation of reactive oxygen species (ROS) (Wang et al., 
2016).  The damage results in activation of the DNA damage response (DDR) pathway, 
subsequently leading to activation of p53, ataxia telangiectasia mutated (ATM) and ATM -
Rad3-related (ATR) protein as well as the activation of growth factor receptors in the plasma 
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membrane, for example the ERBB family of receptors (Dittmann et al., 2017).  In effect, cells 
recognising DNA damage induced by irradiation, utilise complex signalling pathways that 
control cellular responses involved in apoptosis, cell cycle arrest and/or repair (reviewed in 
Lewanski and Gullick, 2001).  More specifically, double strand breaks induced by ionising 
radiation, which are the most deleterious lesions, are repaired by either non-homologous end 
joining (NHEJ) or homologous recombination (HR).  The HR pathway uses a sister chromatid 
or homologous chromosome as a template to repair the broken DNA (Hartlerode and Scully, 
2009).  Due to the reliance of a sister chromatid, HR repair is usually less error prone 
compared to NHEJ and more active during the S and G2 phase of the cell cycle, whereas 
NHEJ is active throughout the cell cycle (Cannan and Pederson, 2017).  The mechanism of 
HR repair requires generation of 3’-single stranded DNA (tail ends) which are rapidly coated 
by replication protein A (RPA) and protects against degradation (Barker and Powell, 2010).  
The RPA is replaced by the BRCA2 protein on single stranded DNA and promotes formation 
of Rad51 filaments (Barker and Powell, 2010). Rad51 assists in the repair of DSBs by 
catalysing the homology and strand exchange between homologous DNA.  Strand invasion 
leads to formation of a ‘D-loop’ which can directly act as the template for repairing DSB 
(Barker and Powell, 2010).  Once the Rad51 is removed, leaving the 3’OH end free, DNA is 
synthesised by the DNA polymerase δ and DNA ends joined by DNA ligase (Borrego-Soto et 
al., 2015).  Once the regions of strand exchange extend and two double stranded molecules 
are separated into 4 strands behind the invading 3’ strand, a structure known as a Holliday 
Junction forms which is a cross shaped structure involved in the exchange of genetic 
information during recombination (Barker and Powell, 2010).  There are many proteins 
involved in HR and their recruitment and functions are promoted by upstream proteins such 
as MRE-11-Rad5—NBS1 (MRN) complex as well as other effectors downstream of DNA 
damage sensor such as ataxia telangiectasia (ATM) (Barker and Powell, 2010).  Defects in 
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any of the steps during HR repair can lead to impairment of damaged DNA including DSB 
induced by ionising radiation, for example, mutations in BRAC1 or BRCA2 increases radio-
sensitivity (Barker and Powell, 2010).   
Majority of the DSBs are repaired by the NHEJ pathway and involves the recognition and 
binding of the Ku70/80 heterodimer and MRN complex to the exposed end of the DSB leading 
to the recruitment of the catalytic subunit of the DNA dependent protein kinase (DNA-PK), 
which translocates the Ku complex along the DNA and allows tethering of the two DNA 
molecules (Borrego-Soto et al., 2015). DNA ligase IV interacts with the Ku heterodimer to 
ligate the DNA ends, which exists in complex with X-ray cross complementing gene 4 
(XRCC4) and XRCC4-like factor (XLF) (Wang and Lees-Miller, 2013). Nucleases 
exonuclease 1 (Exo1), Mre11 and Artemis are involved in processing any damaged DNA 
termini before DNA ligation (Weterings et al., 2009; Xie, Kwok and Scully, 2009; Bahmed et 
al., 2011).   
Furthermore, upon DNA damage, the DNA damage sensors (ATM, ATR and DNA-PK) are 
also involved in activation of Akt (Liu et al., 2014).  The Akt and DNA-PK complex stimulates 
binding of DNA-PK with Ku heterodimer as well as the release of DNA-PKcs from the damage 
needed for ligation and termination of double strand break repair (Liu et al., 2014).  The 
mechanistic target of rapamycin (mTOR) is a prominent downstream effector of Akt signalling 
which upon activation cell survival, growth and proliferation is induced by phosphorylation of 
effector molecules such as ribosomal S6 kinases (reviewed in Karimian et al., 2019).   There 
is evidence of signalling cross talk between the DNA damage response and P13K/Akt 
pathways, as Nbs1 which is a component of the MRN sensor complex for detecting double 
strand break repair, also interacts with the catalytic subunit of P13K and stimulates its activity 
(Chen et al., 2008).   
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Improving our understanding of the signalling pathways involved in radiotherapy-induced 
DNA damage in the target cancer cells may provide a potential method by which radio-
sensitisation of cancer cells can be assessed clinically as well as to prevent resistance.  Many 
of these signalling molecules, for example p53, ATM/ATR, ERK1/2, AKT and mTOR, are 
activated to increase cancer cell survival and ultimately lead to development of radio-resistant 
tumour cells (reviewed in Hein, Ouellette and Yan, 2014). Interestingly, Brk appears to 
interact with most of these signalling molecules and thus, may have a role in sensitising cells 
to radiotherapy.  Following exposure of colon cancer cells to γ-radiation, Brk is induced at 
significantly higher levels in cells with wild type p53 than it is in p53-null cell lines, suggesting 
a potential role for p53 in Brk induction (Gierut et al., 2012).  Furthermore, knockdown of Brk 
was shown to increase apoptosis in p53 +/+ colon cancer cells following DNA damage 
induced by chemotherapeutic agents or γ-radiation (Gierut et al., 2012). Brk and Akt 
association has also been previously shown (Zhang et al., 2005), with Akt activation leading 
to increased tumour cell  proliferation (Zheng et al., 2010).  However, a contradictory function 
for Brk is shown in oesophageal squamous cell carcinoma (ESCC), where it is involved in 
down-regulating Akt activation and thus may have a role as a tumour suppressor (Miah, 
Martin and Lukong, 2012).  In addition, in a non-tumorigenic context,  Brk promotes cell death 
in intestinal crypt epithelial cells via inhibition of Akt and Erk1/2 after DNA damage induced 
by γ-radiation (Haegebarth et al., 2009).   
 
3.1.2 Brk and ATM 
 
Many cancers have deregulated mechanistic target of rapamycin (mTOR) activity and it is 
involved in the development and progression of malignancies (Pópulo, Lopes and Soares, 
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2012). The mTOR pathway is considered a potential therapeutic target in breast cancer and 
early stage clinical studies in HER2 positive breast cancer patients show promising results 
with a combination of mTOR inhibitors and HER2 targeted therapies (Vinayak and Carlson, 
2013).  Since Brk induces ErbB3 phosphorylation and recruitment of P13Kp85 to ErbB3 thus 
enhancing P13K activity (Kamalati et al., 2000), it may have an indirect effect on the 
mechanistic target of rapamycin (mTOR), as ErbB is an upstream activator of mTOR. 
Furthermore, elevated mTOR signalling suppresses ataxia telangiectasia mutated (ATM) 
protein expression by inducing microRNAs targeting ATM for destruction (Shen and 
Houghton, 2013).  One of the major hallmarks of cancer is genomic instability (reviewed in  
Hanahan and Weinberg, 2011) and ATM is a key regulator of the cell cycle (Helt et al., 2005).  
It is an essential component for mediating checkpoint control after cells are exposed to 
ionising radiation leading to double strand breaks (Lavin and Shiloh, 1997). Thus, mutations 
in the ATM gene, which lead to its inactivation or suppression of ATM, may increase cancer 
cell sensitivity to radiotherapy.   
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3.2 Aims and Objectives 
Aims: 
Previous studies have not shown a direct link between Brk and radio-sensitivity in breast 
cancer cell lines.  The aims of this chapter were to investigate if Brk expression influences 
radio-sensitivity of breast cancer cell lines as well as to determine the potential mechanism 
that mediated the radio-sensitivity.  It was hypothesised that cell lines with high Brk 
expression may sensitise breast cancer cell lines to radiotherapy and this may be through 
deregulating the DNA DSB response pathway and through direct interaction with the ataxia 
telangiectasia mutated (ATM) protein. 
The objectives  were to: 
 To determine the radio-sensitivity of different breast cancer cell lines to γ-radiation 
through clonogenic survival in relation to Brk protein expression  
 Investigate the role of Brk in the DDR response pathway through γ-H2AX DNA repair 
assays 
 Examine whether there is a functional link between Brk and ATM signalling through 







3.3.1 Clonogenic assays show a decrease in colony formation after exposure to 
increasing doses of gamma radiation  
 
The first aim was to determine the radio-sensitivity of the cell lines highlighted for study.  
These cell lines included MCF10A an immortalised non-transformed cell line, T47D 
representing Luminal A subtype of breast cancer, SKBR3 and BT474 which are HER2 
positive cell lines, GI101 a metastatic model and triple negative cell lines MDA-MB 231and 
MDA-MB 436.  To do this, radiation experiments were carried out for each cell line in triplicate 
petri dishes from three independent repeats.  Cells were exposed to increasing doses of γ-
radiation then plated and incubated to allow colonies of approximately 50 cells to develop. 
After two weeks, colonies were counted for each cell line and dose.  
With increasing dose of radiation, there was a decrease of methylene blue stained colonies 
as expected for all cell lines.  A representative image of the colony formation is shown in 
Figure 3.1 and it can be seen that colony sizes varied between different breast cancer lines.  
The size of colonies was larger in the HER2 positive BT474 cell line as well as the triple 
negative cell lines MDA-MB 231 and MDA-MB 436 in comparison to some of the other cell 
lines (data not shown).  The difference in size of colonies was initially thought to relate with 
levels of Brk expressed in each cell line.  For example, when the triple (and Brk) negative cell 
line MDA-MB 468 was transfected to express Brk, cells with wild-type Brk formed larger 
colonies than those expressing kinase inactive Brk.  However, comparable results were not 
observed in the MDA-MB-157 cell line and this was not consistent with the rest of the breast 
cancer cell lines.   For example, the T47D colony morphology showed smaller colony sizes 
compared to BT474 but had high levels of Brk expression.  These data suggest that the size 
of colonies formed in the clonogenic assays are not dependent on Brk expression levels.  
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Each survival curve represents the average from three independent experiments.  The 
number of colonies for each time point and cell line in irradiated cells were expressed as 
percentage of control and survival curves were plotted on a semi-logarithmic scale (Figures 
4.2 and 4.3). There is a proportionate decrease in the overall survival in all cell lines as the 
dose of γ-radiation increased.  My experiments involved many different types of breast cancer 
cell lines that were representative of different subtypes of breast cancer in order to investigate 
radio-sensitivity in relation to Brk expression. The MCF10A cell line is classified as a non-
tumorigenic immortalised breast cell line (Physical Sciences - Oncology Centers Network et 
al., 2013).  This cell line was one of the most sensitive cell lines to gamma radiation (Figure 





Figure 3.1. Colony formation decreases with increasing dose of gamma radiation . Cell lines were 
harvested and diluted to 1000 cells per ml (for 0Gy and 2Gy), 1500 cells per ml (for 4Gy) and 2000 
cells per ml (for 6Gy and 8Gy) in 10ml medium and exposed to gamma radiation in 2Gy fractions.  
Cells were plated, incubated at 37˚C, 5% CO2 for two weeks, fixed with 100% IMS and stained with 
methylene blue solution.  Each blue dot represents one colony of at least 50 cells.  .  All images are 








Figure 3.2.  Average clonogenic survival for MCF10A, GI101, T47D and SKBR3 decreasing 
with increasing dose of gamma radiation. Cell lines were harvested and diluted to 1000 cells 
per ml (for 0Gy and 2Gy), 1500 cells per ml (for 4Gy) and 2000 cells per ml (for 6Gy and 8Gy) 
in 10ml medium and exposed to gamma radiation in 2Gy fractions.  Cells were plated, incubated 
at 37˚C, 5% CO2 for two weeks, fixed with 100% IMS and stained with methylene blue 
solution.  . Survival graphs show average of n=3 independent experiments.  Students paired T-
Test was used to determine statistically significant in percentage survival between control and 
treated cells *P<0.05. 
 
 
Figure 3.3.  Average clonogenic survival for BT474, MDA-MB 231 and MDA-MB 436 cell 
lines decreases with increasing dose of gamma radiation . Cell lines were exposed to 0, 
2,4,6 and 8Gy of gamma radiation and colony formation calculated after two weeks in 
incubation at 37ºC, 5% CO2.  Clonogenic survival decreased with increasing dose of radiation 
for all cell lines.  Clonogenic survival decreased with increasing dose of radiation for all cell 
lines. Survival graphs show average of n=3 independent experiments.  Students paired T Test 
was used to determine statistical significant in percentage survival between control and treated 
cells *P<0.05.Figure 3.2.  Average clonogenic survival for MCF10A, GI101, T47D and 
MCF10A



























































Figure 3.3.  Average clonogenic survival for BT474, MDA-MB 231 and MDA-MB 436 cell lines 
decreases with increasing dose of gamma radiation . Cell lines were harvested and diluted to 
1000 cells per ml (for 0Gy and 2Gy), 1500 cells per ml (for 4Gy) and 2000 cells per ml (for 6Gy 
and 8Gy) in 10ml medium and exposed to gamma radiation in 2Gy fractions.  Cells were plated, 
incubated at 37˚C, 5% CO2 for two weeks, fixed with 100% IMS and stained with methylene blue 
solution.  Survival graphs show average of n=3 independent experiments.  Students paired T Test 
was used to determine statistically significant in percentage survival between control and treated 
cells *P<0.05.  
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The T47D cell line had one of the highest survival rates at both 8Gy (17.5% +/- 7.8 standard 
deviation) and 2Gy (73.4% +/- 14.8 standard deviation) as shown in Figure 3.2 indicating 
increased radiotherapy resistance.  GI101 seems to be more radiosensitive with average 
survival percentage of 62.9% +/- 5.1 standard deviation at 2Gy and 6.2% +/- 4.7 standard 
deviation at 8Gy (Figure 3.2).   
The triple negative cell lines, MDA-MB 231 and MDA-MB 436 express differing levels of Brk .  
Both of these cell lines show survival rate at 2Gy with average percentage survival at 78.8% 
+/- 8.2 standard deviation for MDA-MB 231 cell line and 83.4% +/- 6.5 standard deviation for 
the MDA-MB 436 cell line.   In addition, average percentage survival at 8Gy showed survival 
at 14.13% +/- 4.6 standard deviation for MDA-MB 231 (Figure 3.3) and 12.6% +/- 4.64 
standard deviation for MDA-MB 436 cell line (Figure 3.3).   
The HER2 positive cell lines BT474 and SKBR3 both express Brk, although at varying levels. 
They show a steady decrease with increasing radiation dose as with all the other cell lines 
and a similar percentage survival at 2Gy, 4Gy and 6Gy (Figure 3.2 and 3.3).  Percentage 
survival was 63.7% +/- 21.7 standard deviation at 2Gy radiation dose and at 13.3% +/- 9.8 
standard deviation at 8Gy dose. SKBR3 cell line may be more radiosensitive than the BT474 
cell line, average percentage survival at 2Gy showed percentage survival at 60.7% +/- 21.8 
standard deviation and for 8Gy at6.4% (+/- 2.5 standard deviation).    
 
3.3.2 Brk expression does not directly affect clonogenic survival of breast 




It has previously been shown that T47D cells express a high amount of Brk (Barker, Jackson 
and Crompton, 1997) whereas GI101 express a moderate amount.  The difference in 
clonogenic survival may be due to different Brk expression levels.  To further elucidate the 
effect of Brk expression on radio-sensitivity, the MDA-MB 468 and MDA-MB 157 cell lines 
which do not inherently express Brk, were used for transfection.  These cells had previously 
been transfected with wild type (WT) Brk, kinase inactive Brk (KM) and an empty vector (VEC) 
(Harvey et al., 2009), and expression was confirmed by western blotting (Figure 3.4A). Cell 
lines were harvested and lysed in 2X SDS-PAGE loading buffer, transferred onto 
nitrocellulose membrane before blocking with 5% Milk-TBST and incubating with IC-100 Brk 
primary antibody overnight.  Anti-β actin was used as the loading control.  Transfection with 
Brk (either wild type or kinase inactive) did not statistically alter the survival of MDA-MB-468 
cells (Figure 3.4B).  Since conventional schedules of radiotherapy in a clinical setting involve 
fractionated doses of 1.8-2Gy per fraction for a total of 40-50Gy (Plataniotis, 2010), the 
clonogenic survival at 2Gy (SF2 survival) was calculated.  
Figure 3.4A shows Brk expression in the three variant transfected cell lines of MDA-MB 468 
and MDA-MB 157.  In the MDA-MB 468 VEC cell line, there was reduced clonogenic survival 
compared to the other two variants, however overall there was no statistically significant 
variation between these cell lines (Figure 3.4B).  MDA-MB 157 VEC cell line appears (Figure 
3.4C) to have lower overall survival rate after γ-radiation suggesting it is more sensitive to 
radiotherapy compared to MDA-MB 157 Brk KM and WT variants.  ANOVA analysis shows 
a statistically significant difference between the three variants (ANOVA (F (2,6) = 23.572, P= 
0.001). Clonogenic survival rate at 8Gy was as low as 3.42% for MDA -MB 157 VEC in 





















Figure 3.4 No significant difference in clonogenic survival in correlation with Brk 
expression was observed in both transfected cell lines.  Brk expression for both cell line 
variants is shown in Figure 3.4A and clonogenic survival is shown in Figure 3.4B and 3.4C.  Cell 
lines were harvested and diluted to 1000 cells per ml (for 0Gy and 2Gy), 1500 cells per ml (for 
4Gy) and 2000 cells per ml (for 6Gy and 8Gy) and exposed to gamma radiation in 2Gy fractions.  
Cells were plated, incubated at 37˚C, 5% CO2 for two weeks, fixed with 100% IMS and stained 
with methylene blue solution before counting number of colonies formed.  Western blots were 
performed using whole lysates.  Equal volume of lysates were loaded on a stacking gel and a 
12% resolving gel was used. The proteins were then electro-blotted onto nitrocellulose 
membrane in 1x Towbin transfer buffer 1 hour at 300 volts and 400mAps.  Membranes were 
blocked in 5% non-fat skimmed milk/TBS-T before incubating with primary antibodies overnight.  
The membranes were then washed with 1x TBST and incubated with the appropriate secondary  
antibody for 1 hour. Bands corresponding to Brk were detected after primary incubation with Brk 
antibody (ICR100- (Kamalati et al., 1996)) and primary β actin (loading control) antibody 
(Abcam).  Protein bands were detected using chemiluminescent substrates Coumaric acid 
(0.0148g/ml) and luminol (0.0443g/ml) and 1:1000 dilution of H2O2 in 100mM Tris pH 7.0.  Mean 
survival from n=3 experiments is plotted with error bars representing standard deviation.  
ANOVA testing was performed to test significant variance between the three variants for each 







































































































































Figure 3.5 Statistically significant difference was observed for SF2 values between Brk WT 
and Brk KM in MDA-MB 157 cell line.  Figure 3.5 A and B shows SF2 survival (survival at 2Gy 
dose) for MDA-MB 468 and MDA-MB 157 cell line variants respectively.  Figure 3.5 C and D show 
the IC50 doses (IC50 indicates dose at which 50% of cell death occurs) for MDA-MB 468 and 
MDA-MB 157 cell line variants respectively.  Cell lines were harvested and diluted to 1000 cells 
per ml (for 0Gy and 2Gy), 1500 cells per ml (for 4Gy) and 2000 cells per ml (for 6Gy and 8Gy) and 
exposed to gamma radiation.  Cells were plated, incubated for two weeks and stained with 
methylene blue solution before counting number of colonies formed   Mean SF2 survival and IC50 
values from n=3 independent experiments are plotted with error bars representing standard 
deviation. ANOVA statistical test was used to detect significant variance between the three variants 
for each cell line.  Students T Test was used to determine significant difference between vector 
and Brk WT or vector and Brk KM cell lines, *P<0.05.  
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No significant difference between all three variants was observed when comparing SF2 
survival (ANOVA (F (2,6) = 0.449, P = 0.658). This suggests that high or over expression of 
Brk may not influence the clonogenic survival of MDA-MB-468 cells in comparison to Brk-KM 
and empty vector cell lines (Figure 3.5A).   The SF2 values (Figure 3.5A) for MDA-MB 468 
Brk WT was 67.4% (+/- 20.4 standard deviation), for MDA-MB 468 Brk KM it was 62.1% (+/- 
7.8 standard deviation) and for MDA-MB 468 Vector it was 62.24% (+/- 18.53 standard 
deviation). Overall, there was an approximate 1.1-fold increase in SF2 survival rate between 
Vector only and Brk-WT cell lines.   Statistically there was no significant difference observed 
between MDA-MB 468 Brk WT and MDA-MB 468 Vector cell lines for SF2 survival (P= 
0.4606) which indicates Brk expression may not be linked to radiotherapy sensitivity.  The 
SF2 values for all three variants in MDA-MB 157 cell line showed increased variance with 
significantly increased percentage survival for the Brk WT cell line compared to vector only 
cell line whereas this difference is not statistically significant in MDA-MB 468 cell line (Figure 
3.5B).  SF2 value for MDA-MB 157 VEC was at 54.5%, for MDA-MB 157 Brk WT it was at 
76.2% and for Brk-KM variant it was at 65.8%. SF2 survival for Brk WT and Brk KM variants 
show statistically significant difference when compared to vector only (P<0.05).  This 
suggests Brk expression may have some influence on radio-sensitivity with increased 
percentage survival observed in Brk expressing cells compared to the MDA-MB 157 vector 
cell line.  The IC50 doses for all three variants for both MDA-MB 468 and MDA-MB 157 cell 
lines are shown in Figure 3.5C and there was no statistically significant difference between 
the three variants.     
 




3.3.3.1 Brk expression is induced after γ-irradiation 
 
Previously, exposure to γ-radiation induced Brk expression in intestinal crypt epithelial cells 
(Haegebarth et al., 2009); however, this has not been investigated in breast cancer cell lines.  
I sought to determine if Brk expression was induced after exposure to 2Gy γ-radiation dose 
in breast cancer cell lines. T47D, GI101 and SKBR3 cell lines, representative of high, 
moderate and low Brk expression levels, were chosen for these studies.  Cell lines were 
exposed to 2Gy dose of γ-radiation as previously described (Chapter 2, section 2.2.6).  
Protein lysates were collected as described in Chapter 2, section 2.2.9at 4, 6, 24 and 48 
hours post exposure to radiation and western blots were performed (Chapter 2, section 
2.2.15). Figure 3.6 shows an induction in Brk expression levels over time in all cell lines 
examined.    T47D cell line showed moderate induction of Brk with the greatest difference 
observed at 48 hours post treatment compared to the control lysate.  GI101 cell line had the 
most induction of Brk at 6 hours post treatment compared to control lysate and remained at 
similar levels at 24 and 48 hours post radiation.  The greatest induction of Brk was observed 
in the SKBR3 cell line, with the highest levels observed at 48 hours post radiation compared 
to control (Time 0) lysate.  Overall, this suggests Brk is induced after exposure to γ-radiation 




                 
  
Figure 3.6 Brk is induced in response to DNA damage after exposure to γ-radiation.Cell lines 
were plated in 90mm petri dishes and exposed to 2Gy γ-radiation described in section 2.2.6.1 in 
Materials and Methods before preparing whole lysates at 4, 6, 24 and 48 hours post irradiation along 
with a control lysate.  Equal volume of lysates were loaded on a stacking gel and a 12% resolving 
gel was used. The proteins were then electro-blotted onto nitrocellulose membrane in 1x Towbin 
transfer buffer 1 hour at 300 volts and 400mAps.  Membranes were blocked in 5% non-fat skimmed 
milk/TBS-T before incubating with primary antibodies overnight.  The membranes were then washed 
with 1x TBST and incubated with the appropriate secondary antibody for 1 hour. Bands 
corresponding to Brk were detected after primary incubation (1:100 dilution) with Brk antibody 
(ICR100- (Kamalati et al., 1996)) and primary β actin (loading control , 1:1000 dilution) antibody 
(Abcam).  Protein bands were detected using chemiluminescent substrates Coumaric acid 
(0.0148g/ml) and luminol (0.0443g/ml) and 1:1000 dilution of H2O2 in 100mM Tris pH 7.0 .  N=3. 
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3.3.3.2 Brk expression in relation to SF2 survival rates 
 
As Brk expression was induced in breast cancer cell lines, to assess if endogenous Brk 
expression may influence survival; survival at the 2Gy radiation dose (SF2) in a wider panel 
of cell lines was assessed in relation to Brk expression. Observing Brk expression and SF2 
survival, a clear pattern does not emerge (Figure 3.7).   Although statistical significance is 
seen between the SF2 survival rates for all cell lines (ANOVA (F (8,19) = 3.239, P = 0.017), 
this does not relate directly with Brk expression levels.   This suggests differences in SF2 
survival rates are not directly due to levels of Brk expression.  BT474 and T47D cell lines 
express the highest levels of Brk and have some of the highest SF2 values along with the 
triple negative cell lines MDA-MB 231 and MDA-MB 436.  T47D had a higher SF2 value and 
lower Brk expression compared to BT474 which had higher Brk expression but lower SF2 
value.  The results are not consistent for the rest of the cell lines.  In comparison to the highest 
SF2 values (Figure 3.7) for triple negative cell lines MDA-MB-436 at 79.27% and MDA-MB-
231 at 78.9%; the lowest SF2 values were for MCF10A at 57.65%, SKBR3 value at 61.31% 
and GI101 at 63.37%.  BT474 had intermediate SF2 value at 63.73%.  
It should be noted that although there might not be a direct association between SF2 survival 
and Brk expression; 4 out of the 5 cell lines (GI101, BT474, T47D, MDA-MB 436) with highest 
SF2 values show moderate to high Brk expression compared to the lower end of the SF2 










Figure 3.7 SF2 survival which indicates clonogenic survival at 2Gy dose varies between 
the breast cancer cell lines. Cell lines were harvested and diluted to 1000 cells per ml (for 
0Gy and 2Gy), 1500 cells per ml (for 4Gy) and 2000 cells per ml (for 6Gy and 8Gy) in 10ml 
medium and exposed to gamma radiation in 2Gy fractions.  Cells were plated, incubated at 
37˚C, 5% CO2  for two weeks, fixed with 100% IMS and stained with methylene blue solution . 
Western blots were performed using whole lysates for all three variants of both transfected 
cell lines.  Equal volume of lysates were loaded on a stacking gel and a 12% resolving gel was 
used. The proteins were then electro-blotted onto nitrocellulose membrane in 1x Towbin 
transfer buffer 1 hour at 300 volts and 400mAps.  Membranes were blocked in 5% non-fat 
skimmed milk/TBS-T before incubating with primary antibodies overnight.  The membranes 
were then washed with 1x TBST and incubated with the appropriate secondary antibody for  1 
hour. Bands corresponding to Brk were detected after primary incubation with 1:100 diltuion 
of Brk antibody (ICR100- (Kamalati et al., 1996)) and primary Anti-GAPDH (Abcam) antibody 
as the loading control (1:1000 dilution).  Protein bands were detected using chemiluminescent 
substrates Coumaric acid (0.0148g/ml) and luminol (0.0443g/ml) and 1:1000 dilution of H2O2 
in 100mM Tris pH 7.0.  Mean SF2 survival from n=3 experiments is plotted with error bars 




























































3.3.4 IC50 survival and Brk expression 
  
Although there was no clear association between Brk expression and 2Gy survival, there 
might be some significance when looking at IC50 (IC50 indicates dose at which 50% of cell 
death occurs) values and Brk expression.   IC50 was determined using Excel. Brk expression 
in relation with IC50 dose, from lowest to highest is shown in Figure 3.8. Interestingly, the cell 
lines with higher Brk expression (BT474 and T47D) had higher IC50 values whereas cell lines 
with moderate to little Brk expression such as MCF10, GI101 and SKBR3 had lower IC50 
values in comparison.  However, ANOVA analysis showed no significant difference between 































Figure 3.8 IC50 doses for 2 Gy survival, which indicates the dose at which there is a 50% 
reduction in survival at 2Gy dose varies between the breast cancer cell lines .  Clonogenic 
assays were carried out as described in Figure 3.7. IC50s of 2Gy survival were determined (Figure 
3.8A). Western blots were performed as described in Figure 3.7. using whole lysates for all cell 
lines, n=3 (Figure 3.8B).  .  Mean survival from n=3 experiments is plotted with error bars 
representing standard deviation, (ANOVA (F(8,17) = 2.312, P = 0.070).   
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3.3.5 γ-H2AX foci induction for different subtypes of breast cancer  
 
To further examine Brk’s role in radiotherapy, its potential role in DNA repair kinetics was 
investigated.  Since it was originally hypothesised that Brk may be involved in sensitizing 
breast cancer cell lines to radiation, an involvement in DNA repair may demonstrate a 
potential mechanism by which it may do this.  The induction of γ-H2AX post irradiation was 
assessed via immunocytochemistry using γ-H2AX antibody and the number of foci analysed 
with flow cytometry before quantification with Imagesteam IDEAS software.  Originally the 
method of DNA double strand break detection was first introduced by Bonner and colleagues 
in 1999, which showed visual formation of γ-H2AX at the chromosomal sites of DNA double 
strand breaks (Rogakou et al., 1999).  Further studies indicated measuring γ-H2AX at various 
times up to 24 hours post radiation has proven to be a reliable technique to measure DNA 
double strand breaks  (DSB) (Olive and Banáth, 2009; Bourton et al., 2012, 2013). Cell lines 
representative of different subtypes (BT474, MDA-MB 436 and GI101) of breast cancer with 
various levels of Brk expression were selected to detect differences in DNA repair via gamma 
H2AX DNA repair assays.  Cell lines were exposed to 2Gy gamma radiation and then 
processed at 30 mins, 3 hours, 5 hours and 24 hours post irradiation to assess DNA repair 
ability. Image flow cytometry was carried out using ImagestreamX system (Amnis Inc) with 














Figure 3.9 Representative image of gamma H2AX foci staining of BT474 cell line .  The 
time interval of 30 minutes post irradiation showed the most intense fluorescence and highest 
count of H2AX foci being induced.  This decreased gradually over time.  Ch01 shows brightfield 






Figure 3.10 Representative image of gamma H2AX foci staining of MDA-MB 436 cell 
line.  The time interval of 30 minutes post irradiation showed the most intense fluorescence 
and highest count of H2AX foci being induced.  This decreased gradually over time.  Ch01 






Figure 3.11 Representative image of gamma H2AX foci staining of GI101 cell line .  The time 
interval of 30 minutes post irradiation showed the most intense fluorescence and highest count of 
H2AX foci being induced.  This decreased gradually over time.  Ch01 shows brightfield channel, 















Figure 3.12 γ-H2AX assay for MDA-MB 436, BT474 and GI101 cell lines indicate little 
difference in DNA repair kinetics.  After exposure to 2Gy γ- radiation, cell lines were harvested 
after various time points for kinetic analysis of DSB repair using H2AX foci induction.  Each cell 
had untreated control and H2AX foci induction measured at 0.5, 3,5 and 24 hours post radiation 
treatment. Mean H2AX induction from n=3 experiments is plotted with error bars representing 
standard deviation, Students T Test was used to compare H2AX induction post treatment between 
each of the cell lines and time points, *P<0.05. 
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A representative image for H2AX foci staining is shown in Figure 3.9 for the BT474 cell line.  
Figures 4.10 and 4.11 show γ-H2AX staining for MDA-MB 436 and GI101 cell lines 
respectively.  The data in Figure 3.12 shows the induction of gamma H2AX foci in MDA-MB-
436, BT474 and GI101 cell lines.  After irradiation, the DNA damage response is amplified 
with phosphorylation of many H2AX molecules at the double strand break sites at the 30-
minute (Rogakou et al., 1999; Marková, Schultz and Belyaev, 2007; Mariotti et al., 2013; Ji 
et al., 2017).  Gradually, number of cells with phosphorylated H2AX are reduced as the 
number of cells repairing is lowered returning towards near un-irradiated levels at 24 hours.  
As previously shown Brk expression levels are quite high in BT474 and lower for GI101 cell 
line and as Brk increases resistance to radiotherapy as originally thought, there should be 
increasing amount of γ-H2AX phosphorylation at DNA double strand break sites occurring 
and with higher intensity compared to cell lines with lower Brk expression.  The highest 
number of foci and with the most intense fluorescence was seen at 30 minutes post irradiation 
and gradually the number of H2AX foci decreased over time to near control levels.   Looking 
at γ-H2AX foci induction 30 minutes post radiation for BT474 and GI101, there seems to be 
no significant difference (P= 0.0723), however there is a significant difference when 
comparing BT474 and MDA-MB-436 cell line (P= 0.0312).  Nonetheless, this does not 
correspond to Brk expression levels in each cell line and the difference may be due to other 
factors.  There was also no further difference in repair kinetics over the 24 hour time period. 
 
3.3.6 γ-H2AX foci induction for MDA-MB 468 and MDA-MB 157 cell lines 
 
In order to assess whether Brk directly influenced DNA repair in breast cancer cell lines, 
induction of γ-H2AX was measured in the two Brk transfected cell lines: MDA-MB 468 and 
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MDA-MB 157 (Figure 3.13).  The greatest induction and highest fluorescent intensity was 
seen 30 minutes post irradiation for all three variants of both cell lines before H2AX foci levels 
returned to near normal levels after 24 hours. Although there appears to be higher induction 
of gH2AX in MDA-MB 468 Brk WT 30 minutes post radiation, it is not significant when 
compared to MDA-MB 468 Vector cell line (P<0.05).  In contrast, the MDA-MB 157 Brk WT 
cell lines shows show reduced levels of H2AX foci in comparison to MDA-MB 157 Vector cell 
line (P<0.05).  This suggests Brk may not have a direct role in DNA repair process of breast 
cancer cell lines.  Additional data, from independent studies (Emma Bourton -Brunel 
University) which support my studies, show inconsistent induction of H2AX in both MDA-MB 
468 and MDA-MB 157 cell lines respectively (data not shown).   No significant difference in 
H2AX foci induction was observed 30 minutes post radiation between MDA-MB 468 Brk WT 
and Vector cell lines (P<0.05) as well as between MDA-MB 157 Brk WT and Vector cell lines 

































Figure 3.13 γ-H2AX DNA Repair Kinetics for MDA-MB 468 (A) and MDA-MB 157 (B) show no 
variation.  Cell lines were exposed to 2 Gy gamma radiation before the number of cells with double 
strand breaks were measured based on γ-H2AX induction at 0.5, 3, 5 and 24 hours post treatment. 
10,000 cells were analysed for the presence of γ-H2AX foci in each sample along with a control 
sample and compensation samples.  No statistical significance was seen 30 minutes post radiation 
with the highest induction of γ-H2AX for MDA-MB 468 Brk WT and Vector cell lines (p value 0.0965) 
as well as between MDA-MB 157 Brk WT and Vector cell lines (P= 0.1701).   Mean H2AX induction 
from n=3 experiments are plotted with error bars representing standard deviation. ANOVA 
statistical test was done to detect significant variance between the three variants for each cell line.  
Students T Test was used to determine significant difference between vector and Brk WT or vector 
and Brk KM cell lines.  No statistical difference was determined for both transfected cell lines.  
 
Figure 3.15 Representative image of total ATM Figure 3.13 γ-H2AX DNA Repair Kinetics for 
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3.3.7 Total ATM and ATM phosphoserine794 levels in cells before and after 
exposure to 2Gy gamma radiation  
 
To date, there are no direct relationships reported between Brk and DNA repair after γ-
radiation within breast cancer cells.  Since ATM regulates cell cycle checkpoints after double 
strand breaks, a functional connection between total ATM and phosphorylated ATM with Brk 
expression was investigated by immunological staining of total and phosphorylated ATM 
followed by analysis by Imagestream IDEAs analysis software.  Breast cancer cell lines MDA-
MB-468 Brk WT, Brk KM and Vector only as well as MDA-MB 157 Brk WT, Brk KM and Vector 
only were exposed as previously described (Chapter 2, section 2.2.6) to 2Gy of γ-radiation 
before cells were stained with the appropriate total and phospho-ATM antibodies (Chapter 2, 
section 2.1.4). The relative fluorescence intensity of untreated cells was compared with 
irradiated cells.  Statistical significance was determined between Brk-WT-Brk -KM cell lines 
as well as between Brk WT-Vector and Brk KM-vector cell lines and additionally between 
control and irradiation cells. Figure 3.14 shows a representative image of ATM staining. 
 
Figure 3.15 A and B show total ATM relative fluorescence for MDA-MB 468 and MDA-MB 
157 cell lines respectively.   Total ATM relative fluorescence intensity for MDA-MB 468 Brk 
WT cell line was 0.84 compared to 0.92 for MDA-MB-468 Brk KM and 1.02 for MDA-MB 468 
Vector.  Although there was reduction in total ATM for Brk-WT and Brk-KM, the difference 
between the three variants as well as between the un-irradiated controls does not appear to 
be significant.  In MDA-MB-157 cell line when comparing total ATM fluorescence intensity 
between MDA-MB 157 Brk WT cell line and MDA-MB 157 Vector only cell line there is no 
significant difference.  Although, there are lower total ATM levels seen in MDA-MB 157 Brk 
KM cell line (0.8 relative fluorescence) compared to vector only cell line (0.98), however this 
is also not statistically significant.   
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Figure 3.16A and B show relative fluorescence of phosphoserine ATM for MDA-MB 468 and 
MDA-MB 157 cell lines.   Looking at phosphorylation of ATM of the two transfected cell lines, 
MDA-MB 468 Brk WT and MDA-MB 468 Brk KM, there is little difference between the two 
cell lines as well as little difference between control and irradiated cells. No statistically 
significant difference was shown between all three variants in MDA-MB 468 cell lines. 
However, there was significant reduction in phospho-ATM in MDA-MB 468 vector cell line 
when exposed to 2Gy radiation compared to control cells (P=0.04).  For MDA-MB 157 Brk 
WT and Brk KM cell lines, a decline in active ATM was observed and an increase observed 
in MDA-MB-157 Vector only cell line, however there was no statistical significance. 
Overall there are no changes observed in total ATM protein expression in breast cancer cell 
lines in relation to Brk expression nor any significant changes in response to 2Gy gamma 
radiation.  Although there is a reduction in phospho-ATM levels in MDA-MB 468 vector cell 
line in response to gamma radiation this was not confirmed in MDA-MB 157 vector cell line. 





















Figure 3.14 Representative image of total ATM (upper panel) and phosphorylated ATM 
(lower panel).  Breast cancer cell lines; MDA-MB 468 Brk WT, Brk KM, vector a well as cell 
lines; MDA-MB 157 Brk WT, Brk KM were exposed to 2Gy gamma radiation.  For detection of 
total and phosphorylated ATM protein levels, cells were labelled with primary antibody (1.500) 
diluted in blocking buffer and incubated for 24 hours at 4˚C.  Mouse monoclonal antibody ATM 
for C-terminal region (ECM Biosciences) was used for total ATM detection and rabbit polyclonal 
for phosphorylated serine794 of the ATM protein (ECM Biosciences) to detect phosphorylated 
ATM. After washes, cells (except D5 compensation cells) were stained with rabbit anti -mouse 
or goat anti-rabbit secondary antibody solutions containing Alexa Fluor488 IgG (diluted to 
1:1000 in blocking buffer) to detect total and phosphorylated ATM levels respectively.  Cells 
were incubated for 1 hour at room temperature, washed with wash buffer and left overnight at 
4˚C in Accumax solution.  D5 solution was added to each sample except Alexa Fluor488 
compensation cells and cells were analysed using the Imagestream (Amins).   
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  A 
B 
Figure 3.15 Relative fluorescence intensity of breast cancer cell lines for total 
ATM are unchanged compared to control cells.  Cells were exposed to 2Gy 
gamma radiation and stained with mouse monoclonal ATM (C-terminal) antibody 
(1:500 dilution in blocking buffer) and fluorescence intensity of ATM staining in cells 
determined using Ideas software (Amins).  A) MDA-MB 468 Brk WT, Brk KM, vector 
cell lines showing fluorescence intensity of total ATM protein B) MDA-MB 157 Brk 
WT, Brk KM and vector cell lines showing relative fluorescence intensity of total 
ATM protein.  Students T Test was used to assess statistical significance between 






























Figure 3.16 Relative fluorescence intensity of breast cancer cell lines for 
phosphorylated ATM are unchanged compared to control cells.  Cells were 
exposed to 2Gy gamma radiation and stained with rabbit polyclonal ATM (Ser-794), 
phospho-specific (1:500 dilution in blocking buffer) and fluorescence intensity of 
phospho-ATM staining in cells determined using Ideas software (Amins).  A) Shows 
MDA-MB 468 Brk WT, Brk KM, vector cell lines fluorescence intensity of phospho-
ATM vector cells. B) Shows MDA-MB 157 Brk WT, Brk KM and vector cell lines 
difference in relative fluorescence intensity of phospho-ATM protein.  Students T Test 






3.4 Discussion  
In this chapter, the studies sought to determine the link between radio-sensitivity and Brk 
expression levels.  I proposed that cell lines which had high Brk expression may also show 
increased sensitivity of breast cancer cell lines to radiotherapy.  Brk may affect breast cancer 
cell line sensitivity to radiotherapy via deregulation of the DNA repair pathway.  More 
specifically I sought to determine if there was any direct interaction between Brk and the ATM 
pathway by which Brk may affect breast cancer cell sensitivity to radiotherapy as Brk 
expression leads to increased ErbB signalling via P13K/Akt, which is an activator of the 
mTOR pathway and increased levels of mTOR are linked to down-regulation of ataxia 
telangiectasia mutated protein (ATM) (Kamalati et al., 1996; Shen and Houghton, 2013).  
Suppression of ATM, therefore, may increase cancer cell sensitivity to radiotherapy.   
Previous studies have shown Brk may reduce sensitivity of breast cancer cell lines to 
chemotherapy as well as tyrosine kinase inhibitors (Xiang et al., 2008).  This indicates that 
Brk may have some role in relation to treatment responses.  Furthermore, Brk is induced in 
response to DNA damage by gamma radiation (Haegebarth et al., 2009) in intestinal crypt 
epithelial cells.  My studies show for the first time that Brk is also induced in breast cancer 
cells (Figure 3.7) in response to γ-radiation and that induction of Brk was not cell line (or 
subtype) specific. Interestingly the induction of Brk is delayed in response to γ-radiation as 
there were higher Brk levels at the later time points (Figure 3.6).  Other studies have shown 
in the MDA-MB 231 cell line, Brk protein levels are rapidly induced within 5 minutes in 
response to hypoxia (Pires et al; 2014) and also show a delayed induction of Brk protein in 
hypoxic conditions (4 hours) (Anderson et al; 2013).  The delayed induction coincided with 
induction of HIF1α whereas in the Pires study, Brk protein induction appeared to be 
independent of HIF1α suggesting other mechanisms are responsible for the early induction 
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of Brk. Brk protein levels are induced at 6 hours post gamma radiation in intestinal crypt 
epithelial cells (Haegebarth et al, 2009).  These studies suggest early or late Brk induction 
variation may be dependent on other signalling pathways and further investigations may 
show the mechanism of Brk induction in response to radiotherapy in breast cancer cell lines.  
It was hypothesized that Brk increases sensitivity, however my studies suggest, that despite 
being induced, Brk may not play a direct role in the sensitization of breast cancer cell lines to 
radiotherapy. The clonogenic assays show a decrease in colony formation after exposure to 
increasing doses of gamma radiation, although this may be dose dependent and not due to 
Brk expression levels. Variation in SF2 (survival rate after exposure to 2Gy) values were 
observed between all cell lines with statistical significance (P = 0.017) but there was no direct 
association with Brk expression levels.  However, although no direct association was seen 
with Brk expression; 4 out of the 5 cell lines (GI101, BT474, T47D, MDA-MB 436) with highest 
SF2 values also showed moderate to high Brk expression levels suggesting increased 
resistance.      
Histone 2AX (H2AX) is a variant of the H2A protein family which function as vital components 
of the histone octamer in nucleosomes for the localisation and recruitment of DNA repair 
proteins (Kuo and Yang, 2008).   H2AX has proven to be a key component in DNA damage 
response and is rapidly phosphorylated at the sites of double strand break after exposure to 
exogenous stimuli such as ionising radiation (Kuo and Yang, 2008).  γ-H2AX assay, which 
has proven to be a more sensitive technique (Rothkamm and Lobrich, 2003), than comet 
assays and pulsed-field gel electrophoresis (PFGE) (Sharma, Singh and Almasan, 2012) was 
performed to investigate whether Brk influenced DNA repair of breast cancer cell lines.  DNA 
repair was assessed in GI101 (a metastatic model), MDA-MB-436 (a triple negative cell line) 
and BT474 (HER2 positive cell line).   No clear difference in γ-H2AX foci induction was 
observed post treatment between the three cell lines.  Although there was statistical 
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difference observed in foci induction between BT474 and MDA-MB 436 cell lines at 30 
minutes post exposure to γ-radiation (P<0.05), overall there was little statistically significant 
as well as biologically relevant difference noticeable between the three cell lines . It could be 
said that the BT474 cell line which shows high Brk expression levels with moderate SF2 
survival rate (Figure 3.8) as well as lowest induction of γ-H2AX foci at 30 minutes; may 
suggest a role for Brk in protecting cells from cell death in response to γ-radiation or DNA 
damage thus increasing radio-sensitivity.  However, other cell lines such as the GI101 cell 
line also has a similar SF2 survival rate to the BT474 cell line but lower Brk expression levels 
thus indicating Brk may not have any direct influence in radio-sensitivity. This was further 
investigated in the three variants of MDA-MB 468 and MDA-MB 157 cell lines (Brk-WT, Brk-
KM and vector). The γ-H2AX assays comparing the three variants of Brk negative cell lines 
MDA-MB 468 and MDA-MB 157 do not suggest any clear role for Brk in DNA damage 
response, suggesting Brk may not directly affect radio-sensitivity (Figure 3.13).  Nonetheless, 
the vector only cell line had marginally lower induction of H2AX foci for all time points in MDA-
MB 468 compared to MDA-MB 468 Brk WT and Brk KM cells although not significantly 
different.  However, this was not confirmed in the MDA-MB 157 cells. It should be of note, the 
γ-H2AX assay does not specifically detect only radiation induced DSB due to endogenous 
levels of DNA damage such as replication induced DSBs (Banáth, MacPhail and Olive, 2004; 
Kuo and Yang, 2008).  Furthermore, although there are advantages of live cell imaging, often 
there are limitations involving signal background due to high level of expression resulting in 
high background level of foci (reviewed in Vignard, Mirey and Salles, 2013).  Additional DBS 
repair markers along with γ-H2AX foci such as the p53 binding protein, MDC1 and RAD50 
(Xu and Stern, 2003; Yuan and Chen, 2010) may offer a more accurate representation and 
confirmation of DSBs in the cell lines studied.  Other limitations include reduced accuracy 
141 
 
due to lower resolution as compared to in situ fluorescence microscopy thus reducing number 
of observable foci (Bourton et al., 2012).                
Since the ATM protein phosphorylates the H2AX molecules (Burma et al., 2001) upon double 
strand break indication, a potential association between total ATM and phospho-ATM 794 
with Brk may provide further insight into the DNA repair process and thus the radio sensitivity 
of breast cancer cell lines (Burma et al., 2001).  Since, it was hypothesised that increased 
levels of Brk may cause cancer cells to be more radio sensitive by affecting DNA repair 
process via the ATM pathway, the levels of ATM in Brk WT cell lines compared to Brk KM 
and vector only cell lines could be significantly altered.  However, my analysis of total ATM 
protein expression in both MDA-MB 468 and MDA-MB 157 cell lines showed little change 
from the control.   Although there is a reduction in phospho-ATM levels in MDA-MB 468 vector 
cell line in response to gamma radiation suggesting Brk negative cell lines are more sensitive 
to radiation, this was not confirmed in MDA-MB 157 vector cell line which showed higher 
phospho-ATM expression in comparison indicating this difference might be cell line specific 
and not directly related to Brk expression. 
Brk has been shown to interact with a wide variety of substrates (reviewed in Harvey and 
Burmi, 2011), and its function may change in different cellular conditions.  Depending on the 
activation of different signalling pathways in the various cell lines, and their receptor status, 
Brk’s influence in these cell lines may be altered. This may explain some of the discrepancies 
as it has been reported that the MDA-MB-468 cell line has a high level of EGFR and thus has 
a high level of EGF signalling (Filmus et al., 1987), therefore the effects seen with transfected 
Brk may not be as pronounced.   
It should be noted that Brk-targeted therapy which may be a kinase inhibitor may not rely on 
a specific cell cycle phase.  However, since it is involved in cell cycle progression as it 
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promotes cell progression from resting phase to S phase, a Brk-targeted therapy could be 
utilised to prevent cell cycle progression (Chan and Nimnual, 2010).  However, this could 
affect the efficacy of chemotherapy or radiotherapy which are cell cycle dependent. Since 
Brk promotes cell proliferation and, in addition, protects cancer cells from cell death, it could 
reduce the overall effect of radiotherapy thus it must be decided if a potential Brk targeted 
therapy will be useful before or after radiotherapy.    
The main conclusions of this chapter show there is no consistent alterations in determining 
radio-sensitivity of breast cancer cell lines expressing Brk.  This was confirmed in breast 
cancer cell lines expressing either wild type (Brk-WT), kinase mutant Brk (Brk KM) as well as 
a vector only cell line.  Furthermore, investigations in DNA double strand break repair showed 
no differences between all three variants of MDA-MB 468 and MDA-MB 157 cell lines thus 
suggesting there are no significant differences in the repair kinetics of breast cancer cell lines 
in relation to Brk expression status.  In addition, this chapter revealed there was no functional 
link between Brk expression and ATM activity as minor changes were observed of total and 
phosphorylated ATM protein levels in Brk WT, Brk KM and vector only cell lines.  Overall 
these investigations suggest Brk does not affect radiation sensitivity directly nor is the effect 
of Brk on radiation responses mediated through DNA double strand break repair and other 




4.0 Chapter 4: Examining the potential of 







Despite improvements in treatment of breast cancer with adjuvant chemotherapy, there is 
still a need for novel breast cancer therapies.  Treatment of the majority of invasive and higher 
grade/stage cancers is heavily chemotherapy based (Lee and Newman, 2007; Roche and 
Vahdat, 2011) thus the significance of how Brk may influence breast cancer cell sensitivity to 
chemotherapy agents as well as other drug-based treatments needs to be understood.  
Previous studies have shown that Brk may contribute towards influencing chemotherapeutic 
sensitivity in breast cancer (Burmi et al., 2009; Harvey et al., 2009).  The mechanism 
proposed involves Brk altering the ratios of anti and pro-apoptotic proteins; Bcl-XL and Bcl-XS 
respectively, in respect of Bcl-XL.  Suppression of Brk in T47D breast cancer cells, which are 
representative of Luminal A breast cancer subtype, significantly increased sensitivity to 
chemotherapeutic drugs paclitaxel and doxorubicin, however this was not studied in triple 
negative breast cancers (Burmi et al., 2009).   The anti-apoptotic protein Bcl-XL is associated 
with chemotherapeutic resistance (Gul, Basaga and Kutuk, 2008) and reduced levels of Brk 
protein resulted in reduced levels of Bcl-XL protein and thus increased sensitivity to 
chemotherapy (Harvey et al., 2009).  Furthermore, breast cancer cells treated with 
methotrexate and 5-flurouracil showed decreased apoptosis due the inhibition by Bcl-XL in 
vitro and in vivo.  Based on these studies, it is expected a Brk targeted therapy would 
modulate chemotherapeutic drug response.    
 
4.1.1 Brk and targeted therapy   
 
A number of Brk’s functions are dependent on its kinase domain, including anchorage 
independent growth as well as regulation of certain cell death features (reviewed in Harvey 
and Burmi, 2011). Brk-negative breast cancer cells transfected with kinase inactive Brk 
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showed similar levels of suspension-induced cell death compared to cells transfected with 
the vector whereas cells transfected with wild type Brk had almost a 50% reduction in 
suspension-induced cell death, indicating a protective role for Brk’s kinase activity in cancer 
cell death (Harvey et al., 2009).  This is further supported by another study which observed 
Brk downregulation increased apoptosis of breast as well as ovarian cancer cells which were 
deprived of matrix attachment whereas overexpression of Brk resulted in increased survival 
(Irie et al., 2010).  In addition, Brk’s kinase activity is also required for migration and invasion 
of breast cancer cells.  Brk was shown to significantly promote tyrosine phosphorylation of 
paxillin, which was not observed in cells that were transfected with kinase mutant Brk 
indicating dependency on Brk’s catalytic activity (Chen et al., 2004).  Furthermore, 
overexpression of Brk but not kinase mutant Brk indicated a 2.3-fold elevation of Rac1 activity 
(Chen et al., 2004).  Brk kinase activity is also dependent for the phosphorylation of a number 
of cellular proteins (including KAP3A) which was not observed in cells transfected with kinase 
inactive Brk (Lukong and Richard, 2008).  Furthermore, Brk’s kinase activity is essential for 
its association with ARAP1 in an EGF/EGFR dependent manner (Kang et al., 2010).  This 
interaction results in enhanced EGFR signalling and inhibition of EGFR downregulation 
through phosphorylation of ARAP1 in breast cancer cells thus oncogenic functions of Brk 
expression cells are increased (Kang et al., 2010). Taken together these studies provide 
support for inhibiting kinase activity of Brk which may offer some clinical benefit via inhibition 
of these processes especially when used in combination with current breast cancer therapies 
(reviewed in Harvey and Burmi, 2011).      
Overexpression of Brk has previously shown to confer resistance to Lapatinib, the dual 
inhibitor for HER2 and (EGFR), with Brk as studied by Xiang and colleagues (Xiang et al., 
2008).  The ptk6 gene can be coamplified with the HER2 gene and the Brk protein is 
associated with the HER2 protein which prolongs activation of the Ras/MAPK pathway which 
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in turn promotes cell proliferation (Xiang et al., 2008). HER2-induced cell proliferation as 
measured by changes in cell numbers was shown to be dependent on Brk kinase activity.  In 
addition, MCF10A cells expressing HER2 chimera were transfected with a kinase-dead 
version of Brk which significantly inhibited HER2 induced BrdU incorporation in comparison 
to cells transfected with wild type Brk (Xiang et al., 2008).  Furthermore, coexpression of Brk 
with HER2 within the MCF10A cells, in comparison to MCF10A cells expressing only the 
HER2 chimera, increased the concentration of Lapatinib that was required to inhibit HER2 
induced proliferation; this suggests Brk reduces Lapatinib efficacy.  This study, however, did 
not test this effect within breast cancer cells which endogenously overexpress HER2 nor if 
co-treatment with a Brk inhibitor could potentially reduce cell proliferation.  Furthermore, 
downregulation of Brk in Lapatinib resistant breast cancer cells resulted in an induction in 
apoptosis (Park et al., 2015).  Interestingly, another study investigating the simultaneous 
knockdown of Brk and HER2 expression in Lapatinib and Trastuzumab resistant cancer cells 
did not show induction of cell death although there was significant reduction in cancer cell 
proliferation as well as reduced levels of tumour growth in vivo (Ludyga et al., 2013).  
Nonetheless, both studies suggest inhibition of Brk and HER2 kinase activity in combination 
may offer an effective treatment modality.  Thus, my studies hypothesise that, due to the 
interactions between Brk and HER2 as well as EGFR, inhibition of Brk using current small 
molecule inhibitors in combination with Lapatinib may offer a more effective reduction in 
cancer cell proliferation than either agent alone.   
 





Over 70% of breast cancers diagnosed express the oestrogen receptor (ER) or/and the 
progesterone receptor (PR) and grow in the presence of oestrogen (Ito et al., 2017).  
Recently, Brk has been shown to increase growth and survival of ER positive luminal breast 
cancer cells including those that have acquired resistance against endocrine therapies (Ito et 
al., 2017).  Downregulation of Brk in 3D Matrigel cultures resulted in the inhibition of growth 
of two ER+ breast cancer cell lines; T47D and MCF7 as well as variants of these cell line that 
were tamoxifen resistant.  Thus, Brk promotes cancer cell growth even in the presence of 
tamoxifen.   In addition, there was evidence to suggest downregulation of Brk induced 
apoptosis of MCF7 and T47D, tamoxifen-resistant cells, indicating a potential role for Brk in 
endocrine therapy resistance   Although this study has not highlighted whether Brk inhibition 
would potentiate the effects of Tamoxifen; there is convincing evidence for the role Brk plays 
in tamoxifen resistance and the need for a Brk-targeted therapy, especially in patients with 
resistance to current endocrine therapies. My investigations using a Brk inhibitor in 
combination with Tamoxifen treatment on ER+ cell lines may offer further insight and support 
for a Brk targeted therapy. I hypothesise that, due to the proliferative role of Brk in ER+ breast 
cancer cells, a combination of Tamoxifen and Brk inhibition would result in reduced breast 
cancer cell proliferation.   
 
4.1.3 Brk Inhibitors  
 
 
There is a lack of development of Brk inhibitors, therefore no suitable agents have been 
identified to investigate the clinical benefits of Brk inhibition thus far.  Although a few have 
been in development, they have yet to be completely investigated in vitro and in vivo.  A 
specific inhibitor for Brk could reduce cancer cell proliferation for a number of cancers (such 
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as breast, colon and prostate cancers) and I predict that it could sensitize tumours to other 
therapies and potentially as a consequence prevent metastasis.  However, Brk’s kinase 
independent functions, which includes promotion of breast cancer cell proliferation, will need 
consideration (Harvey and Crompton, 2003).  In addition, unpublished data has shown breast 
tumour xenograft growth is independent of Brk kinase activity.  Therefore, a more desirable 
therapeutic intervention may involve protein-protein disruptions for a better therapeutic 
benefit.    
The first inhibitor specific for Brk was discovered in 2011 as part of a focused library screening 
against the Brk enzyme (Zeng et al., 2011).  The results showed the imidazol (1,2-α) pyrazin-
8-amine series of compounds as desirable and potent Brk kinase inhibitors.  Compound 21a 
showed an IC50 (half maximal inhibitory concentration) value of 10nM with mouse 
pharmacokinetics providing a Cmax value of 17.9µM at 30 minutes after injection of 30mg/kg 
intra-peritoneal (Zeng et al., 2011).  Although bioavailability for compound 21a was only 5.8%, 
it may prove to be an important compound to evaluate in vivo Brk inhibitor activity.   Further 
investigations with imidazol (1,2-α) pyrazin-8-amines show co-crystal structure of Brk kinase 
domain with an inhibitor from the imidazo[1,2-a]pyrazine- 8-amine series and IC50 at 80nM 
measured as percentage of Poly (G:T) using ADP-Glo assay kit (Thakur et al., 2017).   Further 
studies have yet to be carried out in vitro to show the inhibitory effects within breast cancers, 
however thus far they have shown to bind to the ATP pocket of Brk and are highly potent as 
well as have moderate to high cellular activity (Zeng et al., 2011).    
The discovery of 4-anilino α-carbolines further indicated that a Brk targeted therapy is a viable 
treatment option (Mahmoud et al., 2014).  The serine/threonine kinase, Haspin, has been 
shown to phosphorylate histone H3 in mitosis thus showing its potential as a target for anti-
cancer drug treatment (Cuny et al., 2012).  From this, came the discovery of β carbolines as 
potential protein kinase inhibitors including for Haspin (Bain et al., 2007).  This provided a 
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rationale to investigate α-carbolines as potential kinase inhibitors.  After chemical synthesis, 
the most active and potent Brk inhibitor identified was compound 4f which was tested for 
growth inhibition (GI) in three breast cancer cell lines producing GI50 value of 0.99µM in 
MCF7 cell line, 1.02µM in HS-578/T cells and 1.58µM in BT-549 cell line (Mahmoud et al., 
2014).  Further studies with 4-anilino α-carbolines derivatives known as MK138 and MK150 
also indicated reduced activity of STAT3, a signalling molecule downstream of Brk, with 
increasing concentration of both derivatives in T47D breast cancer cell line (Oelze et al., 
2015).  In addition, inhibition of Brk with either 100nM of MK138 or MK150 induced cell death 
under loss of adherence conditions.  Further studies using these inhibitors have not been 
published to date thus there is limited information regarding their potential as therapeutic 
agents for breast cancer. 
More recently, a novel drug known as XMU-MP-2 was identified as a potential Brk inhibitor 
(Jiang et al., 2017).  XMU-MP-2 is a small molecule Brk kinase activity inhibitor which targets 
the ATP-binding site and has shown efficacy in inhibiting cell proliferation of oncogenic Brk-
transformed Ba/F3 cells and Brk-overexpressing breast cancer cells in vitro and in vivo (Jiang 
et al., 2017).  This drug was highly selective for Brk when screened against 28 other kinases 
and has shown to be more potent compared to compound 4f.  However, it should be noted 
this was investigated using the cell line Ba/F3, a murine interleukin 3 dependent pro-B cell 
line which was transfected with Brk.      
Another set of Brk inhibitors recently identified include the pyrazolopyrimidines PP1 and PP2 
(Shim, Kim and Lee, 2017), using an ELISA based in vitro kinase assay system for Brk.  The 
most potent inhibitors identified along with PP1 and PP2 were the Lck inhibitor.  IC50 values 
for PP1 included 230nM, for PP2 was 50nM and for Lck inhibitor, it was 60nM (Shim, Kim 
and Lee, 2017).  These were also highly selective for Brk when tested against a panel of 
kinases including Src family of kinases.  STAT3 activity was also significantly reduced with 
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increasing concentration of PP1 and Lck inhibitors in HEK 293 cell line (Shim, Kim and Lee, 
2017).  Furthermore, Brk inhibition with PP1 and PP2 reduced Brk-mediated proliferation of 
T47D breast cancer cell line and although this was also observed when using the Lck 
inhibitor, this effect was also seen in a Brk-independent manner when using the Lck inhibitor 
suggesting it is not specific as PP1 and PP2 when inhibiting Brk.  Further in vitro and in vivo 
studies using PP1 and PP2 have yet to be performed. A summary of all Brk inhibitors is 

















Table 4.1 Summary of Brk inhibitors 
Brk Inhibitor First discovered Summary of inhibitor 
Compound 21a  2011 (Zeng et al., 2011) Imidazol (1,2-α) pyrazin-8-amine compound 
with IC50 of 10nM, Cmax value of 17.9µM at 
30 minutes after injection of 30mg/kg intra-
peritoneal.   
Compound 4f 2014 (Mahmoud et al., 
2014) 
A β carboline compound, GI50 value of 
0.99µM in MCF7 cell line, 1.02µM in HS-





2015 (Oelze et al., 2015) Both inhibitors showed reduced activity of 
STAT3, a signalling molecule downstream 
of Brk.  Inhibition of Brk with either 100nM of 
MK138 or MK150 induced cell death under 
loss of adherence conditions. 
XMU-MP-2 2017 (Jiang et al., 2017) Targets ATP binding site and reduces cell 
proliferation of oncogenic Brk-transformed 
Ba/F3 cells and Brk-overexpressing breast 
cancer cells in vitro and in vivo.   
PP1, PP2 and Lck 2017 (Shim, Kim and Lee, 
2017) 
These are pyrazolopyrimidines with IC50 
values for PP1 at 230nM, for PP2 at 50nM 
and for Lck inhibitor at 60nM.  STAT3 




Considering the proliferating role of Brk in cancer cells as well as its role in tumorigenesis 
(reviewed in Harvey and Burmi, 2011), Brk inhibition using a novel inhibitor is expected to 
reduce Brk phosphorylation and subsequently decreased phosphorylation of its downstream 
signalling molecule, STAT3 (Liu et al., 2006; Weaver and Silva, 2007; Gierut et al., 2011). 
This is important as STAT3 is regarded as an oncogene, with tyrosine phosphorylation of 
STAT3 linked to breast cancer development (Gierut et al., 2011). Activation of STAT3 by Brk 
may contribute towards cell transformation and uncontrolled growth in early stages of breast 
cancer. Brk also mediates STAT3 regulation in established tumours (Liu et al., 2006), and 
constitutive activation of Brk accelerated cell migration and tumour growth in vivo (Miah, 
Martin and Lukong, 2012).   
  
increasing concentration of PP1 and Lck 
inhibitors in HEK 293 cell line. 
153 
 
4.2  Aims and Objectives 
 
Aims: 
There have been a lack of studies investigating the potential of Brk inhibition in breast cancer 
cells.  In this chapter the main aims were to investigate the potential of Brk inhibition as a 
monotherapy and in combination with standard breast cancer therapies as well as the effect 
on downstream signalling in response to Brk inhibition.  Considering the proliferating role of 
Brk in cancer cells as well as its role in tumorigenesis (reviewed in Harvey and Burmi, 2011), 
Brk inhibition using a novel inhibitor is expected to reduce Brk phosphorylation and 
subsequently decreased phosphorylation of its downstream signalling molecule, STAT3 (Liu 
et al., 2006; Weaver and Silva, 2007; Gierut et al., 2011). In addition, Brk inhibition is 
hypothesised to reduce breast cancer cell line viability as well as modulate the response to 
standard breast cancer therapies including Taxol, Doxorubicin, Lapatinib and Tamoxifen. 
The objectives were: 
 To investigate the effect on cell viability of breast cancer cells using the novel Brk 
inhibitor known as Compound 4f (Mahmoud et al., 2014) through MTT assays as a 
monotherapy as well as in combination with breast cancer therapies; Taxol, Doxorubicin, 
Lapatinib and Tamoxifen. 
 To investigate the effect on Brk activity including the activity of its downstream signalling 
molecule STAT3, as well as determine levels of ALT-PTK6 protein in response to 








4.3.1 Effect on breast cancer cell viability using a novel Brk inhibitor, 
Compound 4f. 
 
I sought to investigate the effect of Brk inhibition on cell viability using the Brk inhibitor, 
Compound 4f.  Considering the role that Brk plays in promoting proliferation of cancer cells 
(Kamalati et al 1996, 2000, Xiang et al 2008, Shen et al 2008, Ostrander et al 2007), inhibition 
of Brk’s kinase function may prove to be an effective treatment modality.  To elucidate the 
role Brk inhibition may have on breast cancer cell viability, cells were treated with a novel Brk 
inhibitor known as Compound 4f.  The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay is a widely used colorimetric technique for measurement 
of cell proliferation and cytotoxicity (Liu et al, 1997).  Breast cancer cells were plated in a 96 
well plate at a seeding density of 5 x103 per well in replicates of six wells and left to incubate 
at 37˚C and 5% CO2 overnight before treating with the compound.  Cells were treated either 
with dimethyl sulfoxide (DMSO) as the control or the following concentrations of Compound 
4f: 0.625µM, 1.25µM, 2.5µM, 5µM, 10µM and 20µM.  The 96 well plates were incubated at 
37˚C and 5% CO2 for a total of 7 days with fresh media and compound added every 2/3 days.  
After which, MTT reagent/media mixture was added to each well and left to incubate as before 
for 2 hours before adding 0.04M HCL isopropanol to solubilize the formazan. Absorbance 
was measured at wavelengths 570nm and 620nm to determine cell viability.  Cell viability 
was calculated as percentage of control for all graphs shown in this chapter and XY scatter 
graphs were produced to determine relationship between dose and cell viability. Correlation 
statistical analysis was performed for all graphs using Graphpad prism 5 to determine 
Spearman rho correlation coefficient (denoted as rs value), as well as the statistical 





Figure 4.1 Statistically significant reduction is observed after Brk inhibition using a novel 
Brk inhibitor, Compound 4f for MCF10A, GI101 and T47D cell lines .  MTT assays were 
performed to determine cell viability.  Cells were seeded and allowed to adhere overnight in 96 
wells plates before treatment with a range of doses (0-20µM) with the Brk inhibitor, Compound 
4f.  The cells were left in incubation (37˚C, 5% CO2) for 7 days.  Fresh media and drug were 
added every 2/3 days.  After which, MTT reagent was added to the wells and left in incubation 
for 2 hours before solubilisation with 0.04M HCL isopropanol.  The absorbance at wavelengths 
570 for MTT and 620nm (background) were determined and cell proliferation calculated as 
percentage of control.  XY scatter graphs show each data point as a dot and correlation statistics 
determined using Graphpad software.  Spearman rho correlation coefficient (rs), and two tailed 




   
  
Figure 4.2 Statistically significant reduction in cell proliferation is observed for SKBR3, 
BT474, MDA-MB 231 and MDA-MB 436 cell lines after Compound 4f treatment.  MTT assays 
were performed to determine cell viability.  Cells were seeded and allowed to adhere overnight in 
96 wells plates before treatment with a range of doses (0-20µM) with the Brk inhibitor, Compound 
4f.  The cells were left in incubation (37˚C, 5% CO2) for 7 days.  Fresh media and drug were 
added every 2/3 days.  After which, MTT reagent was added to the wells and left in incubation for 
2 hours before solubilisation with 0.04M HCL isopropanol.  The absorbance at wavelengths 570 
for MTT and 620nm (background) were determined and cell proliferation calculated as percentage 
of control. XY scatter graphs show each data point as a dot and correlation statistics determined 
using Graphpad software.  Spearman rho correlation coefficient (rs), and two tailed p values for 
statistically significant correlation were determined, p <0.05 is significant, n=3. 
SKBR3
































































































The MCF10A cell line does show some reduction in cell proliferation with 78.4% (+/- 7.22 
standard deviation) percentage cell viability at the highest (20µM) concentration of the 
compound.  T47D cell line which expresses high levels of Brk protein, shows a reduction to 
74.2% (+/- 11.3 standard deviation) with 20µM of compound 4f whereas GI101 which 
expresses moderate levels of the Brk protein shows 90.8% (+/- 14.6 standard deviation) at 
the same concentration.  The HER2 positive cell lines; SKBR3 and BT474 show an average 
reduction in cell proliferation to 84.2% (+/- 8.1 standard deviation) and 85.4% (+/- 2.5 
standard deviation) respectively at the 20µM concentration.  Within the triple negative breast 
cancer cell lines; MDA-MB 231 and MDA-MB 436 there is a reduction to 69.6% (+/- 15.6 
standard deviation) and 61.3% (+/- 6.19 standard deviation) respectively.   For the MCF10A 
cell line, the Spearman rho correlation coefficient (rs) value of -0.75 suggests a negative 
correlation with increasing dose and reducing cell viability in response to Brk inhibition, 
although this correlation is not statistically significant (p=0.66). For T47D, the rs value is -
0.8929 with a statistically significant correlation (p =0.0123) observed between cell viability 
and Brk inhibition.  In contrast, GI101 cell line shows no statistical significance in correlation 
between Brk inhibition and cell viability (p =0.2357) and the rs value of -0.5357 shows 
relatively weaker correlation.  The rs value of -0.6429 and -0.75 for SKBR3 and BT474 
respectively show a correlation between reducing cell viability and increasing drug 
concentration. Both these HER2 positive cell lines, however showed statistically no significant 
correlation (p=0.1389 and p=0.06 respectively) as shown in Figure 4.2.  The r value of -
0.8624 and -0.9001 show a strong negative correlation in cell viability after treatment with 
compound 4f in the triple negative cell lines MDA-MB 231 and MDA-MB 436 respectively 
(Figure 4.2). The correlation is also statistically significant with p values of 0.0125 and 0.006 
for MDA-MB 231 and MDA-MB 436 respectively.  Overall majority of the cell lines displayed 
a dose dependent relationship between compound 4f and reducing cell viability except for 
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the GI101 cell line, which showed the weakest correlation that was not statistically significant.  
The cell lines, T47D, MDA-MB 231, MDA-MB 436 showed the strong inverse correlation 
between Brk inhibition and cell viability compared to the other cell lines.  There was statistical 
significance observed suggesting there was a correlation between the cell viability and Brk 
inhibition.  It should be noted, however that although there is a correlation observed between 
decreasing cell viability with increasing compound 4f concentration for these cell lines, the 
correlation analysis does not imply causation.  The statistical significance does not 
necessarily indicate biological relevance and observing the graphs, the reduction in cell 
viability in response to Brk inhibition with compound 4f does not reach IC50 (half maximal 
inhibitory concentration) value even with a higher concentration of 20µM for all cell lines 
suggesting the low potency of the inhibitor.  This suggests that Brk inhibition may not an 
effective monotherapy in these breast cancer cell lines.  .  
 
4.3.2 Combination treatment using compound 4f and chemotherapy 
agents, Taxol and Doxorubicin in breast cancer cell lines.  
 
Treatment of majority of cancers including breast cancer is heavily chemotherapy based thus 
the significance of how Brk may influence breast cancer cell sensitivity to chemotherapy 
agents needs to be understood.  In particular, chemotherapy remains the choice of treatment 
for triple negative breast cancer (reviewed in Collignon et al., 2016).  Therefore, I determined 
the efficacy of Taxol and Doxorubicin in two triple negative breast cancer cell lines; MDA-MB 
231 and MDA-MB 436.  I then sought to determine the difference in cell viability with Brk 
inhibitor treatment in combination with Taxol or Doxorubicin.  The effect of Brk inhibition on 
the activity of its downstream signalling molecule, STAT3 was determined through western 
blots as well as determination of total and phospho-Brk activity and the levels of ALT-PTK6, 
the short isoform of full length Brk.  As before the cell lines were plated in a 96 well plate at 
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a seeding density of 5 x103 per well and left to incubate at 37˚C and 5% CO2 overnight before 
treating with the either Taxol or Doxorubicin.  Cells were treated either with dimethyl sulfoxide 
(DMSO) as the control or the following concentrations of each agent: 0.16µM, 0.3125µM, 
0.625µM, 1.25µM, 2.5µM and 5µM.  For the combination treatments, all cells were treated in 
addition with Compound 4f at a concentration of 5µM.  The 96 well plates were left in 
incubation at 37˚C and 5% CO2 for a total of 7 days before processing as previously stated.  
Cell viability was calculated as percentage of control for all graphs.  Graphs were plotted as 
scatter plots with mean and error bar showing standard deviation using Graphpad Prism 5 
software.  IC50 values showing half maximal inhibitory concentration were determined using 
Excel. Cells were treated with 5µM of compound 4f and protein lysates were collected at 0, 
4, 6, 24 and 48 hours post treatment.  Western blots were performed to determine levels of 
total Brk, phosphorylated Brk (p-Brk), total STAT3,  phosphorylated STAT3 (p-STAT3) with 
β actin as the loading control as per the method in section 2.2.9and 2.2.4 in Chapter 2: 
Materials and Methods.  Additionally, levels of ALT-PTK6 protein, the short isoform of full 





































































































Figure 4.3 Brk modulates Taxol (Tax) and Doxorubicin (Dox) response in triple negative breast 
cancer cell lines: MDA-MB 231 and MDA-MB 436.  Cell lines were plated in a 96 well plate at a 
seeding density of 5 x103 per well and left to incubate at 37˚C and 5% CO2 overnight before treating 
with the either Taxol or Doxorubicin.  Cells were treated either with dimethyl sulfoxide (DMSO) as the 
control or the following concentrations of each agent: 0.16µM, 0.3125µM,  0.625µM, 1.25µM, 2.5µM and 
5µM.  For the combination treatments, all cells were treated in addition with Compound 4f at a 
concentration of 5µM.  The 96 well plates were incubated at 37˚C and 5% CO2 for a total of 7 days with 
fresh media and compound added every 2/3 days.  After which, MTT reagent/media mixture was added 
to each well and left to incubate as before for 2 hours before adding 0.04M HCL isopropanol to solubilize 
the formazan. Absorbance was measured at wavelengths 570nm and 620nm to determine cell viability.  
Scatter plots show mean (line in the middle) and error bars show standard deviation, n= 3.  Students T 
Test indicates statistical significance with P<0.05 as significant. 
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Figure 4.4 Western blots show an overall reduction in total and phosphorylated Brk in 
triple negative cell lines after Brk inhibition. Western blots were performed in A) MDA-MB 
231 and B) MDA-MB 436 cell lines to show total and phosphorylated Brk (p-Brk) protein 
expression, total and phosphorylated STAT3 (p-STAT3) protein expression, ALT-PTK6 
expression and β actin was used as loading control.  Cells were lysed with 2x SDS-PAGE 
loading buffer, 100µl of lysis buffer was used per 1 million cells. Equal volume of lysates were 
loaded on a stacking gel and a 12% or 10% resolving gel was used. The proteins were then 
electro-blotted onto nitrocellulose membrane in 1x Towbin transfer buffer 1 hour at 300 volts 
and 400mAps.  Membranes were blocked in 5% non-fat skimmed milk/TBS-T before incubating 
with primary antibodies overnight.  The membranes were then washed with 1x TBST and 
incubated with the appropriate secondary antibody for 1 hour. Protein expression was detected 
with appropriate primary and secondary antibodies (Chapter 2: Materials and Methods, section 
2.1.4., Table 5).  Protein bands were detected using chemiluminescent substrates Coumaric 
acid (0.0148g/ml) and luminol (0.0443g/ml). N=3.   




Figure 4.5 Shows difference in cell proliferation of T47D cell line is observed with Brk 
inhibition in combination with Taxol or Doxorubicin (Dox).  Cell lines were plated in a 96 well 
plate at a seeding density of 5 x103 per well and left to incubate at 37˚C and 5% CO2 overnight 
before treating with the either Taxol or Doxorubicin.  Cells were treated either with dimethyl 
sulfoxide (DMSO) as the control or the following concentrations of each agent: 0.16µM, 0.3125µM, 
0.625µM, 1.25µM, 2.5µM and 5µM.  For the combination treatments, all cells were treated in 
addition with Compound 4f at a concentration of  5µM.  The 96 well plates were incubated at 37˚C 
and 5% CO2 for a total of 7 days with fresh media and compound added every 2/3 days.  After 
which, MTT reagent/media mixture was added to each well and left to incubate as before for 2 
hours before adding 0.04M HCL isopropanol to solubilize the formazan. Absorbance was 
measured at wavelengths 570nm and 620nm to determine cell viability.  Scatter plots show mean 
(line in the middle) and error bars show standard deviation, n= 3.  Students T Test indicates 
statistical significance with, P<0.05 is significant. 












































Figure 4.3 indicates modest reduction in cell viability for both triple negative breast cancer 
cell lines in response to either Paclitaxel (Taxol) or doxorubicin treatment only.  Observing 
the intermediate dose of 0.625µM, average cell viability using Taxol only treatment was 
90.5% (+/- 8.4 standard deviation) compared to average cell viability of 79.4% (+/- 7.5 
standard deviation) for Taxol with compound 4f within MDA-MB 231 cell line.  At the same 
concentration for MDA-MB 231 with Doxorubicin, cell viability was at 92% (+/- 2.6 standard 
deviation) compared to 76.4% (+/- 5.5 standard deviation) in combination with compound 4f.  
A cell line representative of Luminal A (T47D) was used due to its increased sensitivity to the 
chemotherapy agents in comparison to the two triple negative cell lines.  A clear reduction in 
cell viability was observed in response to both Taxol and Doxorubicin treatment.  IC50 
concentration for treatment with Taxol and Taxol in combination with 4f was determined with 
Excel and showed concentrations of 1.95µM and  1.76µM respectively.  For Doxorubicin 
treatment, the IC50 concentration was 2.49µM and for combination with 4f the IC50 was 
0.89µM.  The IC50 value for combination treatment shows a lower concentration suggesting 
combination treatment may be more effective than using Doxorubicin as a monotherapy.  
Overall, although statistically significant difference was observed, in comparison to treatment 
with either chemotherapy agent, there was greater reduction in cell viability with co-treatment 
using compound 4f (Figure 4.5).   
Figure 4.4 shows the protein levels in MDA-MB 231 and MDA-MB 436 cell lines, after 
treatment with compound 4f, of total Brk, phosphorylated Brk (Tyr342) as well as 
phosphorylation of the downstream substrate, STAT3 as a marker of altered Brk activity.  Total 
levels of Brk in MDA-MB 231 gradually decrease 24 hours post treatment before reaching 
near control levels at 48 hours post treatment.  Levels of phosphorylated Brk (p-Brk) are also 
decreased over time compared to control lysate and STAT3 activity (p-STAT3) increases 4 
hours post treatment before decreasing and remaining relatively constant at 6, 24 and 48 
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hours post treatment.  For the first time, ALT-PTK6 protein expression was also detected in 
this cell line which decreased over time.  In comparison, in MDA-MB 436 cells, total Brk 
protein expression and p-Brk levels are reduced gradually 4, 6, 24 and 48 hours post 
treatment along with total STAT3 and p-STAT3 levels (Figure 4.4).  For the first time, protein 
expression of the short isoform, ALT-PTK6 was detected in the MDA-MB 436 cell line and 
some reduction was observed at 24 hours post treatment.   
 
4.3.3 Combination treatment using compound 4f and the small molecule 
inhibitor, Lapatinib in HER2 positive breast cancer cell lines. 
 
 
In addition to investigating whether Brk modulates chemotherapeutic response in breast 
cancer cell lines, I also sought to determine if Brk modulates response to targeted therapies. 
Since Brk, EGFR and HER2 interactions have previously been documented (Kamalati et al., 
1996, 2000; Born et al., 2005; Aubele et al., 2007, 2010; Xiang et al., 2008; Li et al., 2012; Ai 
et al., 2013; Ludyga et al., 2013); a Brk targeted therapy may prove to be beneficial.   Briefly, 
lapatinib is a dual kinase inhibitor of HER2 and EGFR activity and its efficacy is reduced in 
HER2-trasnfected mammary epithelial cells with increased levels of Brk (Xiang et al., 2008).  
This suggests potential for a novel Brk inhibitor treatment to be used in combination with 
lapatinib for a greater clinical benefit, especially in patients who have acquired resistance to 
lapatinib.  The effect of Brk inhibition on the activity of its downstream signalling molecule, 
STAT3 was determined in HER2 positive cell lines through western blots as well as 
determination of total and phospho-Brk activity and the activity of HER2 protein.  SKBR3 and 
BT474 cell lines were plated in a 96 well plate at a seeding density of 5 x103 per well as 
described previously and treated with either with dimethyl sulfoxide (DMSO) as the control or 
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the following concentrations of Lapatinib: 0.312µM, 0.625µM, 1.25µM, 2.5µM, 5µM and 
10µM.  For combination treatment, cells were treated with 5µM of Compound 4f. The 96 well 
plates were left in incubation and processed as previously stated.  Cell viability was calculated 
as percentage of control for all graphs.  Western blots were carried out to determine levels of 
total Brk, phosphorylated Brk (p-Brk), total STAT3 and phosphorylated STAT3 (p-STAT3) as 
well as total and phosphorylated HER2 levels with β actin as the loading control as per the 

































Figure 4.6 Brk modulates Lapatinib response in HER2 positive breast cancer cell lines: 
SKBR3 and BT474.  SKBR3 (A) and BT474 (B) cell lines were plated in a 96 well plate at a seeding 
density of 5 x103 per well and treated with either with dimethyl sulfoxide (DMSO) as the control or 
the following concentrations of Lapatinib: 0.312µM, 0.625µM, 1.25µM, 2.5µM, 5µM and 10µM.  For 
combination treatment, cells were treated with 5µM of Compound 4f. The 96 well plates were 
incubated at 37˚C and 5% CO2 for a total of 7 days with fresh media and compound added every 
2/3 days.  After which, MTT reagent/media mixture was added to each well and left to incubate as 
before for 2 hours before adding 0.04M HCL isopropanol to solubilize the formazan. Absorbance 
was measured at wavelengths 570nm and 620nm to determine cell viability.  Scatter plots show 
mean (line in the middle) and error bars show standard deviation, n= 3.  Students T Test indicates 
statistical significance with P<0.05 as significant .  
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Figure 4.7 Western blots show an overall reduction in total and phosphorylated Brk in 
HER2 positive breast cancer cell lines after Brk inhibition. Western blots were performed 
in A) SKBR3 and B) BT474 cell lines to show total and phosphorylated Brk (p-Brk) protein 
expression, total and phosphorylated STAT3 (p-STAT3) protein expression and and β actin 
was used as loading control.  Cells were lysed with 2x SDS-PAGE loading buffer, 100µl of 
lysis buffer was used per 1 million cells. Equal volume of lysates were loaded on a stacking 
gel and a 12% or 10% resolving gel was used. The proteins were then electro-blotted onto 
nitrocellulose membrane in 1x Towbin transfer buffer 1 hour at 300 volts and 400mAps.  
Membranes were blocked in 5% non-fat skimmed milk/TBS-T before incubating with primary 
antibodies overnight.  The membranes were then washed with 1x TBST and incubated with 
the appropriate secondary antibody for 1 hour. Protein expression was detected with 
appropriate primary and secondary antibodies (Chapter 2: Materials and Methods, section 
2.1.4., Table 5).  Protein bands were detected using chemiluminescent substrates Coumaric 




My investigations show significant reduction in cell viability for both HER2 positive breast 
cancer cell lines (SKBR3, P=0.023 and BT474, P=0.019) when a Brk inhibitor is used in 
combination with targeted therapy, lapatinib in comparison to either inhibiting Brk alone or 
using lapatinib alone (Figure 4.6A).  Observing the lower concentrations, there is an average 
reduction to 61.74% (+/- 10.6 standard deviation) at the 0.312µM concentration for the 
combination treatment compared to an average reduction to 94.31% (+/- 5.5 standard 
deviation) with lapatinib only in the BT474 cell line.  A greater reduction in cell viability was 
observed in the SKBR3 cell line, with an average reduction in cell proliferation to 71.4% (+/- 
2.5 standard deviation) at the 0.312µM concentration for lapatinib treatment alone compared 
to 28.03% (+/- 9.7 standard deviation) for combination treatment with compound 4f.  This is 
an approximate 2.5-fold reduction in cell viability.       
Figure 4.7 shows an increase in protein levels of total Brk in the SKBR3 cell line at 4 hours 
post treatment with compound 4f before a reduction at 48 hours post treatment.  Phospho-
Brk activity is also reduced post treatment with compound 4f.  Total STAT3 levels remain 
relatively constant before a reduction 48-hour post treatment.  Phosphorylated STAT3 (p-
STAT3) is reduced 4, 6, 24 and 48 hours post treatment compared to control levels.  
Interestingly, p-STAT3 levels are the lowest at 6 and 24 hours post treatment before 
increasing at 48 hours post treatment.   There seems to be no observable change in HER2 
levels.  Figure 4.7B also shows protein levels of total Brk in BT474 cell line, which are 
increased 4 hours post treatment with compound 4f before reducing 6, 24 and 48 hours post 
treatment.  Phospho-Brk (p-BRK) levels increase 4 and 6 hours post treatment relative to 
control levels before reducing 24 and 48 hours post treatment.  Total STAT3 levels remain 
relatively constant post treatment with compound 4f, except at 24 hours post treatment where 
there is a reduction.  STAT3 phosphorylation (p-STAT3) is reduced at all time points post 
treatment and starts to recover by 48 hours.  HER2 levels appear to be relatively constant 
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with very modest increase 6 and 24 hours post treatment.  In comparison phosphorylated 
HER2 (p-HER2) levels are decreased overall for both cell lines. 
 




It has been previously documented there is a strong correlation between high expression of 
PTK6 and positive oestrogen receptor (ER+) status within breast tumours (Zhao et al., 2003).  
Higher levels of PTK6 expression within ER+ breast cancers was also associated with 
adverse patient outcomes (Irie et al., 2010).  In addition, p38 MAPK, a mediator of MEF2 
activation, cyclin D1 up regulation and involved in increased cell migration in response to 
ErbB signalling is a substrate of Brk (J H Ostrander et al., 2007), with high levels of active 
phosphorylated p38 MAPK significantly correlated with elevated levels of HER2 and 
increased Tamoxifen resistance (Gutierrez et al., 2005).   More recently, Brk/PTK6 has been 
shown to enhance the growth of ER+ breast cancer cells basally as well as in oestrogen 
deprived conditions, and in the presence of Tamoxifen, further indicating a role for Brk in drug 
resistance (Ito et al., 2017).  These studies suggest targeting PTK6 for inhibition would 
potentially increase sensitivity of breast cancer cells to Tamoxifen and other endocrine 
therapies as well as overcome potential mechanism of drug resistance.   I sought to determine 
sensitivity of ER+ breast cancer cells to Tamoxifen in combination with Brk inhibition.  The 
effect of Brk inhibition on the activity of its downstream signalling molecule, STAT3 was 
determined in this luminal A breast cancer subtype cell line through western blots as well as 
determination of total and phospho-Brk activity, levels of the oestrogen receptor and the 
levels of ALT-PTK6, the short isoform of full length Brk.  T47D cells were plated as before 
but, due to presence of low levels of oestrogen and to remove endogenous serum steroids, 
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phenol red free growth media supplemented with 10% charcoal stripped foetal bovine serum 
(FBS) was used.  Cells were treated either with dimethyl sulfoxide (DMSO) as the control or 
the following concentrations of Tamoxifen: 0.312µM, 0.625µM, 1.25µM, 2.5µM, 5µM and 
10µM.  The cells were additionally treated with 5µM of compound 4f in combination therapy.  
The cells were processed as mentioned previously.  Cell viability was calculated as 
percentage of control for all graphs.   Western blots were performed as per the method in 













Figure 4.8 Brk modulates endocrine therapy, Tamoxifen response in ER+ breast cancer cell 
line T47D.  Cells were cultured in phenol red free growth media supplemented with 10% charcoal 
stripped foetal bovine serum. Cells were plated in a 96 well plate at a seeding density of 5 x103 per 
well and treated either with dimethyl sulfoxide (DMSO) as the control or the following concentrations 
of Tamoxifen: 0.312µM, 0.625µM, 1.25µM, 2.5µM, 5µM and 10µM.  The cells were additionally 
treated with 5µM of compound 4f in combination therapy.  The 96 well plates were incubated at 37˚C 
and 5% CO2 for a total of 7 days with fresh media and compound added every 2/3 days.  After which, 
MTT reagent/media mixture was added to each well and left to incubate as before for 2 hours before 
adding 0.04M HCL isopropanol to solubilize the formazan. Absorbance was measured at 
wavelengths 570nm and 620nm to determine cell viability. Scatter plots show mean (line in the 
middle) and error bars show standard deviation, n= 3.  Students T Test indicates statistical 
significance with P<0.05 as significant.  


























Figure 4.9 Relative expression ratios of ALT-PTK6 to PTK6 after compound 4f treatment some 
show some variation.  Western blots were performed in T47D cell line to show total and 
phosphorylated Brk (p-Brk) protein expression, total and phosphorylated STAT3 (p-STAT3) protein 
expression and and β actin was used as loading control.  Cells were lysed with 2x SDS -PAGE 
loading buffer, 100µl of lysis buffer was used per 1 million cells. Equal volume of lysates were 
loaded on a stacking gel and a 12% or 10% resolving gel was used. The proteins were then electro-
blotted onto nitrocellulose membrane in 1x Towbin transfer buffer 1 hour at 300 volts and 400mAps.  
Membranes were blocked in 5% non-fat skimmed milk/TBS-T before incubating with primary 
antibodies overnight.  The membranes were then washed with 1x TBST and incubated with the 
appropriate secondary antibody for 1 hour. Protein expression was detected with appropriate 
primary and secondary antibodies (Chapter 2: Materials and Methods, section 2.1.4., Table 5).  
Protein bands were detected using chemiluminescent substrates Coumaric acid (0.0148g/ml) and 
luminol (0.0443g/ml). N=3.   
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Treatment with Tamoxifen, the selective oestrogen receptor modulator (SERM), shows 
relative sensitivity of T47D cell line, a luminal A subtype of breast cancer (Figure 4.8).  There 
is an average reduction in cell viability to 66.6% (+/- 10.9 standard deviation) at the highest 
concentration of 10µM when using Tamoxifen alone.  In comparison, there is an average 
reduction to 52.8% (+/- 5.6 standard deviation) when treated in combination with compound 
4f at the same concentration.  A greater reduction is observed at the lower end doses, for 
example, at the concentration of 5µM, there was an average reduction in cell viability to 
80.9% (+/- 6.1 standard deviation) using Tamoxifen only compared to 58% (+/- 5.2 standard 
deviation) when used in combination with the Brk inhibitor. Overall, there is statistically 
significant difference between Tamoxifen as a single agent and Tamoxifen in combination 
with compound 4f (P=0.004).  
Figure 4.9 shows western blots for total Brk, phosphorylated Brk (p-Brk), total STAT3, 
phosphorylated STAT3 (p-STAT3), oestrogen receptor alpha (ERα) and the short isoform of 
full length Brk, ALT-PTK6.  The western blot showed little difference in total Brk levels after 
treatment with 5µM of compound 4f, although there appears to be a reduction in Brk activity 
(p-Brk) levels at 6, 24 and 48 hours post treatment. There is reduction in total STAT3 and p-
STAT3 levels relative to control levels at 48 hours post treatment.  Oestrogen receptor alpha 
(ERα) levels showed a reduction at 6 and 48 hours post treatment compared to control levels.  
Interestingly ALT-PTK6 protein expression appeared to increase 4, 6, 24 and 48 hours post 






The studies in this chapter are some of the first to investigate the potential role of a novel Brk 
inhibitor in modulating breast cancer cell response to various anticancer drugs currently used 
in the treatment of breast cancer patients.  These include chemotherapeutic agents Paclitaxel 
(Taxol) and Doxorubicin, small molecule inhibitor Lapatinib and endocrine therapy, 
Tamoxifen (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005; Mamounas 
et al., 2005; Ogawa and Lindquist, 2018).   Due to the role of Brk in promoting tumour cell 
proliferation including anchorage independent growth in breast cancer cells (Kamalati et al., 
1996; J H Ostrander et al., 2007; Harvey et al., 2009; Chan and Nimnual, 2010), I 
hypothesised a potential Brk inhibitor would decrease proliferation as well as sensitise breast 
cancer cells to these treatments.  Using a novel Brk inhibitor known as compound 4f 
(Mahmoud et al., 2014), I first sought to determine the effect on cell viability of breast cancer 
cell lines (Figures 4.1 and 4.2).  There was  reduction in cell viability observed with increasing 
concentration of compound 4f at low doses for majority of the breast cancer cell lines, 
especially at the mid to high end (5-20µM) of the drug concentrations used compared to 
untreated control cells.  The greatest reduction in cell viability with compound 4f treatment 
was observed mainly in the triple negative cell lines (Figure 4.2).  It should be noted that 
although there is some statistical significance observed with compound 4f treatment, the 
biological relevance of this may be small as overall the cell lines did not reach an IC50 (half 
maximal (50%) inhibitory concentration) value with Brk inhibition.  The IC50 values are 
commonly used as a measure of a drug’s efficacy (Aykul and Martinez-Hackert, 2016).  In 
addition, the sample size of n=3 is small and a bigger sample may increase the power of any 
statistical analysis.  The variations in cell viability for all cell lines upon Brk inhibition may be 
dependent on the levels of Brk expression.   Observing Brk expression levels in the cell lines 
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that were used, MDA-MB 231 and MDA-MB 436 cell lines show moderate levels of Brk 
expression, T47D and BT474 cell lines show high Brk expression, GI101 and SKBR3 show 
lower Brk expression.  In relation to efficacy to compound 4f, there is no clear pattern with 
Brk expression as cell lines with low and high Brk expression levels show similar sensitivity 
whereas the two triple negative cell lines which show moderate levels of Brk show the 
greatest sensitivity to compound 4f.  This may suggest additional factors may influence cell 
line sensitivity to Brk inhibitor, for example, expression of other breast cancer receptors 
including: HER2, ER, PR and EGFR, within each cell line.  Furthermore, due to the triple 
negative cell lines lacking HER2, ER and PR, and the role these receptors play in cell 
proliferation (Fanelli et al., 1996; Conley et al., 2016), inhibiting Brk may therefore reduce the 
number of signalling pathways by which the cancer cells are able to continue cell proliferation 
thus indicating reduced cell viability.    I then further sought to determine if Brk modulated 
chemotherapeutic response in triple negative breast cancers (Figure 4.3).  Triple negative 
breast cancers (TNBCs) showing chemo-sensitivity to anthracyclines (Doxorubicin) and 
taxanes (Taxol), indicate an overall survival which remains poor (O’Reilly et al., 2015).  In 
addition, chemo-resistance accounts for 90% of drug failures for metastatic cancers (Longley 
and Johnston, 2005) and there are a number of mechanism which induce chemo-resistance 
in TNBC including mutations in DNA repair enzymes, alterations in genes involved in 
apoptosis as well as due to overexpression of β tubulin III subunit which induces resistance 
to Taxol (Tommasi et al., 2007).  In addition, patients with triple negative breast cancer 
(TNBC) have limited therapeutic options and most do not respond to current endocrine or 
targeted therapies, thus there is a need for novel therapies for this subgroup of patients 
(Tomao et al., 2015).  Moreover, TNBC has become an attractive area of research within 
oncology and continuous understanding of its molecular characteristics would identify novel 
targets and allow for investigations of their therapeutic potential (Tomao et al., 2015).  Since 
176 
 
other breast molecular markers (ER, HER and PR) are absent in TNBC but Brk expression 
is present in triple negative cancers; any potential therapy targeting Brk inhibition may also 
be beneficial to TNBC patients.  Thus, I sought to determine if compound 4f would reduce 
breast cancer cell viability in combination with standard of care chemotherapy agents Taxol 
or Doxorubicin within triple negative breast cancer cell lines.    Overall, Taxol or Doxorubicin 
treatment resulted in reduction in cell viability of both of the triple negative cell lines MDA-MB 
231 and MDA-MB 436 (Figure 4.3).  These results showed both cell lines were more sensitive 
to Taxol and Doxorubicin as monotherapies compared to the Brk inhibitor, compound 4f 
alone.  Thus suggesting, Brk kinase inhibition may not be effective as a monotherapy.  
Although it should be noted the two cell lines (MDA-MB 231 and MDA-MB 436) also express 
epidermal growth factor receptor (EGFR) and Brk association with EGFR leading to cell 
proliferation even in the absence of epidermal growth factor has previously been shown 
(Kamalati et al., 1996).  Brk also potentiates EGFR signalling by inhibiting the downregulation 
of EGFR and thus prolonging EGFR signalling (Kang et al., 2012; Li et al., 2012; Kang and 
Lee, 2013).  EGFR signalling has shown to increase cancer cell proliferation and survival 
(reviewed in Kim and Muller, 1999).  However, co-treatment with compound 4f and either 
Taxol or Doxorubicin indicated reduction in cell viability compared to either chemotherapy 
agent on its own, although this was not significantly different with Taxol treatment.  This 
indicates inhibition of Brk kinase activity may improve the sensitivity of triple negative breast 
cancers to chemotherapy agents, Taxol and Doxorubicin.   
In addition to cell viability for both triple negative cell lines, protein expression of Brk and Brk 
activity (p-Brk) as well as activity of its downstream signalling molecule signal transducer and 
activator of transcription 3 (STAT3) was determined after treatment with the Brk inhibitor, 
compound 4f over a 48-hour time period (Figure 4.4).   STAT3 is a substrate of Brk and is 
involved in a number of cellular process including cell proliferation, migration and survival in 
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breast cancers (Liu et al., 2006; Weaver and Silva, 2007).   Brk has also shown to be auto-
phosphorylated in its activation loop, most likely at Tyr-342 as well as additional sites at lower 
levels (Qiu and Miller, 2002; Castro and Lange, 2010).  Thus, I hypothesised inhibition of Brk 
kinase domain would also result in reduced total Brk expression levels as well as reduced 
total and phosphorylated levels of STAT3.  Overall there is a reduction in total Brk expression 
over time post treatment with compound 4f as well as a reduction in Brk activity within the 
MDA-MB 231 cell line.  However total STAT3 protein expression as well as activity (p-STAT3) 
remain relatively unchanged.  Within the MDA-MB 436 cell line, there is relative reduction in 
total Brk protein expression as well as Brk activity including reduced STAT3 activity post 
treatment with compound 4f.  STAT3 activation has been linked to all subtypes of breast 
cancer especially the more aggressive types and thus its activation is important for survival 
of triple negative breast cancers (Marotta et al., 2011; Walker and Frank, 2015).  The 
difference observed with total STAT3 and phospho-STAT3 levels between the two cell lines 
after Brk inhibition may be explained due to increased levels of STAT3 gene within MDA-MB 
231 cell line as well as increased number of STAT3 binding sites which is specific for the 
MDA-MB 231 cell line (McDaniel et al., 2017).  Since STAT3 has a prominent role in TNBC 
migration and invasion leading to metastasis, inhibition of Brk as an upstream regulator of 
STAT3, may have potential to reduce these oncogenic functions in the TNBC subtype 
(Jackson and Lozano, 2017).  Both cell lines also expresses low levels of ALT-PTK6, which 
is the short isoform of full length Brk.  ALT-PTK6 has been proposed to act as a competitive 
inhibitor of full length Brk as well as negatively regulate cell growth in prostate cancer cells 
and increasing levels of transfected ALT-PTK6 within HEK293 cells showed reducing levels 
of Brk proportionally (Brauer et al., 2011; Harvey and Burmi, 2011). However, little else is 
known regarding its role in breast cancer.  ALT-PTK6 expression remains relatively 
unchanged within MDA-MB 436 cell lines (Figure 4.4B) after treatment with the Brk inhibitor.  
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Although there is a reduction at 24 hours post treatment, this may be explained due to lower 
loading as the β actin levels as the loading control are lower than the other samples.   In the 
MDA-MB 231 cell line, interestingly ALT-PTK6 levels reduce over time with Brk inhibition. 
This may be due to the concurrently reducing levels of the full length form.   Any Brk targeted 
therapy may have potential effects on the short isoform due to interactions of Brk with RNA 
binding proteins such as Sam68, SLM1 and SLM2 which regulate the splicing process 
(Brauer et al., 2011).   Thus, a reduction in Brk levels may also result in reduced ALT-PTK6 
protein.  Alternatively, ALT-PTK6 itself has shown to associate with Sam68 thus it may 
regulate its own splicing.  In other cellular contexts, a reduction in Brk may shift the balance 
in favour of ALT-PTK6 for any SH3 binding partners of Brk and thus result in reduced Brk at 
the membrane and more localisation of Brk in the nucleus, where it has shown to have growth 
inhibitory functions (Brauer et al., 2011). However, there appears to be minor change in ALT-
PTK6 expression within the MDA-MB 436 cell line, indicating compound 4f does not affect 
ALT-PTK6 protein levels and thus would not negatively affect its potential role as a negative 
regulator of growth in breast cancer cells. 
To further elucidate the role of Brk in modulating breast cancer cell response to current breast 
cancer therapies, I sought to determine if Brk decreased cell viability in combination with 
targeted therapy, Lapatinib within two HER2 positive cell lines: SKBR3 and BT474.   Both 
cell lines showed high sensitivity to lapatinib as a monotherapy (Figure 4.6).  Co-treatment 
with compound 4f, however, resulted in a reduction of cell viability to an average of less than 
3% at the dose of 10µM for both cell lines. Significant difference was observed between 
lapatinib as a single agent and in combination with compound 4f (P=0.023 for SKBR3 and 
P=0.019 for BT474).  These results are further supported by other in vitro studies which have 
shown simultaneous knock down of HER2 and Brk leads to significant reduction in cell 
proliferation (Ludyga et al., 2013).  Overall, there is a reduction in protein expression of Brk 
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as well as Brk activity with compound 4f treatment in both cell lines as well as reduced levels 
of total STAT3 and p-STAT3 activity (Figure 4.7B).  Due to Brk and HER2 co-expression 
(Ludyga et al., 2013), Brk inhibition may result in downregulation of HER2 activity.  However, 
there appears to little observable change in HER2 levels.  In comparison, overall there is a 
clear reduction in p-HER2 levels for both cell lines indicating Brk inhibition results in a 
reduction in HER2 activity.  Previous studies have shown comparable results for Brk inhibition 
in HER2 positive cell lines.  siRNA knockdown of PTK6 in breast cancer cell lines including 
a trastuzumab resistant cell line JIMT-1, showed little change in HER2 and HER2 protein 
expression whereas phosphorylated HER2, levels were reduced (Ludyga et al., 2011).  
Taken together, these results suggest inhibition of Brk and HER2 in combination may offer a 
more effective alternative therapy than to use either as a monotherapy.   
I next sought to determine the role of Brk in sensitizing breast cancer cells to endocrine 
therapy, more specifically Tamoxifen.  Tamoxifen is a selective oestrogen receptor modulator 
(SERM) that binds to the oestrogen receptor and functions by antagonizing the effects of 
oestrogens (Abdulkareem and Zurmi, 2012).  It has shown clinical efficacy in combination 
with other chemotherapy drugs for the treatment of early as well as advanced breast cancer 
(Clemons, Danson and Howell, 2002).  However, some tumours do not show any response 
to Tamoxifen and some will eventually acquire resistance through various mechanisms 
including mutation or loss of oestrogen receptors, impaired co activator signalling and altered 
Tamoxifen metabolism (Ali and Coombes, 2002; Abdulkareem and Zurmi, 2012).  Tamoxifen 
resistance is also linked to increased insulin growth factor (IGF)-1 signalling through the IGF-
1 receptor (IGF-1R) and cross talks with oestrogen receptor (Parisot et al., 1999).  Thus, 
breast cancer cells with resistance to Tamoxifen indicate upregulation of IGF-1R. There have 
been few published studies investigating the role between Brk and endocrine therapies.  
However Brk has been shown to co-precipitate with IGF-1R and regulate IGF-1 induced 
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anchorage independent survival, inhibition of Brk may therefore sensitise breast cancer cell 
lines to Tamoxifen treatment and overcome a potential resistance mechanism (Irie et al., 
2010).  Elevated levels of PTK6 transcript have also been associated with adverse outcomes 
for oestrogen receptor (ER) positive subset of patients (Irie et al., 2010).   This was further 
confirmed more recently, when the Irie group showed that breast cancer patients with positive 
oestrogen receptor status and higher relative expression of PTK6 transcript had poorer 
overall survival (Ito et al., 2017). Brk and oestrogen receptor interactions have also been 
shown to indicate a rationale for Brk as a positive prognostic marker despite being 
overexpressed in high grade tumours as the oestrogen receptor is associated with positive 
prognosis and increased disease free survival (Harvey et al., 2009).      
My studies show a proportionate reduction in cell viability with increasing concentration of 
Tamoxifen in ER positive breast cancer cell line T47D (Figures 4.8).  There is also a 
significant difference between co-treatment with compound 4f for T47D cell line compared to 
Tamoxifen treatment alone (P=0.004).  Protein expression of total Brk is relatively unchanged 
to control levels after treatment with compound 4f (Figure 4.9).  However, Brk activity is 
reduced at 6, 24 and 48 hours post treatment compared to control levels, thus indicating 
reduction in active Brk in the oestrogen receptor positive cell line.  Total STAT3 levels remain 
relatively unchanged until 48 hours post treatment where there is a reduction compared to 
control levels as well as very moderate reduction in p-STAT3 levels.   Interestingly, oestrogen 
receptor alpha (ERα) levels vary with compound 4f treatment.  ERα levels are relatively 
similar to control levels 4 hours post treatment then reduced 6 hours post treatment before 
increasing 24 hours post treatment and subsequently decreasing 48 hours post treatment.  
Nonetheless, there is an overall reduction in oestrogen receptor levels as well as reduced 
Brk activity, indicating Brk inhibition modulates breast cancer cell response to endocrine 
therapies, potentially via downregulation of oestrogen receptor although this needs further 
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validation.  In addition, ALT-PTK6 protein expression was increased in response to Brk 
inhibition over the time period.  A reduction in Brk activity shows reduced interaction with its 
downstream substrates and considering that ALT-PTK6 may compete for Brk’s SH3 binding 
partners, reduced Brk activity may therefore result in increased ALT-PTK6 levels at the 
protein level.  Although there was an increase in ALT-PTK6 protein expression within the 
T47D cell line and a decrease in the MDA-MB 231 cell line, this may be due to the expression 
levels of Brk and ALT-PTK6.  Considering the low level of ALT-PTK6 expression in the MDA-
MB 231 cell line, additionally inhibiting Brk may reduce the production of the alternatively 
spliced isoform due to Brk’s interaction with proteins involved in alternative splicing.  
However, this effect is not as pronounced in the T47D cell line due to the much higher level 
of ALT-PTK6.  Recently, Brk overexpression has shown to enhance growth of ER positive 
breast cancer cells including in oestrogen deprived conditions as well as in the presence of 
Tamoxifen (Ito et al., 2017).  ER positive breast cancer cell lines, MCF7 and T47D were stably 
expressed with activated Brk which was enough to enhance growth of these cell lines thus 
suggesting a role for Brk in promoting ER positive breast cancer growth basally as well as 
under oestrogen deprived conditions (Ito et al., 2017).  Downregulation of Brk impaired 
growth and induced apoptosis in both Tamoxifen sensitive and resistant breast cancer cells 
in vivo as well as in vitro  (Ito et al., 2017).  Thus, my studies with compound 4f corroborate 
results with Brk inhibition in ER positive breast cancer cells.    
Overall, my studies provide insight to the potential of Brk targeted therapy.  Brk modulates 
response of breast cancer cells to a number of commonly used treatment modalities in breast 
cancer including Paclitaxel (Taxol), Doxorubicin, Lapatinib as well as endocrine therapy, 
Tamoxifen.  The co-treatments with Brk also indicate significant reduction in cell viability at 
lower doses.   There are number of issues with current breast cancer therapies including an 
increasing number of patients treated using anthracyclines and taxanes in the adjuvant 
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setting have shown to present with metastatic disease (Hassan et al., 2010).  Resistance to 
these therapies, including to hormone and targeted therapies, remains a major challenge to 
overcome (Hussain et al., 2005).  In addition, there are a number of acute, immediate and 
long-term toxicities associated with many chemotherapeutic agents used in breast cancer 
therapy, including cardiac toxicities with anthracycline based regimens (Bird and Swain, 
2008), an increased relative risk of secondary cancers by 22% (Schaapveld et al., 2008), 
increased risk of cognitive impairment as well as neurotoxicity by 20-30% (Azim et al., 2011). 
Thus, there is a need for novel breast cancer therapies that, when used in combination with 
existing drugs, could allow for increased efficacy at potentially lower doses, thereby reducing 
side effects. My investigations indicate Brk as a monotherapy may not be effective to reduce 
breast cancer cell viability, however there is potential for Brk inhibitors to be used in 
combination with other treatments.  Nonetheless, it should be noted that the overall very 
moderate reduction in cell viability using compound 4f alone may be due to the actual 
inhibitor.  At the time of these studies, a Brk inhibitor was not commercially available.    Thus 
my studies utilised a novel Brk kinase inhibitor known as compound 4f as developed by 
Hilgeroth and group (Mahmoud et al., 2014).  There are also few published studies 
investigating the role of compound 4f as well as its potency in inhibiting Brk in vivo as well as 
in vitro.   In addition, through personal communication with other research groups working 
with Brk, we discovered compound 4f was not found to be a particularly stable drug once it 
is in solution thus this will affect its activity and potency.  A more potent version of compound 
4f or another more potent inhibitor for Brk may indicate a more effective reduction in cell 
viability as a monotherapy as well as in combination therapy.    
The main conclusions from this chapter were that Brk as a monotherapy may not be effective, 
however, there is potential in combination with other breast cancer treatments. There was a 
correlation between Brk inhibition and reducing cell viability, however it should be noted that 
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this does not imply compound 4f was the only cause of the reduction in cell viability and other 
factors may be involved including breast cancer receptor status and stability of the 
compound.  In addition, it should be noted although there was some significant correlation 
observed, the biological relevance of this may not be substantial due to low efficacy of the 
inhibitor. Furthermore, the specificity of the inhibitor to target Brk was not evaluated in this 
study and will need consideration in any future studies using this inhibitor.    
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5.0 Chapter 5: Investigating the 
ratios of ALT-PTK6 to PTK6 
transcripts in breast cancer cell 







The ptk6 gene comprises of 8 exons which span 10kb, and fluorescent in situ hybridization 
(FISH) studies indicate its localisation to chromosome 20q13.6 (Mitchell et al., 1997).  
Alternative splicing of the PTK6 transcript produces a separate mRNA sequence encoding 
the truncated protein ALT-PTK6 (alternative PTK6 isoform), which shares the first 77 amino 
acids and SH3 domain with the full length protein (Mitchell et al., 1997).  Both transcripts 
were shown to be co-expressed in prostate and colon cancer primary cell lines and human 
prostate tumour and normal tissue (Brauer et al., 2011).  Tyner and group also revealed 
potential functions of the short isoform (Brauer et al., 2011).  Ectopic expression of ALT-PTK6 
was shown to enhance repression of β-catenin/TCF transcription,  which is involved in the 
WNT pathway and enhances cancer growth, (Palka-Hamblin et al., 2010; Brauer et al., 2011).  
PC3 prostate cancer cell lines with induced ALT-PTK6 expression also had reduced 
proliferation and colony formation compared to controls without ALT-PTK6 induction (Brauer 
et al., 2011).  In addition, ALT-PTK6 may enhance the nuclear functions of Brk and previous 
studies have indicated subcellular localisation of Brk significantly influenced its ability to 
regulate β-catenin transcriptional activity (Palka-Hamblin et al., 2010; Brauer et al., 2011).  
Furthermore, PTK6 to ALT-PTK6 mRNA expression ratios were shown to be higher in 
prostate tumour cells in comparison to normal prostate cells (Brauer et al., 2011).    
Co expression of the full length PTK6 transcript and the alternative isoform have also been 
shown in breast cancer cell lines including T47D, SKBR3, BT474, MDA-MB 231 (Peng et al., 
2014). It was originally believed the PTK6 was present in mainly breast cancer cell lines and 
breast cancer tissues and not in normal breast (Mitchell et al., 1997).  However, more recently 
Brk was detected in normal mammary tissue as well as in the non-transformed mammary 
gland epithelial cell line MCF10A (Peng et al., 2014).  Furthermore, protein expression of ptk6 
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was detected in the cytoplasm and nucleus of luminal and myoepithelial cells within the cores 
of mammary gland tissue from 27 patients (Peng et al., 2014) 
Interestingly, active Brk  was not detected in epithelial cells of normal mammary glands, 
indicating perhaps Brk has kinase-independent functions in the normal mammary gland 
(Peng et al., 2014).  Studies have shown high expression of PTK6 in high grade invasive 
ductal carcinomas compared to low or undetectable levels in low grade tumours; suggesting 
a negative correlation with patient survival outcomes and that PTK6 expression levels may 
be used to determine prognosis (Harvey et al., 2009; Irie et al., 2010; Peng et al., 2014).  It 
should also be noted, other investigations have shown a positive correlation with high Brk 
expression and improved probability of distant recurrence free survival in breast cancer 
patient cohorts, although this was observed at the later months (240 months) (Born et al., 
2005; Aubele et al., 2007).  This was later confirmed in a different and smaller (n=80) patient 
cohort with Brk expression correlating with a good prognosis (P=0.018) (Aubele et al., 2010).  
This contradiction may be due to the presence of other breast molecular markers such as 
ER, which has shown positive association with Brk expression and ER is a known positive 
prognostic indicator (reviewed in Taneja et al., 2010). 
My investigations focused on the detection and expression of full length PTK6 transcript as 
well as the short isoform splice variant ALT-PTK6 in a number of breast cancer cell lines at 
the basal level.  Using qPCR allowed for the quantification of the relative expression ratios of 
both variants in comparison to full length PTK6 at basal level, as well as in response to Brk 
inhibition using the compound 4f (Mahmoud et al., 2014).  Relative expression and 
expression ratios were also determined post treatment with a number of breast cancer 
anticancer agents including; Paclitaxel (Taxol), Doxorubicin, Lapatinib and Tamoxifen.  Due 
to the role of ALT-PTK6 in negative regulation of cell growth as well as its role as a regulator 
of Brk activity and as a competitive inhibitor of Brk substrates; any reduction in Brk may shift 
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the balance in favour of ALT-PTK6 expression (Brauer et al., 2011).  Since ALT-PTK6 is 
proposed to be a negative regulator of Brk activity and higher PTK6 mRNA expression is 
associated with poorer outcomes  (Harvey et al., 2009; Brauer et al., 2011) it was predicted  
ALT-PTK6 to PTK6 ratios will be higher in cancerous tissues and reduced in normal/ low 




5.2 Aims and Objectives  
Aims: 
Previous studies have shown PTK6 transcript is associated with adverse patient survival 
outcomes in breast cancer as well as expression of both PTK6 and ALT-PTK6 expression in 
a limited number of breast cancer cell lines.  The aims of this chapter were to investigate the 
ratio of mRNA expression levels of ALT-PTK6 and PTK6 in breast cancer cell lines in 
response to Brk inhibition and standard breast cancer therapies.  In addition, previous studies 
have not investigated the role of ALT-PTK6 and PTK6 transcripts in breast cancer tissue in 
relation to overall and disease free survival and it was hypothesised that ALT-PTK6 to PTK6 
ratios will be higher in cancerous tissues/cell lines and reduced in normal/ low grade breast 
tumours/cell lines.  
 
The objectives were: 
 To determine expression of both full length PTK6 transcript and the short splice 
variant; ALT-PTK6 in breast cancer cell lines using Real Time-PCR. 
 To quantify the relative mRNA expression and ratios of both PTK6 transcripts in breast 
cancer cell lines at basal levels and before and after treatment with compound 4f as 
well as in response to standard breast cancer treatments: Taxol, Doxorubicin, 
Lapatinib as well as Tamoxifen. 
 To determine ALT-PTK6 to PTK6 mRNA expression ratios in normal and tumour 






5.3.1 Determination of PTK6 and ALT-PTK6 expression in breast cancer cell 
lines using RT-PCR 
 
I first sought to determine gene expression of PTK6 as well as the short isoform ALT-PTK6.  
For reverse transcriptase PCR (RT-PCR), RNA was extracted from the cell lines and 200ng/µl 
concentration of RNA in a final volume of 20µl was reverse transcribed and the cDNA used 
as template for PCR.  RT-PCR was performed in the following cell lines: MCF10A, GI101, 
T47D, SKBR3, BT474, MDA-MB 231 and MDA-MB 436.  REDTaq Readymix PCR Reaction 
Mix with MgCI2 (Sigma-Aldrich) was prepared with either Brk primers (Sigma Aldrich) or 
loading control gene, β actin as described in Materials and Methodology (section 2.2.18).  All 
experiments were carried out with three independent sets of RNA lysates. PCR products 
were visualised using the Gel Doc Imaging System (BioRad) and a representative image of 
the RT-PCR products is shown in Figure 5.1.   
Expression of both PTK6 (407 bp) and ALT-PTK6 (285bp) was detected in most of the cell 
lines examined under basal conditions (Figure 5.1).  Expression was not detected in the 
immortalised transformed cell line MCF10A as well as one of the triple negative cell lines, 
MDA-MB 231.  High levels of expression were seen in GI101, T47D, SKBR3 and BT474 cell 
lines.  The MDA-MB 436 cell line had moderate expression of the both PTK6 and ALT-PTK6 






Figure 5.1 Representative RT-PCR showing basal expression of PTK6 and ALT-
PTK6 (upper panel) as well as β actin as loading control  (lower panel) in MCF10A, 
GI101, T47D, SKBR3, BT474, MDA-MB 231 and MDA-MB 436 cell lines.  PTK6 and ALT-
PTK6 are 407 and 285 bp respectively.  β actin is 350bp. 1x of REDTaq Readymix PCR 
Reaction Mix with MgCI2 (Sigma-Aldrich), sterile distilled water, Forward Primer (1µM), 
Reverse Primer (1µM), cDNA (250ng/µl) were mixed together before running a RT-PCR 
reaction with β actin parameters: 35 cycles of denaturing at 95˚C for 30 seconds, primer 
annealing at 58˚C for 30 seconds and extensions at 72˚C for 45 seconds. The final step 
was at 72˚C for 10 minutes.  The parameters for PTK6 RT-PCR were: 35 cycles of 
denaturing at 95˚C for 30 seconds, pimer annealing at 63˚C 30 seconds and extensions 
at 72˚C for 45 seconds and the final step was at 72˚C for 10 minutes. RT-PCR was 
performed on 3 independent sets of RNA.   
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5.3.2 Determination of reference genes with GeNORM analysis 
 
Reverse transcriptase PCR (RT-PCR) only allows for detection or absence of gene 
expression with the endpoint of the experiments visualised as PCR bands and is, at best, 
semi-quantitative although there is no quantification of the expression levels measured during 
the exponential phase.  Thus quantitative polymerase chain reaction (qPCR) is a better 
method which has proven to be more precise and makes quantification easier (Bonetta, 
2005). 
Before beginning analysis of target gene expression, it has become essential to decide the 
most stable reference genes expressed for all the cell lines used in the experimental 
conditions.  This allows for a reliable qPCR experiment set up that is normalised to these 
reference genes and is compliant with the Minimum Information for Publication of Quantitative 
Real Time PCR experiments or the MIQE guidelines (Bustin et al., 2009).  This is particularly 
important when using a set of cell lines with high heterogeneity as is the case with breast 
cancer cell lines.  Often a single reference gene is used for qPCR experiment normalisation, 
however normalisation against a single gene is considered unreliable due to a greater chance 
of introducing relatively large errors, whereas increasing the number of reference genes leads 
to greater resolution and increased accuracy (Kozera and Rapacz, 2013); therefore the 
optimal number and choice of reference genes needed to be determined (Vandesompele et 
al., 2002; Bustin et al., 2009). 
In order to determine the reference genes to use with the following cell lines; MCF10A, GI101, 
T47D, SKBR3, BT474, MDA-MB 231 and MDA-MB 436, the GeNORM array kit for 12 
reference genes was used (Primer Design). The geNORM kit contains a panel of either 6 or 
12 candidate genes that are used to determine the optimal reference gene for the 
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experimental conditions.  The relative expression of these genes is determined with 
quantitative PCR and the data analysed using the geNORM analysis software called qbase+ 
provided by Biogazelle. The reference genes included in the kit are shown in Table 2.12 
(Chapter 2, section 2.2.16). The qPCRs were performed in duplicate wells for each reference 
gene and performed twice for control or basal and treated experimental conditions, with 
5ng/µl of cDNA loaded in each well, according to the manufactures protocol.  Primer Design 
do not disclose the primer sequences of their GeNORM analysis reference genes therefore 
once reference genes were determined via GeNORM analysis, primers for these genes of 
known sequence were designed and purchased from Sigma Aldrich.  The qPCR data was 
analysed using qBase+ software (Biogazelle) as recommended by Primer Design for their 
GeNORM analysis kit. 
The qBase+ software determines which genes to use as well as the optimal number of 
reference genes to use for the cell lines tested.  Data analysis issues a geNORM M value for 
each of the 12 reference genes which indicates gene stability between the samples (Figure 
5.2).  The lower the M value the more stable the reference gene is.   In addition to an M value, 
a bar graph indicating a V value was generated (Figure 5.3).  This shows the levels of 
variation in reference gene stability with sequential addition of each candidate gene.  This 
measure is known as ‘pairwise variation V’.  The geNORM V value, in conjunction with the 





Figure 5.2 GeNORM 12 gene reference kit (Primer Design) was used to assess the stability of 
expression of 12 reference (housekeeping) genes in breast cancer cell lines . For each cell line, 
5ng/µl of cDNA was used in duplicate wells in a 96 well plate and the data analysed using qBase+ 
software (Biogazelle).  The software generated a geNORM M value for each reference gene 
indicating the stability of each gene.  The lower the M value, the more stable the gene.  The graph 
shows the least stable genes to the most stable genes from left to right.  The two most stable genes 
















The qBase+ software recommends that anything below or equal to 1.0 for the value of M 
indicates a stable gene.  The geNORM V value shows average variation of stability between 
successive genes, with the average geNORM V value of 0.15 or below as the recommended 
value for deciding the number of reference genes to use.  Therefore, the optimal number of 
2-4 reference genes to use was indicated and the four most stable reference genes 
recommended to use are as follows:  18S, UBC, SDHA and RPL13A.  The qbase+ manual 
Figure 5.3 GeNORM 12 gene reference kit (Primer Design) was used to determine number of 
optimal reference genes. For each cell line, 5ng/µl of cDNA was used in duplicate wells in a 96 
well plate and the data analysed using qBase+ software (Biogazelle).  The software generated a 
geNORM V value indicating variability between successive sets of genes.  A V value of 0.15 or 
lower indicates the optimal number of reference genes to used (indicated by green line).  Optimal 




states: “The proposed 0.15 value must not be taken as a too strict cut off” and the number of 
reference genes was the recommendation, and since the MIQE guidelines suggest at least 
two reference genes to be used and the use of only one reference gene is not acceptable in 
addition to the third and fourth most stable genes (UBS and 18S respectively) beginning to 
incline in the gene stability graph (Figure 5.2); I decided to use the two most stable genes; 
Succinate Dehydrogenase complex flavoprotein subunit A (SDHA) and Ribosomal protein 
L13a (RPL13A) as the reference genes (Bustin et al., 2009; Kałużna, Kuras and Puławska, 
2017). The SDHA gene encodes a catalytic subunit of the succinate-ubiquinone 
oxidoreductase complex which is involved in the mitochondrial respiratory chain and the 
RPL13A gene encodes a member of the L13p family of ribosomal proteins.   
 
5.3.3 Determination of PTK6 and ALT-PTK6 mRNA expression in breast cancer 
cell lines and mRNA expression ratios of ALT-PTK6 to PTK6 at basal level.  
 
There are no commercially available primers for the PTK6 or the short isoform ALT-PTK6 
thus custom primers were designed for both transcripts by Primer Design.  Primers were 
designed to specifically detect the full-length isoform, PTK6.  Primers were also designed 
that detected the short isoform, ALT-PTK6, however due to issues with the primer specificity 
Primer Design were unable to design primers which only detected the short isoform.  Primers 
that were able to detect the short isoform, were also able to detect the full-length isoform.  
ALT-PTK6 expression was therefore determined from subtraction from the full-length values.  
Previous studies have not used qPCR to evaluate levels of ptk6 transcripts in breast cancer 
cell lines, although there are higher PTK6 to ALT-PTK6 ratios in prostate cancer cell lines as 
well as in higher grade prostate tumours compared to normal tissue and low grade tumours 
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(Brauer et al., 2011).  However, within breast cancer tissues, although ALT-PTK6 transcript 
levels were not investigated, Brk mRNA expression was detected in 85% of breast tumours 
and shown to be overexpressed in tumour samples compared to normal mammary tissues 
(Harvey et al., 2009).  To further elucidate the significance of ALT-PTK6 expression within 
breast cancer cell lines, I determined ratios of ALT-PTK6 to PTK6 under normal growth 
conditions.  In addition, ALT-PTK6 protein expression was determined by western blotting as 
previously described (Chapter 2, section 2.2.11) with an anti-Brk polyclonal antibody N-
Terminal (Abcam).   In order to confirm the PCR band sizes of the primers purchased, I 
performed reverse transcriptase PCR and agarose gel electrophoresis (Figure 5.4).  I then 
performed qPCRs on cDNA from the following breast cancer cell lines: MCF10A, GI101, 
T47D, SKBR3, BT474, MDA-MB 231 and MDA-MB 436.  PrecisionPLUS MasterMix 
premixed with SYBRgreen (Primer Design) was prepared with either transcript’s primer mixes 
(300nM final concentration) (Primer Design) and RNase/DNase free water per manufacturers 
protocol.  The qPCR was carried out on the Applied Biosystems Quantstudio 7 Flex Real-
Time PCR machine.  The qPCRs were prepared in duplicate well using three 3 independent 
sets of RNAs for each cell line.  The reference genes used for normalisation were SDHA and 
RPL13A.  These were determined and validated by geNORM analysis as performed in 
section 5.3.2.  The geNORM analysis shows the number of reference genes and the most 
stable genes to use for the experimental conditions (Adeola, 2018) It has been suggested 
use of more than one reference gene as internal control for normalisation might generate 
more reliable results (Adeola, 2018).  qPCR analysis was performed using the average CT 
(Cycle Threshold) values obtained after each run.  This value is determined as the number 
of cycles required for the fluorescent signal to exceed the background (threshold) levels and 
is proportional to amount of target gene expressed in the sample.  These CT values were first 
normalised by calculating the difference between gene of interest and reference gene before 
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determining the ΔCT values which were normalised to control untreated samples (Livak and 
Schmittgen, 2001).  Using this ΔCT value, the relative quantification (RQ) value was obtained.  
This indicates the amplification of the target gene relative to the untreated samples, which 
were used as endogenous control for all experimental conditions.  Graphs show average 
relative quantification of either transcript in breast cancer cells, with error bars showing 
standard deviation.  Additionally, mean RQ values for ALT-PTK6 expression over mean RQ 
values of PTK6 only expression (ALT-PTK6/PTK6) were determined to show ALT-PTK6 to 




Figure 5.4 Confirmation of A) PTK6 only and B) expression of both 
transcripts (PTK6 and ALT-PTK6) using custom designed primers. Reverse 
transcriptase-PCR was performed to detect end point bands using custom 
designed primers for PTK6 only transcript and primers to detect both isoforms.  
RNA was extracted using RNeasy Plus Mini Spin Kit (Qiagen), cDNA 
synthesised using SuperScript II Reverse Transcriptase Kit (Invitrogen) before 
reverse transcription PCR using REDTaq® ReadyMix™ PCR Reaction Mix  
















































Figure 5.5 Relative expression of PTK6 and ALT-PTK6 is varied between cell lines at 
basal conditions. PrecisionPLUS MasterMix with ROX at a lower level premixed with 
SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The 
experimental parameters were 40x cycles of enzyme activation for 2 minutes at 95 ˚C and 
denaturation for 10 seconds at 95˚C.  Data was analysed by calculating average Cycle 
Threshold (CT) of both isoforms and normalised to average CT values of reference genes: 
SDHA and RPL13A. This gave the delta CT (ΔCT) value which was used to calculate relative 
quantification (RQ) as follows: RQ= 2-ΔΔCT.  Figure 5.5A shows relative expression of PTK6 of 
breast cancer cell lines (ANOVA F(6,13)=11.16, P= 0.0002).  Figure 5.5B shows relative 
expression for ALT-PTK6 (ANOVA F(6,13)=4.318, P =0.0130). qPCRs were performed using 
n=3 independent sets of RNA for all cell lines with error bars representing standard deviation. 
Statistical variance between cell lines was determined with ANOVA test .  
 
 
Figure 5.5 Relative expression of PTK6 and ALT-PTK6 is varied between cell lines at 
basal conditions. Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔCT.  Figure 5.4A shows relative expression of PTK6 of breast cancer cell 
lines (ANOVA F(6,13)=11.16, P= 0.0002), which shows lowest expression in SKBR3 and the 
highest in the T47D cell.  Figure 5.4B shows relative expression for ALT-PTK6 (ANOVA 
F(6,13)=4.318, P =0.0130) and shows SKBR3 cell line with the lowest expression compared 
to BT474 with the highest relative expression under basal conditions. qPCRs were performed 
using 3 independent sets of RNA for all cell lines with error bars representing standard 






















































Figure 5.6 Relative ratio of ALT-PTK6 to PTK6 after at basal levels show higher levels 
of ALT-PTK6 transcript in non-tumourigenic cell line and mostly in hormone positive 
breast cancer cells. PrecisionPLUS MasterMix with ROX at a lower level premixed with 
SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The 
experimental parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and 
denaturation for 10 seconds at 95˚C.  Data was analysed by calculating average Cycle 
Threshold (CT) of both isoforms and normalised to average CT values of reference genes: 
SDHA and RPL13A. This gave the delta CT (ΔCT) value which was used to calculate relative 
quantification (RQ) as follows: RQ= 2-ΔΔCT.  Results were used to determine mean ratios of 
ALT-PTK6/PTK6. Western blot (n=3) using anti-Brk polyclonal antibody N-Terminal (Abcam) 
was performed to determine ALT-PTK6 protein expression as well as Brk expression levels. 
qPCRs were performed using n=3 independent sets of RNA for all cell lines with error bars 
representing standard deviation. ANOVA statistical analysis was carried out to demonstrate 




Relative expression of the PTK6 transcript (Figure 5.4A) and ALT-PTK6 (Figure 5.5B) show 
variation between the cell lines. The T47D cell line showed the highest mean relative 
expression (RQ=0.18 +/- 0.05 S.D) with the HER2 positive cell line SKBR3 (RQ=0.003 +/- 
0.002 S.D) showing the least relative expression of PTK6 full-length transcript.  Statistical 
analysis with ANOVA testing between the cell lines (ANOVA F(6,13)=11.16, P= 0.0002) 
showed highly significant variation of PTK6 between all the breast cancer cell lines.  mRNA 
expression of ALT-PTK6 was highest in SKBR3 with an RQ value of 0.15 (+/- 0.02 S.D) 
compared to the lowest RQ value of 0.018 +/- 0.012 S.D for the MCF10A cell line.  Statistical 
analysis with ANOVA testing between the cell lines showed significant variation of expression 
(ANOVA F(6,13)=4.318, P =0.0130).  For PTK6 transcript, the cell lines with high RQ values 
(T47D, MDA-MB 436, BT474) all show high or moderate Brk expression at the protein level 
in comparison to GI101, MDA-MB 231 and MCF10A which show low levels of Brk protein 
expression.   
Overall, the cell lines with the most expression of the full-length form were the luminal A 
subtype cell line T47D, HER2 positive cell line BT474 and the triple negative cell line MDA-
MB 436. The cell lines with highest ALT-PTK6 expression were BT474, MDA-MB 436, GI101 
and T47D.  It appears expression of ALT-PTK6 transcript may not be cell type specific, nor 
limited to cancerous cells and is expressed at varying levels in the breast cancer cell lines.   
Figure 5.6 shows ALT-PTK6/PTK6 ratios at basal levels for the breast cancer cell lines.    
Overall, cell lines with higher ALT-PTK6 to PTK6 ratio were MCF10A, GI101 and the HER2 
positive cell lines (SKBR3 and BT474).  In comparison, lower ratios were observed in the 
T47D cell line and the two triple negative cell lines (MDA-MB 231 and MDA-MB 436).  ANOVA 
testing shows significant variation in in ALT-PTK6/PTK6 ratios (ANOVA F(6,14)=3.601, P 
=0.023).  Protein expression of ALT-PTK6 was confirmed in the T47D cell line and was 
detected at low levels in MDA-MB 231 and MDA-MB 436 cell lines.       
202 
 
5.3.4 Determination of ALT-PTK6 to PTK6 mRNA expression ratios in breast 
cancer cell lines after Brk inhibition.  
 
Transcript levels of ptk6 isoforms have not been investigated especially in response to Brk 
inhibition within breast cancer cell lines. It has previously been suggested ptk6 may 
potentially regulate its own expression due to its impact on alternative splicing via its 
substrates that include a number of RNA binding proteins such as Sam68, SLM1 and SLM2 
as well as polypyrimidine tract-binding protein-associated splicing factor (PSF) which are all 
involved in regulating splicing (Derry et al., 2000; Haegebarth et al., 2004; Lukong, Huot and 
Richard, 2009; Brauer et al., 2011). Thus, I next sought to assess whether expression of the 
ptk6 variants at the mRNA level are affected with inhibition of Brk after treatment with 5µM of 
Compound 4f.   Due to inhibition of Brk, it is expected there will be a reduction in the full 
length PTK6 transcript, which may favour up-regulation of the shorter isoform, ALT-PTK6.   
Additionally, ratios of ALT-PTK6/PTK6 transcripts within the breast cancer cell lines in 
response to Brk inhibition were calculated.  Ratios were determined within the control 
(untreated) cells as well as the treated cells.  
Cells were seeded at 200,000 cells per well in a 6 well plate and treated with 5µM of the Brk 
inhibitor.  Cell lysates were taken at the following time points along with untreated controls: 
0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  For RNA extraction, the RNeasy Mini 
Spin Column kit from Qiagen was used to elute high quality and yield of RNA free of 
contamination as described in Materials and Methods (Chapter 2, section 2.2.16).   cDNA 
was prepared using SuperScript II Reverse Transcriptase (Invitrogen) kit and PrecisionPLUS 
MasterMix with ROX at a lower level premixed with SYBRgreen (Primer Design) was 
prepared with primer mixes for either transcript along with the primers for two reference 
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genes, SDHA and RPL13A.  Each master mix for each gene was pipetted in duplicate in a 
96 well plate and 5µl of cDNA was pipetted using sterile filter tips as per manufacturer’s 
protocol.  The Applied Biosystems Quantstudio 7 Flex Real-Time PCR machine was used, 
and qPCRs were carried out using 3 sets of independent RNA. Data was analysed using the 
QuantStudio™ Software V1.3—for QuantStudio™ 6 and 7 Flex and ViiA™ 7 Real-Time PCR 
















Figure 5.7 qPCR showing relative mRNA expression of PTK6 after compound 4f treatment 
shows decrease in MDA-MB 231 cells and little change in MDA-MB 436 cells. Cells were 
seeded at 200,000 cells per well in a 6 well plate and treated with compound 4f (5µM).  Cells 
were harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 
hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 
seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔΔCT.  Results show PTK6 relative expression in control, untreated (blue) and 
treated cells (red) in MDA-MB 231 cell line (A) and MDA-MB 436 cell line (B). qPCRs were 
performed using 3 independent sets of RNA for all cell lines with error bars representing standard 
deviation.  ANOVA statistical analysis was performed to demonstrate variation within control 
cells as well as within treated groups. Students T Test was used to assess significant difference 


















Figure 5.8 qPCR showing relative mRNA expression of ALT-PTK6 after compound 4f 
treatment shows minor change in MDA-MB 231 cells and a reduction in MDA-MB 436 at 48 
hours. Cells were seeded at 200,000 cells per well in a 6 well plate and treated with compound 4f 
(5µM).  Cells were harvested for RNA at the following time points along with untreated controls: 0, 
2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 
seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both isoforms 
and normalised to average CT values of reference genes: SDHA and RPL13A. This gave the delta 
CT (ΔCT) value which was used to calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  
Results show PTK6 relative expression in control, untreated (blue) and treated cells (red) in MDA-
MB 231 cell line (A) and MDA-MB 436 cell line (B). qPCRs were performed using 3 independent 
sets of RNA for all cell lines with error bars representing standard deviation.  ANOVA statistical 
analysis was performed to demonstrate variation within control cells as well as within treated 
groups. Students T Test was used to assess significant difference between each control and 
treated time points, * P<0.05. qPCRs were performed using 3 independent sets of RNA for all cell 
lines with error bars representing standard deviation.   
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The triple negative cell line MDA-MB 231 PTK6 mRNA expression shows an increase over 
time before decreasing at 24 and 48 hours (Figure 5.7A) within the untreated control group 
(ANOVA F(4,10) =3.699, P = 0.042).  There seems to be no significant difference in PTK6 
expression within the treated group (ANOVA F(4,10) =0.74, P = 0.586).  Nonetheless, there 
is statistically significant reduction observed at 4 and 8 hours post treatment with compound 
4f when compared to untreated control cells at the same time points.  Overall, MDA-MB 231 
cells treated with compound 4f show lower levels of PTK6 mRNA expression overtime 
compared to untreated control cells.    
Within MDA-MB 436 cells, PTK6 expression shows a similar pattern within the control group 
and treated group (Figure 5.7B).  Overall, there seems to be no statistical difference within 
the control group (ANOVA F(4,10) =3.213, P = 0.061).  There was greater statistically 
significant difference within the treated group (ANOVA F(4,10) =4.409, P = 0.026). There were 
reduced level of PTK6 mRNA expression compared to control cells at 2 and 4 and 48 hour 
time points, although this is not statistically significant.   
ALT-PTK6 mRNA expression decreases over time post treatment compared to control cells 
in the MDA-MB 231 cell line (Figure 5.8A).  Although there was no statistically significant 
reduction within the treated group (ANOVA F(4,10) =1.589, P = 0.251), overall there are 
reduced levels of ALT-PTK6 compared to control cells.  mRNA expression levels of ALT-PTK6 
in MDA-MB 436 cells show a significant difference within the treated group (ANOVA F(4,10) 
=10.593, P = 0.001) as seen in Figure 5.8B.  Overall there was a reduction in expression in 
treated cells compared to control cells, with statistically significant difference at 48 hours post 






Figure 5.9 Relative expression ratios of ALT-PTK6 to PTK6 after compound 4f treatment 
show little difference compared to control ratios.  Cells were seeded at 200,000 cells per 
well in a 6 well plate and treated with compound 4f (5µM).  Cells were harvested for RNA at the 
following time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 
48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. PrecisionPLUS 
MasterMix with ROX at a lower level premixed with SYBRgreen (10µl) , primer mix (1µl), 
RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters were 40x 
cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  Data 
was analysed by calculating average Cycle Threshold (CT) of both isoforms and normalised to 
average CT values of reference genes: SDHA and RPL13A. This gave the delta CT (ΔCT) value 
which was used to calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Ratios were 
determined from mean RQ values of ALT-PTK6/PTK6.  Results show ALT-PTK6/PTK6 ratios in 
control, untreated (blue) and treated cells (red) in MDA-MB 231 cell line (A) and MDA-MB 436 
cell line (B).. qPCRs were performed using 3 independent sets of RNA for all cell lines with error 
bars representing standard deviation.  ANOVA statistical analysis was performed to demonstrate 
variation within control cells as well as within treated groups. Students T Test was used to assess 
significant difference between each control and treated time points, * P< 0.05.  
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ALT-PTK6 to PTK6 ratios were relatively unchanged after compound 4f treatment compared 
to control cells in the MDA-MB 231 cell line (Figure 5.9A).  Although there was higher ALT-
PTK6 to PTK6 ratio at 4 hours post treatment, overall no statistically significant variance was 
observed within the control group (ANOVA F(5,12) =0.417, P = 0.828) and treated group 
(ANOVA F(5,12) =2.734, P = 0.071).   
Within the MDA-MB 436 cell line, ratio of ALT-PTK6 to PTK6 ratios were also relatively 
unchanged after compound 4f treatment compared to control cells (Figure 5.9B). There were 
no statistically significant variance shown in ALT-PTK6 /PTK6 ratios within control group 

































Figure 5.10 qPCR showing relative mRNA expression of PTK6 after compound 4f 
treatment shows decrease in SKBR3 cells and increase in BT474 cells . Cells were seeded 
at 200,000 cells per well in a 6 well plate and treated with compound 4f (5µM).  Cells were 
harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 
hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activat ion for 2 minutes at 95˚C and denaturation for 
10 seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔΔCT.  Results show PTK6 relative expression in control, untreated (blue) and 
treated cells (red) in SKBR3 cell line (A) and BT474 cell line (B). qPCRs were performed using 
3 independent sets of RNA for all cell lines with error bars representing standard deviation.  
ANOVA statistical analysis was performed to demonstrate variation within control cells as well 
as within treated groups. Students T Test was used to assess significant di fference between 










Figure 5.11 qPCR showing relative mRNA expression of ALT-PTK6 after compound 4f 
treatment shows overall reduction in SKBR3 cells and increase in BT474 cells. Cells were 
seeded at 200,000 cells per well in a 6 well plate and treated with compound 4f (5µM).  Cells 
were harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 
hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activat ion for 2 minutes at 95˚C and denaturation for 10 
seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as follows: 
RQ= 2-ΔΔCT.  Results show PTK6 relative expression in control, untreated (blue) and treated 
cells (red) in SKBR3 cell line (A) and BT474 cell line (B). qPCRs were performed using 3 
independent sets of RNA for all cell lines with error bars representing standard deviation.  ANOVA 
statistical analysis was performed to demonstrate variation within control cells as well as within 
treated groups. Students T Test was used to assess significant di fference between each control 




PTK6 expression in SKBR3 cell line (Figure 5.10A) showed a marked decrease at 8 and 24 
hours post treatment compared to control cells (P<0.05).   Overall there was a clear decrease 
in PTK6 expression over time in response to compound 4f treatment (ANOVA F(4,10) =7.282, 
P = 0.005).   
BT474 cell line showed an increase in relative PTK6 expression (Figure 5.10B) levels at 2,4 
and 8 hours within the control group before decreasing at 24 and 48 hours (ANOVA F(4,10) 
=3.814, P = 0.039).  Overall, there was significant induction in PTK6 expression at 24-hour 
post treatment (P<0.05) compared to control cells with little change at other time points. 
Expression levels of ALT-PTK6 transcript were significantly higher within in the SKBR3 cell 
line (Figure 5.11A) at 2 hours post treatment compared to control cells; however overall there 
was reduction with statistically significant difference at 8 and 24 hours post treatment 
(P<0.05).  On the other hand, ALT-PTK6 expression increased overtime in response to Brk 
inhibition within the BT474 cell line (Figure 5.11B), with significant difference observed at 24 
and 48 hours post treatment compared to control cells (P<0.05).  ANOVA statistical analysis 
does not show statistical difference within the treated group time points (ANOVA F(4,10) 

























Figure 5.12 Relative expression ratios of ALT-PTK6 to PTK6 after compound 4f treatment 
are unchanged compared to control in HER2 positive breast cancer cell lines.  Cells were 
seeded at 200,000 cells per well in a 6 well plate and treated with compound 4f (5µM).  Cells 
were harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 
4 hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activat ion for 2 minutes at 95˚C and denaturation for 
10 seconds at 95˚C.  Data was analysed as previously described and results were used to 
determine mean ratios of ALT-PTK6 over PTK6.  Results show ALT-PTK6/PTK6 ratios in 
control, untreated (blue) and treated cells (red) in SKBR3 cell line (A) and BT474 cell line (B).  
qPCRs were performed using 3 independent sets of RNA for all cell lines with error bars 
representing standard deviation. ANOVA statistical analysis was carried out to demonstrate 
variation within control and treated groups.  Students T Test was used to assess significant 
difference between each control and treated time points, *P<0.05. 
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Within the HER2 positive cell line, SKBR3 no statistically significant difference in ALT-PTK6 
to PTK6 ratios (Figure 5.12A) were observed between control and treated groups.  However, 
overall there were reduced ratios of ALT-PTK6 to PTK6 in the treated group (2, 8, 24 and 48 
hours post treatment) compared to control cells.   
Little difference is observed in ALT-PTK6 to PTK6 ratios after compound 4f treatment 
compared to control cells in BT474 cell line (Figure 5.12B).  There are no statistically 
significant variance observed within the control (ANOVA F(5,12) =0.556, P = 0.732) and 
treated groups (ANOVA F(5,12) =0.534, P = 0.747).  Although not significant, there appear to 
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Figure 5.13 qPCR showing A) unchanged relative mRNA expression of PTK6 in T47D cells 
and B) reduction at 4 hours post treatment in ALT-PTK6 expression (B). Cells were seeded 
at 200,000 cells per well in a 6 well plate and treated with compound 4f (5µM).  Cells were 
harvested for RNA at the following time points along with untreated controls: 0,  2 hours, 4 hours, 
8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer 
mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters were 
40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  
Data was analysed by calculating average Cycle Threshold (CT) of both isoforms and 
normalised to average CT values of reference genes: SDHA and RPL13A. This gave the delta 
CT (ΔCT) value which was used to calculate relative quantification (RQ) as follows: RQ= 2 -
ΔΔCT.  Results show PTK6 (A) expression and ALT-PTK6 (B) expression in control (blue) and 
treated cells (red).  qPCRs were performed using 3 independent sets of RNA for all cell lines 
with error bars representing standard deviation.  ANOVA statistical analysis was carried out to 
demonstrate variation within control and treated groups. Students T Test was used to assess 
significant difference between control and treated time points, *P<0.05. 
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T47D cells showed moderate increase in PTK6 expression after 4 hours post treatment 
compared to 0 and 2 hours but began to gradually reduce over time compared to control cells 
(Figure 5.13A).  Statistically PTK6 expression within the treated group (ANOVA F(4,10) 
=8.692, P = 0.003) showed significant difference. ALT-PTK6 expression showed there was a 
significant difference within the treated group as seen in Figure 5.14B (ANOVA F(4,10) 
=15.27, P = 0.0002).  mRNA Expression, although was increased initially (2 hours post 
treatment), it began to decline over time (4 and 8 hours).  The main statistical difference 





Figure 5.14 Relative expression ratios of ALT-PTK6 to PTK6 after compound 4f treatment 
show some variation.  Cells were seeded at 200,000 cells per well in a 6 well plate and treated 
with compound 4f (5µM).  Cells were harvested for RNA at the following time points along with 
untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using 
SuperScript II reverse transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed 
with SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The 
experimental parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and 
denaturation for 10 seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold 
(CT) of both isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. 
This gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔΔCT.  The results were used to determine mean ratios of ALT-PTK6 over PTK6. 
Results show ALT-PTK6/PTK6 mRNA ratios for T47D cell line.  qPCRs were performed using 3 
independent sets of RNA for all cell lines with error bars representing standard deviation. ANOVA 
statistical analysis was carried out to demonstrate variation within control and treated groups.  
Students T Test was used to assess significant difference between each control and treated time 
points, *P<0.05.   
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Figure 5.14 showed the T47D cell line had no statistically significant variance in ALT-PTK6 to 
PTK6 ratios within the control group (ANOVA F(5,12) =0.999, P = 0.459) as well as no 
statistically significant variance within treated group (ANOVA F(5,12) =2.797, P= 0.067).  
However, ALT-PTK6 to PTK6 ratios were initially higher at 2 hours post treatment with 
compound 4f, before significantly decreasing at 4 hours post treatment (P<0.05).  
 
5.3.5 mRNA expression of both isoforms and ALT-PTK6 to PTK6 ratios in breast 
in breast cancer cell lines after Taxol and Doxorubicin treatment (5µM). 
 
It is worth investigating the alterations in PTK6 and ALT-PTK6 transcript levels in response 
to chemotherapeutic agents because as previously mentioned, breast cancer treatment is 
heavily chemotherapy based and thus potential effect on both isoforms in response to 
common chemotherapy agents, Paclitaxel/Taxol (Tax) and Doxorubicin (Dox) needs to be 
examined.   Taxol functions as a taxane which are a group of chemotherapy agents that 
disrupt microtubule formation leading to arrest in mitosis (reviewed in Weaver, 2014). These 
have been used as first line treatment for triple negative breast cancer (TNBC) subtypes of 
which MDA-MB 231 and MDA-MB 436 cell lines are representative of (reviewed in Mustacchi 
and De Laurentiis, 2015).  Doxorubicin, an anthracycline, causes DNA intercalation and also 
disrupts topoisomerase II mediated DNA repair eventually leading to DNA damage and 
apoptosis (reviewed in Thorn et al., 2011).  Doxorubicin has shown to be effective in TNBC 
and there is also evidence for using both chemotherapy drugs in combination therapy for 
triple negative breast cancers (reviewed in Isakoff, 2010).     
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The triple negative breast cancer cell lines, MDA-MB 231 and MDA-MB 436 were seeded as 
before and treated with either 5µM of Taxol or Doxorubicin. For RNA extraction, the RNeasy 
Mini Spin Column kit from Qiagen was used to elute high quality and yield of RNA free of 
contamination as described in Materials and Methods (Chapter 2, section 2.2.16).   cDNA 
was prepared using SuperScript II Reverse Transcriptase (Invitrogen) kit and qPCR 
performed using PrecisionPLUS MasterMix with ROX at a lower level premixed with 
SYBRgreen (Primer Design) with primer mixes for either transcript along with the primers for 
two reference genes, SDHA and RPL13A.  Each master mix for each gene was pipetted in 
duplicate in a 96 well plate and 5µl of cDNA was pipetted using sterile filter tips as per 
manufacturer’s protocol.  The Applied Biosystems Quantstudio 7 Flex Real-Time PCR 
machine was used, and qPCRs were carried out using 3 sets of independent RNA. Data was 
analysed using the QuantStudio™ Software V1.3—for QuantStudio™ 6 and 7 Flex and 
ViiA™ 7 Real-Time PCR software (Applied Biosystems). Ratios of ALT-PTK6 to PTK6 
transcripts within the breast cancer cell lines in response to Taxol or Doxorubicin were also 






Figure 5.15 No significant change in PTK6 expression in response to Taxol (5µM) 
treatment in triple negative breast cancer cell lines. Cells were seeded at 200,000 cells 
per well in a 6 well plate and treated with Taxol (5µM).  Cells were harvested for RNA at the 
following time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours 
and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer 
mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters 
were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds 
at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both isoforms 
and normalised to average CT values of reference genes: SDHA and RPL13A. This gave the 
delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as follows: 
RQ= 2-ΔΔCT.  Results show PTK6 relative expression in control, untreated (blue) and 
treated cells (green) in MDA-MB 231 cell line (A) and MDA-MB 436 cell line (B). qPCRs were 
performed using 3 independent sets of RNA for all cell lines with error bars representing 
standard deviation.  ANOVA statistical analysis was performed to demonstrate variation 
within control cells as well as within treated groups. Students T Test was used to assess 
significant difference between each control and treated time points, * P<0.05. 
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  A B 
Figure 5.16 No significant change in expression of ALT-PTK6 in response to Taxol (5µM) 
treatment in triple negative breast cancer cell lines. Cells were seeded at 200,000 cells per 
well in a 6 well plate and treated with Taxol (5µM).  Cells were harvested for RNA at the following 
time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  
cDNA was prepared using SuperScript II reverse transcriptase. PrecisionPLUS MasterMix with 
ROX at a lower level premixed with SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free 
water, cDNA (5µl) were mixed. The experimental parameters were 40x cycles of enzyme 
activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  Data was analysed by 
calculating average Cycle Threshold (CT) of both isoforms and normalised to average CT values 
of reference genes: SDHA and RPL13A. This gave the delta CT (ΔCT) value which was used to 
calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Results show PTK6 relative 
expression in control, untreated (blue) and treated cells (green) in MDA-MB 231 cell line (A) and 
MDA-MB 436 cell line (B). qPCRs were performed using 3 independent sets of RNA for all cell 
lines with error bars representing standard deviation.  ANOVA statistical analysis was performed 
to demonstrate variation within control cells as well as within treated groups. Students T Test was 
used to assess significant difference between each control and treated time points, * P<0.05.  
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MDA-MB 231 cell lines showed moderate response when treated with Taxol (Figure 5.15A), 
there was no significant difference in expression levels for PTK6 mRNA expression within the 
treated group (ANOVA F(4,10) =1.518, P = 0.269) as well as no significant difference between 
control and treated cells. However, there is an overall reduction in PTK6 expression over time 
in response to Taxol.  For MDA-MB 436 cells, PTK6 expression was increased in response 
to Taxol treatment over time (Figure 5.16B), however little significant difference in response 
to Taxol treatment compared to control cells was observed.  Within the treated group there 
was also little variation in PTK6 expression levels (ANOVA F(4,10) =1.113, P = 0.403).   
ALT-PTK6 expression after Taxol treatment showed similar levels as control group in MDA-
MB-231 cell line (Figure 5.16A) and showed no significant difference within treated group 
(ANOVA F(4,10) =3.427, P = 0.052).  Overall, lower expression of both isoforms was 
observed overtime but there was no statistically significant difference between control and 
treated cells. Expression of ALT-PTK6 did not differ significantly after Taxol treatment 
compared to control cells in MDA-MB 436 cell line (Figure 5.16B) and variation within the 
treated group did not statistically differ (ANOVA F(4,10) =1.19, P = 0.373).  Statistical analysis 
did not reveal any significance between control and treated cells for MDA-MB 436 cell line.  
Overall it appears expression of PTK6 isoforms are not significantly altered in response to 































Figure 5.17 Relative ratio of ALT-PTK6 to PTK6 after Taxol treatment shows little 
difference compared to control cells in triple negative breast cancer cell lines. Cells 
were seeded at 200,000 cells per well in a 6 well plate and treated with Taxol (5µM).  Cells 
were harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 
4 hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 
10 seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔΔCT.  Ratios were determined from mean RQ values of ALT-PTK6/PTK6. 
Results show ALT-PTK6/PTK6 ratios in control, untreated (blue) and treated cells (green) in 
MDA-MB 231 cell line (A) and MDA-MB 436 cell line (B).. qPCRs were performed using 3 
independent sets of RNA for all cell lines with error bars representing standard deviation.  
ANOVA statistical analysis was performed to demonstrate variation within control cells as 
well as within treated groups. Students T Test was used to assess significant difference 

































































MDA-MB 231 cell line shows relatively unchanged ALT-PTK6 to PTK6 ratios in Figure 5.17A 
between control and treated cells.  There was no statistical variance observed within the 
treated group (ANOVA F(5,12) =2.224, P = 0.119).  For the MDA-MB 436 cell line, ALT-PTK6 
to PTK6 ratios (Figure 5.18B), there was no statistically significant difference between control 
and treated groups and no significant variation was observed within the treated group 
(ANOVA F(5,12) =0.712, P = 0.626).  Overall, there was no statistically significant difference 














Figure 5.18 No significant change in PTK6 expression in response to Doxorubicin (Dox) 
at 5µM concentration in triple negative breast cancer cell lines. Cells were seeded at 
200,000 cells per well in a 6 well plate and treated with Dox (5µM).  Cells were harvested for 
RNA at the following time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 
hours and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer 
mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters 
were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds 
at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both isoforms and 
normalised to average CT values of reference genes: SDHA and RPL13A. This gave the delta 
CT (ΔCT) value which was used to calculate relative quantification (RQ) as follows: RQ= 2 -
ΔΔCT.  Results show PTK6 relative expression in control, untreated (blue) and treated cells 
(light blue) in MDA-MB 231 cell line (A) and MDA-MB 436 cell line (B). qPCRs were performed 
using 3 independent sets of RNA for all cell lines with error bars representing standard 
deviation.  ANOVA statistical analysis was performed to demonstrate variation within control 
cells as well as within treated groups. Students T Test was used to assess significant difference 









Figure 5.19 ALT-PTK6 mRNA expression levels remain relatively unchanged in MDA-MB 
231 and MDA-MB-436 cell lines in response to Doxorubicin (Dox) treatment (5µM).    Cells 
were seeded at 200,000 cells per well in a 6 well plate and treated with Dox (5µM).  Cells were 
harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 hours, 
8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer mix 
(1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters were 40x 
cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  Data 
was analysed by calculating average Cycle Threshold (CT) of both isoforms and normalised to 
average CT values of reference genes: SDHA and RPL13A. This gave the delta CT (ΔCT) value 
which was used to calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Results show 
ALT-PTK6 relative expression in control, untreated (blue) and treated cells (light blue) in MDA-
MB 231 cell line (A) and MDA-MB 436 cell line (B). qPCRs were performed using 3 independent 
sets of RNA for all cell lines with error bars representing standard deviation.  ANOVA statistical 
analysis was performed to demonstrate variation within control cells as well as within treated 
groups. Students T Test was used to assess significant difference between each control and 
treated time points, * P<0.05. 
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Observing the MDA-MB 231 cell line, overall there is a reduction in PTK6 expression (Figure 
5.18A) in response to Doxorubicin. However there does not seem to be a significant 
difference in expression between control and treated cells. ANOVA testing showed no 
statistically significant variation within treated group (ANOVA F(4,10) =1.518, P = 0.269).   
PTK6 expression is generally increased in the MDA-MB 436 cell line within both the control 
and treated groups overtime.  However, there was no statistically significant difference 
between control and cells treated with Dox treatment (Figure 5.18B).   
A similar pattern is seen for ALT-PTK6 mRNA expression levels in MDA-MB 231 as with PTK6 
expression (Figure 5.19A).   Although not statistically significant, compared to control cells, 
there is an overall reduction in expression levels in the treated cells. Interestingly, ALT-PTK6 
levels are largely increased at 4 hours post treatment in MDA-MB 436 cell lines before 
remaining relatively unchanged at 24 and 48 hours compared to control samples (Figure 
5.19B).  However, no significant difference was seen when treated cells were compared to 








Figure 5.20 Relative ratio of ALT-PTK6 to PTK6 after Doxorubicin (Dox) treatment shows 
variation in triple negative cell lines MDA-MB 231 and MDA-MB 436. Cells were seeded at 
200,000 cells per well in a 6 well plate and treated with Taxol (5µM).  Cells were harvested for 
RNA at the following time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 
hours and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer 
mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters were 
40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  
Data was analysed by calculating average Cycle Threshold (CT) of both isoforms and norm alised 
to average CT values of reference genes: SDHA and RPL13A. This gave the delta CT (ΔCT) 
value which was used to calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Ratios 
were determined from mean RQ values of ALT-PTK6/PTK6. Results show ALT-PTK6/PTK6 ratios 
in control, untreated (blue) and treated cells (green) in MDA-MB 231 cell line (A) and MDA-MB 
436 cell line (B).. qPCRs were performed using 3 independent sets of RNA for all cell lines with 
error bars representing standard deviation.  ANOVA statistical analysis was performed to 
demonstrate variation within control cells as well as within treated groups. Students T Test was 
used to assess significant difference between each control and treated time points, * P<0.05. 
228 
 
For Doxorubicin treatment in MDA-MB 231 cells,  ALT-PTK6 to PTK6 ratios showed variation 
(Figure 5.20A) with significantly reduced ALT-PTK6 to PTK6 ratios at 8 hours before 
significant increase at 48 hours post treatment. Significant variation was observed in the 
treated groups for ALT-PTK6 and PTK6 ratios (ANOVA F(5,12) =8.97, P = 0.001).   
For Doxorubicin treatment in MDA-MB 436 cells, ratios of ALT-PTK6 to PTK6 (Figure 5.20B) 
showed higher levels in treated cells compared to control cells at 4 hours post treatment 
(P<0.05).  However, ratios remain relatively unchanged at the other time points.   Variance 
analysis showed no statistical difference within the treated group for ALT-PTK6/PTK6 ratios 
(ANOVA F(5,12) =0.97, P= 0.473).       
Overall, there are higher ALT-PTK6 to PTK6 ratios in both the triple negative cell lines in 
response to Dox treatment compared to control cells with significance at 48 hours post 
treatment for MDA-MB 231 cell line and 4 hours post treatment in the MDA-MB 436 cell line.   
 
5.3.6 mRNA expression of both isoforms and ALT-PTK6 to PTK6 ratios in breast 
in breast cancer cell lines after Lapatinib treatment (2.5µM). 
 
In addition to examining the changes in PTK6 and ALT-PTK6 expressions in response to 
chemotherapy agents, I also investigated the expression of both isoforms in response to 
targeted therapy, Lapatinib.   This is important as ptk6 gene and HER2 have previously shown 
to be co-expressed and cooperation between the two increases proliferative potential of 
HER2 positive cancers (Xiang et al., 2008).  In addition,  co-expression of Brk with HER2 has 
shown to increase resistance to lapatinib as higher concentrations of the drug were needed 
in Brk positive cells to reduce cellular proliferation (Xiang et al., 2008).  Thus, due to the 
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involvement of Brk in HER2 signalling, lapatinib could potentially impact mRNA expression 
of PTK6 transcripts.   
The HER2 positive cell lines, SKBR3 and BT474 were seeded as before and treated with 
2.5µM of lapatinib. For RNA extraction, the RNeasy Mini Spin Column kit from Qiagen was 
used to elute high quality and yield of RNA free of contamination as described in Materials 
and Methods (Chapter 2, section 2.2.16).   cDNA was prepared using SuperScript II Reverse 
Transcriptase (Invitrogen) kit and qPCR performed using PrecisionPLUS MasterMix with 
ROX at a lower level premixed with SYBRgreen (Primer Design) with primer mixes for either 
transcript along with the primers for two reference genes, SDHA and RPL13A.  Each master 
mix for each gene was pipetted in duplicate in a 96 well plate and 5µl of cDNA was pipetted 
using sterile filter tips as per manufacturer’s protocol.  The Applied Biosystems Quantstudio 
7 Flex Real-Time PCR machine was used, and qPCRs were carried out using 3 sets of 
independent RNA. Data was analysed using the QuantStudio™ Software V1.3—for 
QuantStudio™ 6 and 7 Flex and ViiA™ 7 Real-Time PCR software (Applied Biosystems).  
Additionally, ratios of ALT-PTK6 to PTK6 transcript within the breast cancer cell lines in 
response to Lapatinib treatment were calculated.  Ratios were determined within the control 






Figure 5.21 Lapatinib (Lap) treatment (2.5µM) decreases PTK6 expression in MDA-MB 231 
with some increase in MDA-MB 436 cells. Cells were seeded at 200,000 cells per well in a 6 well 
plate and treated with Lap (2.5µM).  Cells were harvested for RNA at the following time points 
along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  cDNA was 
prepared using SuperScript II reverse transcriptase. PrecisionPLUS MasterMix with ROX at a lower 
level premixed with SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) 
were mixed. The experimental parameters were 40x cycles of enzyme activation for 2 minutes at 
95˚C and denaturation for 10 seconds at 95˚C.  Data was analysed by calculating average Cycle 
Threshold (CT) of both isoforms and normalised to average CT values of reference genes: SDHA 
and RPL13A. This gave the delta CT (ΔCT) value which was used to calculate relative 
quantification (RQ) as follows: RQ= 2-ΔΔCT.  Results show PTK6 relative expression in control, 
untreated (blue) and treated cells (purple) in SKBR3 cell line (A) and BT474 cell line (B). qPCRs 
were performed using 3 independent sets of RNA for all cell lines with error bars representing 
standard deviation.  ANOVA statistical analysis was performed to demonstrate variation within 
control cells as well as within treated groups. Students T Test was used to assess significant 





Figure 5.22 Lapatinib (Lap) treatment (2.5µM) does not significantly alter mRNA expression  
of ALT-PTK6 in HER2 positive cell lines. Cells were seeded at 200,000 cells per well in a 6 well 
plate and treated with Lap (2.5µM).  Cells were harvested for RNA at the following time points along 
with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared 
using SuperScript II reverse transcriptase. PrecisionPLUS MasterMix with ROX at a lower level 
premixed with SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were 
mixed. The experimental parameters were 40x cycles of enzyme activation fo r 2 minutes at 95˚C 
and denaturation for 10 seconds at 95˚C.  Data was analysed by calculating average Cycle 
Threshold (CT) of both isoforms and normalised to average CT values of reference genes: SDHA 
and RPL13A. This gave the delta CT (ΔCT) value which was used to calculate relative quantification 
(RQ) as follows: RQ= 2-ΔΔCT.  Results show ALT-PTK6 relative expression in control, untreated 
(blue) and treated cells (purple) in SKBR3 cell line (A) and BT474 cell line (B). qPCRs were 
performed using 3 independent sets of RNA for all cell lines with error bars representing standard 
deviation.  ANOVA statistical analysis was performed to demonstrate variation within control cells 
as well as within treated groups. Students T Test was used to assess significant difference between 
each control and treated time points, * P<0.05. 
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SKBR3 cell line showed relatively unchanged levels of the full-length transcript PTK6 in 
response to lapatinib treatment (2.5µM) as shown in Figure 5.21A.  There was greater 
statistical variance shown within the treated group (ANOVA F(5,12) =5.178, P = 0.009), as 
expression decreased over time. Although there was statistically significant reduction in PTK6 
levels at 24 hours post treatment (P<0.05), overall expression was increased over time in the 
BT474 cell line (Figure 5.21B).  ANOVA testing revealed significant variance of PTK6 
expression within the treated group (ANOVA F(5,12) =7.952, P = 0.002).   
ALT-PTK6 expression in the SKBR3 cell line showed similar pattern as expression of PTK6 
and there was no statistically significant difference between control and treated cells (Figure 
5.22A). Overall, there was a decrease in expression over time and variance analysis within 
the treated group showed statistical significance (ANOVA F(5,12) =10.092, P = 0.001). 
Within the BT474 cell line, overall there were no statistically significant differences observed 
in ALT-PTK6 expression between control and treated cells in response to lapatinib treatment 
(Figure 5.22B).  However, overall there was an increase in expression over time, with ANOVA 
statistical analysis showing significant difference between the time points within the treated 
group (ANOVA F(5,12) =10.257, P = 0.001). 
Overall, within the SKBR3 cell line, lapatinib treatment reduces expression of both isoforms, 
however this was not statistically significant compared to control cells. Although there is 
significant reduction in PTK6 expression within the BT474 cell line at 24 hours post treatment 
with lapatinib, there are no significant differences at the other time points between control 






Figure 5.23 Relative ALT-PTK6/PTK6 ratios are unchanged in response to Lapatinib (Lap) 
treatment in SKBR3 cells but there is some variation in the BT474 cell line. Cells were 
seeded at 200,000 cells per well in a 6 well plate and treated with Lap (2.5µM).  Cells were 
harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 hours, 
8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse transcriptase. 
PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen (10µl), primer 
mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental parameters were 
40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 10 seconds at 95˚C.  
Data was analysed by calculating average Cycle Threshold (CT) of both isoforms and normalised 
to average CT values of reference genes: SDHA and RPL13A. This gave the delta CT (ΔCT) 
value which was used to calculate relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Ratios 
were determined from mean RQ values of ALT-PTK6/PTK6. Results show ALT-PTK6/PTK6 ratios 
in control, untreated (blue) and treated cells (purple) in SKBR3 cell line (A) and BT474 cell line 
(B). qPCRs were performed using 3 independent sets of RNA for all cell lines with error bars 
representing standard deviation.  ANOVA statistical analysis was performed to demonstrate 
variation within control cells as well as within treated groups. Students T Test was used to assess 
significant difference between each control and treated time points, * P<0.05.  
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Ratios of ALT-PTK6 to PTK6 were relatively unchanged in SKBR3 cell line (Figure 5.23A) in 
response to lapatinib treatment compared to the untreated control cells.  There were no 
statistically significant variations observed within control (ANOVA F(5,12) =0.413, P = 0.083)  
and treated group (ANOVA F(5,12) =1.063, P = 0.427 ) for ALT-PTK6/PTK6 ratios. Overall 
ALT-PTK6 to PTK6 ratios were reduced compared to control cells after lapatinib treatment 
(Figure 5.23B) in the BT474 cell line.  Although there were higher ALT-PTK6 to PTK6 ratios 
at 8 hours post treatment suggesting induction of ALT-PTK6 transcript, the ratios were lower 
at the other time point and were significantly lower compared to control cells after 48 hours 
of lapatinib treatment.  There was statistically significant variance within the treated group 
(ANOVA F(5,12) =5.562, P = 0.007).    
In summary, ratios of ALT-PTK6 to PTK6 were not statistically different in control and treated 
cells in response to lapatinib treatment at 2.5µM concentration within the SKBR3 cell line.  
For BT474 cell line, there are lower ratios of ALT-PTK6 to PTK6 overall in response to 




5.3.7 mRNA expression of both isoforms and ALT-PTK6 to PTK6 ratios in breast 
in breast cancer cell line after Tamoxifen treatment (5µM). 
 
I next sought to determine alterations in mRNA expression of both PTK6 isoforms in response 
to endocrine therapy using Tamoxifen (5µM) which has not been previously investigated.  As 
a large majority of diagnosed breast cancers are oestrogen receptor (ER) expressing (and/or 
progesterone receptor expressing) and are stimulated via interaction with oestrogen 
(reviewed in Zhang et al., 2014) and treated with oestrogen targeting therapies including the 
selective oestrogen receptor modulator (SERM) Tamoxifen; potential consequences on PTK6 
and ALT-PTK6 mRNA levels in response to these treatments need to be determined. 
Furthermore, studies have shown there is high expression of PTK6 transcript in breast 
cancers that are ER positive (Irie et al., 2010; Peng et al., 2014).  
ER positive cell line, T47D was seeded as before and treated with 5µM of Tamoxifen. For 
RNA extraction, the RNeasy Mini Spin Column kit from Qiagen was used to elute high quality 
and yield of RNA free of contamination as described in Materials and Methods (Chapter 2, 
section 2.2.15.2).  cDNA was prepared using SuperScript II Reverse Transcriptase 
(Invitrogen) kit and qPCR performed using PrecisionPLUS MasterMix with ROX at a lower 
level premixed with SYBRgreen (Primer Design) with primer mixes for either transcript along 
with the primers for two reference genes, SDHA and RPL13A.  Each master mix for each 
gene was pipetted in duplicate in a 96 well plate and 5µl of cDNA was pipetted using sterile 
filter tips as per manufacturer’s protocol.  The Applied Biosystems Quantstudio 7 Flex Real-
Time PCR machine was used, and qPCRs were carried out using 3 sets of independent RNA. 
Data was analysed using the QuantStudio™ Software V1.3—for QuantStudio™ 6 and 7 Flex 
and ViiA™ 7 Real-Time PCR software (Applied Biosystems). Additionally, ratios of ALT-PTK6 
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to PTK6 transcripts within the breast cancer cell lines in response to Tamoxifen were 







Figure 5.24 Tamoxifen (Tam) treatment shows A) increase in levels of PTK6 and (B) 
increase in ALT-PTK6 before significant reduction at 48 hours post treatment. Cells were 
seeded at 200,000 cells per well in a 6 well plate and treated with Tam (5µM).  Cells were 
harvested for RNA at the following time points along with untreated controls: 0, 2 hours, 4 
hours, 8 hours, 24 hours and 48 hours.  cDNA was prepared using SuperScript II reverse 
transcriptase. PrecisionPLUS MasterMix with ROX at a lower level premixed with SYBRgreen 
(10µl), primer mix (1µl), RNase/DNase Free water, cDNA (5µl) were mixed. The experimental 
parameters were 40x cycles of enzyme activation for 2 minutes at 95˚C and denaturation for 
10 seconds at 95˚C.  Data was analysed by calculating average Cycle Threshold (CT) of both 
isoforms and normalised to average CT values of reference genes: SDHA and RPL13A. This 
gave the delta CT (ΔCT) value which was used to calculate relative quantification (RQ) as 
follows: RQ= 2-ΔΔCT.  Results show PTK6 (A) and ALT-PTK6 (B) relative expression in 
control, untreated (blue) and treated cells (brown) in the T47D cell line. qPCRs were 
performed using 3 independent sets of RNA for all cell lines with error bars representing 
standard deviation.  ANOVA statistical analysis was performed to demonstrate variation within 
control cells as well as within treated groups. Students T Test was used to assess significant 
difference between each control and treated time points, * P<0.05. 
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PTK6 expression appeared to increase in response to Tamoxifen treatment (5µM) in 
comparison to control cells in T47D cell line (Figure 5.24A), with significantly higher PTK6 
levels in treated cells at 2 hours (P<0.05).   In addition, there was statistical variance observed 
within the treated group (ANOVA F(5,12) =19.932, P<0.001). However, overtime PTK6 
expression is reduced 48 hours post treatment compared to expression at the 0-hour 
timepoint.  Similarly, ALT-PTK6 expression, although not statistically significant, is higher 
compared to control cells (Figure 5.24B).  There was a significant reduction at 48 hours post 
treatment compared to control cells (P<0.05).  Statistically significant variance within the 
treated group was observed (ANOVA F(5,12) =8.655, P = 0.001).      
Overall, initially there was induction of PTK6 expression in the T47D cell line in response to 
Tamoxifen treatment (5µM) but this was reduced overtime.  ALT-PTK6 expression was higher 
in treated cells compared to control cells until at 48 hours post treatment were there was 












Figure 5.25 Relative ALT-PTK6/PTK6 ratios are unchanged in response to Tamoxifen (Tam) 
treatment compared to control cells in T47D cell lines . Cells were seeded at 200,000 cells per 
well in a 6 well plate and treated with Tam (5µM).  Cells were harvested for RNA at the following 
time points along with untreated controls: 0, 2 hours, 4 hours, 8 hours, 24 hours and 48 hours.  
cDNA was prepared using SuperScript II reverse transcriptase. PrecisionPLUS MasterMix with 
ROX at a lower level premixed with SYBRgreen (10µl), primer mix (1µl), RNase/DNase Free water, 
cDNA (5µl) were mixed. The experimental parameters were 40x cycles of enzyme activation for 2 
minutes at 95˚C and denaturation for 10 seconds at 95˚C.  Data was analysed by calculating 
average Cycle Threshold (CT) of both isoforms and normalised to average CT values of reference 
genes: SDHA and RPL13A. This gave the delta CT (ΔCT) value which was used to calculate 
relative quantification (RQ) as follows: RQ= 2-ΔΔCT.  Ratios were determined from mean RQ values 
of ALT-PTK6/PTK6. Results show ALT-PTK6/PTK6 ratios in control, untreated (blue) and treated 
cells (brown) in the T47D cell line.  qPCRs were performed using 3 independent sets of RNA for 
all cell lines with error bars representing standard deviation.  ANOVA statistical analysis was 
performed to demonstrate variation within control cells as well as within treated groups. Students 





Within the T47D cell line, there was no statistically significant differences observed in ALT-
PTK6/PTK6 ratios in response to Tamoxifen treatment (Figure 5.25).  There was no 
statistically significant variance observed within the treated cells (ANOVA F(5,12) =2.65, P 
=0.077) suggesting little variation of PTK6 transcripts in response to Tamoxifen.   
 
5.3.8 mRNA expression analysis of PTK6 and ALT-PTK6 in breast cancer tissues 
 
ALT-PTK6 mRNA expression has not been investigated until now in breast cancer tissue 
samples.   Previous studies have shown expression of PTK6 mRNA in normal non-neoplastic 
breast tissues as well as in breast tumour tissues (Zhao et al., 2003; Born et al., 2005; Aubele 
et al., 2007, 2009; Harvey et al., 2009), with higher expression in tumour cells which increases 
with increasing tumour grade (Harvey et al., 2009; Irie et al., 2010) suggesting PTK6 
expression is associated with adverse patient outcomes.  Previously the ALT-PTK6 protein 
has shown to negatively regulate Brk expression and is associated with reduced cancer cell 
proliferation (Brauer et al., 2011).  In addition, my investigations in ALT-PTK6 to PTK6 ratios 
within breast cancer cell lines showed higher ratio of ALT-PTK6 to PTK6 in non-cancerous 
breast cells and in breast cancer cell lines representative of breast cancer subtypes with 
better patient outcomes; therefore, it was predicted higher ALT-PTK6/PTK6 ratios would be 
associated with better overall patient survival within breast cancer patients.  PTK6 and ALT-
PTK6 mRNA expression levels were assessed in normal (n=33) and malignant (n=127) 
breast tissue samples using real time qPCR and correlated with conventional clinic-
pathological parameters and clinical outcomes. Tissue samples with informed consent and 
ethical approval for the experiments were obtained as stated in (Wazir et al., 2013).  Breast 
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cancer tissues and normal background tissue were collected and stored in -80˚C until 
commencement of study.  The patient cohort has been part of a number of completed and 
on-going studies and the clinicopathological data describing the patient cohort is further 
described in (Wazir et al., 2013).  Breast tissue samples were collected immediately after 
excision and RNA extracted before reverse transcription and determination of transcript levels 
with β-actin as the reference gene used for normalisation.  It should be noted that the 
experimental work for this section was performed by the group’s clinical collaborators and so 
the choice of reference genes for these investigations were out of our control.  Transcript 
levels within the breast cancer tissues were compared in relation to the background normal 
breast tissues and analysed against the tumour node and metastasis (TNM) stage, nodal 
involvement, tumour grade and clinical outcome over a 10 year follow up period.  Results 
below show Kaplan Meier survival curves with y-axis as the cumulative survival (probability) 
and the x-axis shows the timeframe.  Statistical analysis to determine difference in survival 
distributions in relation to PTK6 and ALT-PTK6 transcript levels and ratios was determined at 
multiple levels using a number of statistical tests including Logrank (Mantel Cox) for 
significant difference between high and low PTK6 expression in relation to overall survival at 
later time points with Breslow (generalized Wilcoxon) test showing significant difference at 
the earlier time points.  The Tarone-Ware test was used to further assess distribution of overall 
survival with assumptions that there is identical distribution as well as equal variance.  All 





      
Overall Comparisons 
 Chi-Square Df Sig. 
Log Rank (Mantel-Cox) 8.600 1 .003 
Breslow (Generalized 
Wilcoxon) 
6.339 1 .012 
Tarone-Ware 7.213 1 .007 
Test of equality of survival distributions for the different 
levels of VAR00019. 
Means and Medians for Survival Time 
VAR00019 Meana Median 
Estimate Std. Error 95% Confidence Interval Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
.00 139.600 5.515 128.791 150.408 . . . . 
1.00 97.292 12.077 73.621 120.964 132.000 25.888 81.259 182.741 
Overall 131.451 5.594 120.487 142.415 . . . . 




Figure 5.26 High mRNA expression of PTK6 in breast cancer tissues is associated with 
reduced overall survival.  PTK6 transcript expression was determined in breast cancer tissue 
(n=127) in relation to the normal background tissue (n=33) using real time qPCR and correlated with 
conventional clinic-pathological parameters and clinical outcomes.  Kaplan Meier curve shows high 
PTK6 (green) and low PTK6 (blue) levels in relation to overall survival over time. Statistical analysis 
was carried out using log rank (Mantel Cox), Breslow (generalized Wilcoxon) and Tarone-Ware to 
determine survival distributions in relation to PTK6 expression levels .   
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 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 4.517 1 .034 
Breslow (Generalized 
Wilcoxon) 
4.488 1 .034 
Tarone-Ware 4.505 1 .034 
Test of equality of survival distributions for the different levels of 
VAR00019. 
Means and Medians for Survival Time 
VAR00019 Meana Median 
Estimate Std. Error 95% Confidence Interval Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
.00 132.496 6.200 120.343 144.648 . . . . 
1.00 92.813 11.417 70.436 115.191 120.000 . . . 
Overall 125.752 5.965 114.061 137.443 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
Figure 5.27 High mRNA expression of PTK6 in breast cancer tissues is associated with 
reduced disease-free survival.  PTK6 transcript expression was determined in breast cancer 
tissue (n=127) in relation to the normal background tissue (n=33) using real time qPCR and 
correlated with conventional clinic-pathological parameters and clinical outcomes.  Kaplan Meier 
curve shows high PTK6 (green) and low PTK6 (blue) levels in relation to disease free survival over 
time. Statistical analysis was carried out using log rank (Mantel Cox), Breslow (generalized 




 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 1.153 1 .283 
Breslow (Generalized 
Wilcoxon) 
.639 1 .424 
Tarone-Ware .915 1 .339 
Test of equality of survival distributions for the different levels 
of VAR00035. 
Means and Medians for Survival Time 
VAR00035 Meana Median 
Estimate Std. Error 95% Confidence Interval Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
.00 114.411 10.272 94.277 134.545 . . . . 
1.00 133.032 6.747 119.808 146.256 . . . . 
Overall 130.029 5.876 118.512 141.547 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 
  
Figure 5.28 High mRNA expression of ALT-PTK6 in breast cancer tissues is associated with 
improved overall survival.  ALT-PTK6 transcript expression was determined in breast cancer 
tissue (n=127) in relation to the normal background tissue (n=3) using real time qPCR and correlated 
with conventional clinic-pathological parameters and clinical outcomes.  Kaplan Meier curve shows 
high ALT-PTK6 (green) and low ALT-PTK6 (blue) levels in relation to overall survival over time. 
Statistical analysis was carried out using log rank (Mantel Cox), Breslow (generalized Wilcoxon) 




 Chi-Square df Sig. 
Log Rank (Mantel-Cox) .734 1 .392 
Breslow (Generalized 
Wilcoxon) 
.329 1 .566 
Tarone-Ware .514 1 .474 
Test of equality of survival distributions for the different levels of 
VAR00035. 
Means and Medians for Survival Time 
VAR00035 Meana Median 
Estimate Std. Error 95% Confidence Interval Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
.00 109.935 10.599 89.161 130.708 . . . . 
1.00 126.414 7.312 112.082 140.746 . . . . 
Overall 123.929 6.255 111.668 136.190 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
 
  
Figure 5.29 High mRNA expression of ALT-PTK6 in breast cancer tissues is associated with 
improved disease-free survival.  ALT-PTK6 transcript expression was determined in breast cancer 
tissue (n=127) in relation to the normal background tissue (n=33) using real time qPCR and 
correlated with conventional clinic-pathological parameters and clinical outcomes.  Kaplan Meier 
curve shows high ALT-PTK6 (green) and low ALT-PTK6 (blue) levels in relation disease free survival 
over time. Statistical analysis was carried out using log rank (Mantel Cox), Breslow (generalized 





 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 5.360 1 .021 
Breslow (Generalized 
Wilcoxon) 
4.730 1 .030 
Tarone-Ware 5.071 1 .024 
Test of equality of survival distributions for the different levels of 
VAR00014. 
  
Means and Medians for Survival Time 
VAR00014 Meana Median 
Estimate Std. Error 95% Confidence Interval Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
.00 121.357 7.657 106.349 136.364 . . . . 
1.00 139.333 4.535 130.444 148.222 . . . . 
Overall 130.029 5.876 118.512 141.547 . . . . 
a. Estimation is limited to the largest survival time if it is censored. 
Figure 5.30 High ALT-PTK6/PTK6 ratios in breast cancer tissues are associated with 
improved overall survival.  ALT-PTK6 and PTK6 transcript expression was determined in breast 
cancer tissue (n=127) in relation to the normal background tissue (n=33) using real time qPCR and 
correlated with conventional clinic-pathological parameters and clinical outcomes.  Kaplan Meier 
curve shows high ALT-PTK6/PTK6 ratio (green) and low ALT-PTK6/PTK6 ratio (blue) levels in 
relation to overall survival over time. Statistical analysis was carried out using log rank (Mantel Cox), 
Breslow (generalized Wilcoxon) and Tarone-Ware to determine survival distributions in relation to 
ALT-PTK6/PTK6 ratios levels.  
 
Figure 5.32 High ALT-PTK6/PTK6 ratios in breast cancer tissues are associated with 
improved overall survival.  ALT-PTK6 and PTK6 transcript expression was determined in breast 
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Kaplan Meier curves are used to determine the estimate probability of overall or disease free 
survival over a 10 year time period in relation to PTK6 and ALT-PTK6 expression levels.  The 
median copy number of full-length transcript (PTK6) was higher in breast cancer tissues 
compared to normal breast tissue and increased with increasing tumour grade (364 vs 13 for 
TNM3 vs TNM1 respectively, P=0.019 and 374 vs 23 for TNM3 vs TNM2 respectively, 
P=0.0244).  Figures 5.26 and 5.27 show higher PTK6 expression correlates with decreased 
overall survival as well as decreased disease-free survival compared to cancers with lower 
PTK6 expression respectively.  Figures 5.28 and 5.29 show higher ALT-PTK6 levels in breast 
cancer are associated with improved overall and disease-free survival respectively.  As 
previously determined (Zhao et al., 2003; Irie et al., 2010), high Brk expression was 
associated with oestrogen receptor positivity (P=0.061).  Furthermore, high PTK6 transcript 
levels were present for patients who developed recurrence (P=0.03) as well as patients who 
died of breast cancer (P=0.003).  Interestingly, ALT-PTK6 levels were higher in normal breast 
tissue compared to malignant breast tissue and also decreased with increasing tumour grade.  
Comparing high and low ALT-PTK6/PTK6 ratios (Figure 5.30), a significant difference was 
observed; higher ALT-PTK6/PTK6 ratios were associated with longer overall survival 






My studies confirm the expression of PTK6 (407bp) within breast cancer cell lines as well as 
mRNA expression of ALT-PTK6 (285bp), as shown in Figure 5.1.  The alternatively spliced 
PTK6 transcript (ALT-PTK6) was first identified in the T47D breast cancer cell line during the 
characterisation and chromosome mapping of the Brk gene (Mitchell et al., 1997).  ALT-PTK6 
has a 122 base pair deletion at the 3’ of the SH3 coding region with a novel proline rich 
sequence at the C-terminal and is 134 amino acids long which encodes a 15KDa protein 
(Mitchell et al., 1997).   Although previous groups have shown mRNA expression of PTK6 in 
breast cancer cell lines (Barker, Jackson and Crompton, 1997), expression of ALT-PTK6 
mRNA was not previously investigated. Breast cancer cell lines T47D, MDA-MB 436 and 
BT474 showed the highest PTK6 expression.  Each cell line is representative of a different 
breast cancer subtype; Luminal A (T47D), triple negative (MDA-MB 436) and Luminal 
B/HER2 positive (BT474) breast cancer, suggesting high expression of PTK6 is not limited to 
a single subtype.  Furthermore, the cell lines with low PTK6 transcript expression include 
MCF10A and SKBR3 which is consistent with Tyner and group findings (Peng et al., 2014).   
These variations may be dependent on the expression of molecular markers in the breast 
cancer, for example, high Brk expression has been shown in over 80% of Luminal A (ER 
negative, PR positive and HER2 negative) and) and Luminal B (ER positive, PR negative or 
low and HER2 negative) breast cancers (Peng et al., 2014).  Overall, majority of the breast 
cancer cell lines showed much greater PTK6 transcript expression compared to the non-
cancerous cell line MCF10A, which is consistent with previous reports (Peng et al., 2014).  
My polymerase chain reaction (PCR) experiments corroborate the detection of ALT-PTK6 
expression within SKBR3, BT474 and T47D breast cancer cell lines and additionally within 
GI101 and MDA-MB 436 with other studies (Peng et al., 2014).  Overall, there was higher 
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PTK6 expression and lower ALT-PTK6 expression within the breast cancer cell lines 
compared to MCF10A cell line (Figure 5.1).  ALT-PTK6 transcript has further been detected 
in prostate and colon cancer cell lines thus far (Brauer et al., 2011) suggesting ALT-PTK6 is 
not limited to a specific cancer type.  Although ALT-PTK6 expression was also shown in 
normal prostate cells (Brauer et al., 2011), interestingly no PTK6 or ALT-PTK6 transcripts 
were detected in the immortalised non-tumorigenic cell line MCF10A in my PCR experiments 
using standard PCR (Figure 5.1). In addition, no PTK6 or ALT-PTK6 expression was detected 
in the triple negative cell line, MDA-MB 231 using standard PCR.  However, this is in contrast 
to Tyner and group which showed PTK6 mRNA expression in MCF10A cell line as well as 
expression of both transcripts in MDA-MB 231 cell line (Peng et al., 2014). This discrepancy 
may be due to the different experimental conditions and set of primers used in the studies as 
well as lower levels of PTK6 and ALT-PTK6 transcripts in the cell lines. Quantitative PCR 
(qPCR) is a more sensitive and reliable method that is able to detect very low amounts of 
target DNA (reviewed in Rocha et al., 2015), further experiments were carried out using 
quantitative PCR.  The expression of PTK6 and ALT-PTK6 transcripts were thus detectable 
using qPCR in the breast cancer cell lines including MCF10A and MDA-MB 231 (Figure 5.5).  
Previously it had been reported, PTK6 expression was not detectable in normal mammary 
tissues, however since PTK6 mRNA expression was detectable in the non-transformed 
mammary epithelial cell line MCF10A, this lead to investigations of PTK6 expression in 
normal mammary tissue and thus confirmation that the PTK6 transcript was expressed in 
normal mammary tissue (Peng et al., 2014). In addition to PTK6 expression, expression of 
ALT-PTK6 transcript was also detectable in MCF10A cell line (Figures 5.5).  There was higher 
ALT-PTK6 expression within MCF10A cell line compared to PTK6 transcript, although this is 
contrary to Tyner and group which showed very low levels of ALT-PTK6 transcript although 
this may be due to the volume of cDNA input and method of detection (Peng et al., 2014).  
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ALT-PTK6 transcript has previously been detected in normal human prostate and colon cells 
(Brauer et al., 2011) and now in the non-transformed mammary epithelial cell line MCF10A, 
suggesting ALT-PTK6 transcript expression is also not limited to only cancerous cells.  This 
is of interest as ALT-PTK6 protein has been shown to enhance the nuclear functions of Brk 
and negatively regulate cell proliferation in cancer cells (Brauer et al., 2011); thus, any Brk- 
therapy which disrupts the SH3 domain will need consideration for potential consequences 
of PTK6 and ALT-PTK6 expression in normal tissues, considering both isoforms contain 
functioning SH3 domains.   
Interestingly, ratios of ALT-PTK6 to PTK6 transcripts (Figure 5.6) were higher in mainly breast 
molecular marker expressing cell lines (ER/PR/HER2) and the non-cancerous MCF10A cell 
line compared to cell lines representative of triple negative breast cancers.  ER expression 
has also shown to be a positive prognostic factor in breast cancer (Ademuyiwa et al., 2013).   
In addition, studies have shown a positive association with PTK6 mRNA levels in breast 
tumours and positive oestrogen receptor status and HER2 expression (Zhao et al., 2003; 
Born et al., 2005).   If higher ALT-PTK6 expression is detected in breast cancer cells 
expressing higher levels of ER, this could suggest there is potentially more than one 
mechanism for improved breast cancer prognosis.  Furthermore, triple negative breast 
cancers are linked with an overall poorer survival compared to hormone expressing breast 
cancers including HER2 positive breast cancers (Caggiano, Bauer and Parise, 2011).  
Although ALT-PTK6 protein expression was detectable in MDA-MB 231 and MDA-MB 436, 
this was at a low level compared to T47D, a luminal A subtype of breast cancer (Figure 5.6).   
Since elevated levels of PTK6 transcript are detected with increasing tumour grade in breast 
cancers as well as higher levels of PTK6 transcript compared to ALT-PTK6, this suggests 
higher ALT-PTK6/PTK6 ratios may be associated with less aggressive and low-grade 
tumours.   
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My studies are some of the first to investigate the consequence of Brk inhibition on both PTK6 
transcripts.  Using a novel Brk inhibitor, compound 4f (5µM), the ratio of ALT-PTK6/PTK6 
transcripts was determined using qPCR after treatment along with control untreated samples.  
Ratios of ALT-PTK6 to PTK6 showed variation from cell line to cell line. Table 5.1 shows the 
cell lines in order of high to low ratios of ALT-PTK6/PTK6.   However, generally with higher 
PTK6 mRNA levels, there was conversely lower ALT-PTK6 in comparison and vice versa. 
Within the MDA-MB 231 cell line, representative of triple negative breast cancer, ALT-
PTK6/PTK6 ratios increased at 4 hours and 48 hours post treatment.  In the MDA-MB 436 
cell line, there was a moderate increase in ALT-PTK6/PTK6 ratios at 2, 4 and 24 hours post 
treatment compared to at 0 hours.  Although these were not statistically significant, the higher 
ALT-PTK6 levels may suggest Brk inhibition results in reduced levels of PTK6 transcript which 










Table 5.1 High to Low ALT-PTK6/PTK6 transcript ratios 
High to Low ALT-PTK6/PTK6 










As breast cancer treatment is heavily chemotherapy based, the effect on both PTK6 
transcripts was investigated.  Generally, PTK6 expression (Figure 5.16) and ALT-PTK6 
expression (Figure 5.17) as well as ratios (Figure 5.18) did not statistically differ significantly 
compared to control untreated cells in MDA-MB 231 and MDA-MB 436 cell lines in response 
to Taxol suggesting Taxol does not significantly alter PTK6 transcript ratios in these cell lines.  
Previous studies have shown hypoxia inducible factor alpha (HIFα) protein expression is 
induced in response to Paclitaxel/Taxol (Samanta et al., 2014).  Hypoxia inducible factors are 
mediators of transcriptional responses to hypoxia and are involved in many cellular functions 
within cancer cells leading to progression and metastasis (Semenza, 2010). HIFα subunits 
are overexpressed in breast cancers especially in triple negative breast cancers (Yamamoto 
et al., 2008) and indicate higher risk of metastasis (Dales et al., 2005).   Hypoxia has shown 
to counteract Taxol-induced apoptosis in breast cancer cell lines including MDA-MB 231 
suggesting potential mechanism of chemotherapeutic resistance (Notte et al., 2013). Since 
Brk is co-expressed with HIF-1α (Regan Anderson et al., 2013), the total effect of Taxol on 
PTK6 transcripts may not be as pronounced in the triple negative cell lines compared to the 
luminal A T47D cell line which appear to be more sensitive to chemotherapy agents (Figure 
4.5, Chapter 4). It should be noted, however, that other studies have shown Brk expression 
is induced prior to induction of HIF-1α suggesting that Brk expression is independent of HIF-
1α and that there are alternative mechanisms that are HIF-independent which mediate Brk 
protein expression (Pires et al., 2014).       
Interestingly within MDA-MB 231 cell line there were significantly lower ALT-PTK6/PTK6 
ratios in response to doxorubicin compared to untreated control cells at 8 hours post 
treatment (Figure 5.21A), however at 48 hours post treatment there were significantly higher 
ALT-PTK6/PTK6 ratios in comparison.  MDA-MB 436 cell line also shows generally higher 
ALT-PTK6/PTK6 ratios with significantly higher ratios at 4 hours post treatment in response 
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to doxorubicin (Figure 5.21B).  Previously, Brk has shown to be induced in response to DNA 
damage via gamma irradiation or doxorubicin (Haegebarth et al., 2009; Gierut et al., 2012) 
albeit in colon cancer cells. Thus, the initial induction of PTK6 mRNA expression may be in 
response to the DNA damage by doxorubicin. In addition, hepatocyte growth factor (HGF) 
which is involved in protecting cancer cells against cytotoxicity and apoptosis induced by DNA 
damage (including doxorubicin) is an upstream activator of Brk in breast cancer cells (Fan et 
al., 2005; Castro and Lange, 2010) further indicating a potential mechanism by which Brk 
levels may increase in response to doxorubicin. The reduction of full length transcript and 
induction of ALT-PTK6 at the later time points may suggest increased number of apoptotic 
cells resulting due to doxorubicin treatment over time leading to reduced levels of PTK6 and 
concurrently higher ALT-PTK6 transcript levels.  Previous studies have shown as ALT-PTK6 
levels are increased, Brk levels are reduced (Brauer et al., 2011).  Furthermore, as ALT-PTK6 
levels increase, interaction with Brk with other proteins may reduce due to the two isoforms 
competing via their SH3 domains as well as reduction of Brk phosphorylation by other kinases 
if they interact via the SH3 domain.  In addition, ALT-PTK6 also associates with β-catenin 
which is also a substrate of Brk (Brauer et al., 2011).  β catenin/WNT signalling has 
extensively been examined in breast cancer tumorigenesis and metastasis (Wang et al., 
2015) and has shown to be involved in cell migration as well as chemo-resistance of triple 
negative breast cancers in vitro (Xu et al., 2015) suggesting ALT-PTK6 and β catenin 
interactions may have some role in chemotherapy response.   As increasing amounts of ALT-
PTK6 protein in transfected prostate cancer cells enhanced repression of β catenin and T-
cell factor (TCF) transcriptional target proteins, Cyclin D and c-Myc (Brauer et al., 2011) and 
increasing levels of ALT-PTK6 resulted in reduced cell proliferation, it may be a point of 
interest that ALT-PTK6 could sensitise cancer cells to chemotherapy via repression of β 
catenin/WNT signalling and reduced cellular proliferation.  However, Brk and ALT-PTK6 
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interactions with this signalling pathway will need further validation in breast cancer cells.   
Furthermore, as ALT-PTK6 may decrease cell proliferation and chemotherapy targets mainly 
rapidly dividing cells, this could result in reduced sensitivity to chemotherapeutic agents and 
indicate a potential mechanism that confers resistance.    
Brk inhibition in the HER2 positive cell lines showed significant reduction in PTK6 transcript 
levels compared to control cells in SKBR3 and ALT-PTK6 to PTK6 ratios, however showed 
no meaningful change between treated and control cells in both cell lines.   Although no 
statistical significance was observed, there are generally higher ALT-PTK6/PTK6 ratios in 
response to Brk treatment in BT474 cell line compared to control cells.  ALT-PTK6/PTK6 
ratios in response to lapatinib within HER2 positive cell line SKBR3 (Figure 5.24A) were not 
statistically significantly different compared to ratios in untreated control cells.  In BT474 cell 
line, ALT-PTK6/PTK6 ratios (Figure 5.24B) show higher ALT-PTK6 to PTK6 transcript at 8 
hours before significant reduction at 48 hours post treatment compared to ratios in control 
cells. Studies have shown ptk6 gene is coamplified with erB2 gene and promotes cell 
proliferation as well as confers resistance to HER targeted therapies such as lapatinib (Xiang 
et al., 2008).  Downregulation of Brk has shown to sensitize breast cancer cells to lapatinib 
by enhancement of Bim expression via p38 activation (Park et al., 2015).  My results show 
overall ALT-PTK6/PTK6 ratios decrease in BT474 cell line in response to lapatinib but remain 
relatively unchanged in SKBR3 cell line.  As lapatinib resistance has been linked to Brk, high 
PTK6 levels were expected in response to lapatinib treatment.  Taken together, these results 
support combination treatment with Brk inhibition and HER2 targeted therapy would 
significantly reduce cancer cell viability as shown in Figure 4.6 (Chapter 4, section 4.3.3).  In 
addition, these results along with results shown in chapter 4, section 4.3.3, show HER2 
positive cell lines appear to be more sensitive to Brk inhibition than triple negative breast 
cancers.      
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Although not statistically significant, PTK6 levels are reduced with Brk inhibition compared to 
control cells in T47D cell line.  Overall, ALT-PTK6/PTK6 ratios are generally increased with 
Brk inhibition compared to control cells. T47D cell line did not significantly alter ALT-
PTK6/PTK6 ratios (Figure 5.26), suggesting Tamoxifen does not directly influence PTK6 and 
ALT-PTK6 ratios. PTK6 transcript expression remains more dominant compared to ALT-PTK6 
in this cell line.  Brk inhibition with Tamoxifen treatments have shown strong synergism in ER 
positive breast cancers (Jiang et al., 2017).  It has been now reported Brk is involved in 
promoting survival and growth of endocrine therapy (Tamoxifen) resistant breast cancer cells 
(Ito et al., 2017) and downregulation of Brk promoted apoptosis of ER positive breast cancer 
cells including in tamoxifen-resistant cells.  My results corroborate this as PTK6 expression 
is not significantly altered in the presence of Tamoxifen thus breast cancer cells will continue 
to proliferate via Brk signalling.   Table 5.2 shows the summary description of all ALT-


















and treated cells 
observed. 
Ratios reduce at 8hrs 
post treatment and 
significantly increase 
at 48hrs post 
treatment.  No 
changes observed at 
other time points.  
  
MDA-MB 436 Ratios increase at 
4hrs post treatment 
compared to control.  
No other changes 






and treated cells 
observed 
  No change 
between control 
and treated cells 
observed 
 




control cells and 
decrease at 48hrs 
post treatment. 
No other changes 
observed at other 
time points. 
T47D Ratios increase at 
2hrs after 
treatment before 
decreasing at 4hrs 
after treatment 
compared to 
control cells.  No 
difference 
observed at other 
time points.   





Table 5.2 Summary of ALT-PTK6/PTK6 mRNA expression ratios in response to Brk inhibition and 
other breast cancer therapies. 
257 
 
Previous studies have shown expression of PTK6 mRNA in normal non-neoplastic breast 
tissues as well as in breast tumour tissues (Zhao et al., 2003; Born et al., 2005; Aubele et al., 
2007, 2009; Harvey et al., 2009), with higher expression in tumour cells which increases with 
increasing tumour grade (Harvey et al., 2009; Irie et al., 2010).  PTK6 to ALT-PTK6 ratios 
have also been shown to be higher in prostate cancer tissues compared to normal or low-
grade tumour prostate tissue (Brauer et al., 2011).  However, expression ratios of ALT-PTK6 
to PTK6 have yet to be investigated in breast cancer tissue samples.  Brk expression has 
shown to be associated with increasing tumour grade and adverse patient outcomes (Harvey 
et al., 2009; Irie et al., 2010) and ALT-PTK6 is associated with inhibition of Brk 
phosphorylation and reduced cancer cell proliferation as well as reduced levels with higher 
grade tumours in prostate tissues; thus higher ALT-PTK6/PTK6 ratios may indicate potentially 
better prognosis and overall survival in breast cancer tumours.  In addition, my in vitro studies 
show higher ALT-PTK6/PTK6 ratios in non-cancerous cell line as well as in cell lines 
representative of breast cancer subtypes which are less aggressive and have a better 
prognosis (Lumina A/B). Investigation of ALT-PTK6 and PTK6 transcripts in normal and 
malignant breast tissue showed increasing levels of PTK6 transcript with increasing tumour 
grade and reduced overall survival as well as disease free survival compared to breast cancer 
tissues with lower PTK6 levels (Figures 5.27 and 5.28).  Conversely, higher ALT-PTK6 
transcript levels were associated with improved overall and disease-free survival and 
decreased with increasing tumour grade (Figures 5.29 and 5.30) which corroborate my 
experiments in the cell lines.  Additionally, higher ALT-PTK6/PTK6 ratios significantly 
correlated with longer overall and disease-free survival (Figure 5.31) suggesting ALT-PTK6 
and PTK6 ratios are important prognostic predictors of disease free and overall survival in 
breast cancers.  This further validates an inverse relationship between both transcripts in 
breast cancer cells.  This could have a potential impact on therapies targeting Brk inhibition 
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and investigations on ALT-PTK6 influence on Brk inhibition, especially in relation to 
localisation within breast cancers may offer further insight on the roles of ALT-PTK6 as 
previous groups have suggested ALT-PTK6 may be able to localise Brk to the nucleus and 
nuclear Brk has shown to have growth inhibitory functions, an inverse to cytoplasmic Brk 
which has oncogenic functions (Derry et al., 2003; Ie Kim and Lee, 2009; Brauer et al., 2011). 
It is worth mentioning that validation of ALT-PTK6 and PTK6 transcript ratios in breast cancer 
tissues in a larger cohort of patient samples may show further statistical as well as biological 
relevance.   
The main conclusions of this chapter were that the in vitro investigations show higher levels 
of ALT-PTK6/PTK6 ratios in non-cancerous cell line as well as in cell lines representative of 
breast cancer subtypes which are less aggressive and have a better prognosis (Lumina A/B) 
compared to triple negative breast cancer cell lines which have higher level of the PTK6 
transcript. There were no significant differences in PTK6 and ALT-PTK6 mRNA expression in 
response to standard breast cancer therapies suggesting these therapies do not affect Brk 
at the transcript level.  Furthermore, expression of ALT-PTK6 and PTK6 transcripts in normal 
and malignant breast tissue showed increasing levels of PTK6 transcript with increasing 
tumour grade and reduced overall survival as well as disease free survival compared to 
breast cancer tissues with lower PTK6 levels.   Conversely, there were higher levels of the 
short transcript, ALT-PTK6 in normal and low grade breast cancer tissues.  The expression 
ratios of ALT-PTK6/PTK6 show higher ratios were associated with longer overall survival.  
These data suggest there is potential for ALT-PTK6/PTK6 expression ratios to be used as 









Previous studies have not shown a direct association between radio-sensitivity and Brk 
expression in breast cancer cell lines nor any link between Brk and DNA repair after γ-
radiation induced DNA damage in the context of breast cancer.  This is important due to the 
use of radiotherapy and cytotoxic chemotherapeutic agents which function via inducing DNA 
damage in breast cancer treatments.   I hypothesised, Brk positive breast cancer cell lines 
may be more susceptible to gamma radiation.  Brk expression has shown to potentiate ErbB 
signalling via P13K/Akt, which is an activator of the mTOR pathway and increased levels of 
mTOR are linked to down-regulation of ataxia telangiectasia mutated protein (ATM) (Kamalati 
et al., 1996; Shen and Houghton, 2013). Downregulation of ATM may increase cancer cell 
sensitivity to radiotherapy as cancer cells have reduced repair capacity (Truman et al., 2005; 
Hammond and Muschel, 2014).  
Although my studies did not indicate a role for Brk in directly influencing radio-sensitivity of 
breast cancer cell lines, there was indication that cell lines with high SF2 survival rates 
(survival rate 2Gy dose) had moderate to higher Brk expression (Figure 3.7, Chapter 3).  In 
addition, Brk was induced in response to gamma radiation showing an increase in Brk protein 
expression in response to DNA damage (Figure 3.6, Chapter 3).  Further investigations using 
transfected cell lines expressing Brk WT, Brk KM and vector only in cell lines that were 
endogenously Brk negative (MDA-MB 468 and MDA-MB 157) showed increased radio-
resistance in Brk WT and Brk KM cell lines (Figure 3.4, Chapter 3 ).  Interestingly SF2 survival 
did show statistically significant higher survival rates for MDA-MB 157 Brk WT and Brk KM 
cell lines compared to MDA-MB 157 Vector cell line (Figure 3.5 Chapter 3).   However, this 
was not confirmed in the MDA-MB 468 cell line which showed no statistically significant 
variation.  The difference in part can be explained due to the activation of signalling pathways 
between the two cell lines as MDA-MB 468 shows considerably higher expression of EGFR 
in MDA-MB 468 cell line compared to MDA-MB 157 as well as mutations in the P13K/Akt 
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inhibitor PTEN (Bamford et al., 2004; Burness, Grushko and Olopade, 2010), suggesting little 
impact by Brk within a cell line with already elevated EGFR signalling.  Furthermore, there 
were no statistically significant differences in gamma H2AX DNA repair kinetics as well as no 
functional relationship with ATM activity in the MDA-MB 468 and MDA-MB 157 cell lines 
suggesting Brk expression may not directly influence radio-sensitivity through the ATM 
signalling pathway.  Thus, radiotherapy remains a viable treatment option for breast cancer 
patients and Brk may not have a significant impact on sensitivity.   
My studies of Brk influence on breast cancer sensitivity in response to common breast cancer 
therapies such as Taxol, Doxorubicin, Lapatinib as well as Tamoxifen showed significant 
reduction in cell proliferation in combination with Brk inhibition using a novel inhibitor, 
compound 4f (Figures 4.3, 4.5, 4.6, and 4.8, Chapter 4) suggesting Brk kinase inhibition as 
a combination therapy may prove to be a viable and effective treatment for the diverse 
subtypes of breast cancer.  Although Brk did not show a direct role in sensitising breast 
cancer cell lines to radiotherapy, it was induced in response to radiation and since it 
modulates response to chemotherapeutic agents, patients undergoing treatments involving 
radiotherapy and chemotherapy in combination may benefit additionally with Brk inhibition. 
Further investigations in vivo will reveal the impact of Brk inhibition in mice models.  In 
addition, although Brk inhibition using compound 4f did not significantly reduce breast cancer 
cell proliferation as a monotherapy, this does not suggest more potent Brk inhibitors will show 
improved efficacy.  Irie and group have recently shown P21d, a variant of imidazo[1,2-
a]pyrazin-8-amines (Zeng et al., 2011) as a potent Brk kinase activity inhibitor in breast 
cancer cells (Ito et al., 2016).  P21d treatment showed downregulation of the SNAIL protein, 
restoration of E-cadherin expression as well as induction of anoikis and reduced metastasis 
in TNBC cells (Ito et al., 2016). More recent development of Brk inhibitors include 
pyrazolopyrimidine (PP)1, PP2 and a lymphocyte-specific protein tyrosine kinase inhibitor 
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which show promise as selective kinase inhibitors of Brk activity with reduced 
phosphorylation of Brk substrate proteins including STAT3 (Shim, Kim and Lee, 2017).  
Further investigations in vitro and in vivo will shed light on the effectiveness of these inhibitors. 
However, identification of novel Brk inhibitors and continued investigations with Brk inhibitors 
show Brk kinase inhibition remains an area of interest.       
Along with PTK6, an alternatively spliced Brk transcript was identified which was named 
originally as λm5 and much later coined as ALT-PTK6 (Mitchell et al., 1997; Brauer et al., 
2011).  The short isoform has a 122 base pair deletion at the 3’ end of the SH3 coding region 
thus it lacks a functional SH2 and tyrosine kinase domain but instead has a C-terminal proline 
rich sequence (Figure 1.1, Chapter 1).  Thus far ALT-PTK6 expression has been shown in 
breast, colon and prostate cancer cells (Brauer et al., 2011; Mitchell et al, 1997).  The exact 
role of this isoform in breast cancer has not been fully investigated previously.  My 
investigations show ALT-PTK6 protein expression in T47D and low expression in the two 
triple negative cell lines, MDA-MB 231 and MDA-MB 436.  Interestingly for MDA-MB 231 cell 
line, ALT-PTK6 protein levels appeared to reduce over time due to Brk inhibition suggesting 
Brk reduction may also affect the levels of ALT-PTK6.  The potential mechanism for this may 
involve Brk’s association with proteins that regulate alternative splicing such as sam68, SLM1 
and SLM2.  Due to reduced Brk activity, phosphorylation of downstream substrates is also 
reduced which may in consequence lead to reduced levels of the alternative isoform.  This is 
of importance as any Brk targeted therapy may have potential effects on the short isoform 
due to interactions of Brk with these RNA binding proteins.    
Previous studies have shown expression of PTK6 mRNA in normal breast tissues as well as 
in breast tumour tissues (Zhao et al., 2003; Born et al., 2005; Aubele et al., 2007, 2009; 
Harvey et al., 2009), with higher expression in tumour cells which increases with increasing 
tumour grade (Harvey et al., 2009; Irie et al., 2010) suggesting PTK6 expression is associated 
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with adverse patient outcomes.  ALT-PTK6 has been proposed to potentially negatively 
regulate Brk expression and is associated with reduced cancer cell proliferation (Brauer et al, 
2011).  Moreover, the higher ratio of ALT-PTK6 to PTK6 expression in non-cancerous breast 
cells (MCF10A) and in breast cancer cell lines representative of breast cancer subtypes with 
better patient outcomes (Figure 5.5, Chapter 5); suggests higher ALT-PTK6 to PTK6 ratios 
would be associated with better overall patient survival within breast cancer patients.  Indeed, 
ALT-PTK6 expression was higher in normal breast tissue and low grade tumours and 
decreased with increasing tumour grade/stage, whereas PTK6 expression conversely was 
higher in malignant tissue compared to normal breast tissue and increased with advancing 
tumour stage.  Thus, suggesting a role for both transcripts in predicting breast cancer 
prognosis.  This was confirmed with high ALT-PTK6/PTK6 ratios significantly correlating with 
improved overall breast survival over a 10 year period (Figure 5.30, Chapter 5).  These results 
confirm and corroborate the oncogenic role for PTK6 in relation to poor prognosis in breast 
cancers (Harvey et al., 2009; Irie et al., 2010) and offer the potential of ALT-PTK6/PTK6 
mRNA expression ratio as a predictive prognostic marker.  It should be noted, other groups 
have suggested a positive prognostic potential for PTK6, with high PTK6 expression beyond 
50-100 months correlating with improved probability of distant recurrence free survival 
(Aubele et al., 2007).  This discrepancy may be due to the association of Brk expression with 
the oestrogen receptor which is linked to positive prognosis in breast cancer (reviewed in 
Cao and Lu, 2016).   
Breast cancer survival rates have doubled over the last 40 years and continue to improve 
(Cancer research UK, 2014), however breast cancer along with bowel and prostate cancers 
account for almost half of all cancer related deaths in the UK (Cancer research UK, 2014).       
In addition, incidence rates continue to increase, and breast cancer remains one of the most 
common cancers in the UK.  Furthermore, chemotherapy and radiotherapy although continue 
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to be improved with advancing technology, still show severe adverse side effects (Erban and 
Lau, 2006; Azim et al., 2011; Henson et al., 2013; Sardar et al., 2017).  Hormonal therapies  
such as Tamoxifen, have been used for early stage and metastatic breast cancer since its 
license in 1972 (Smith, 2012).  Although proven to be effective against pre-menopausal 
breast cancer, especially those that are oestrogen receptor positive, there are still many 
issues that need to be overcome, including the diverse adverse toxicities, development of 
secondary cancers, resistance against Tamoxifen and subsequent recurrence in some 
patients. Furthermore, this drug is only effective against oestrogen or progesterone receptor 
positive breast cancers thus making it unsuitable for other types of breast cancer such as 
HER2 positive/ER/PR negative and triple negative breast cancers (den Hollander, Savage 
and Brown, 2013). Treatments available for HER2 positive cancers include monoclonal 
antibodies such as Herceptin that binds to HER2 thus negatively effecting receptor function. 
Unfortunately the more advanced stages of breast cancer do not always respond to Herceptin 
therapy and those that do, often progress in 12 months from the start of the treatment (Fink 
and Chipuk, 2013). In addition resistance may occur due to the involvement of a number of 
signalling pathway molecules such as activation of the PI3K/AKT pathway, loss of PTEN and 
activation of PIK3CA (reviewed in Brauer and Tyner, 2010).  The multiple issues with standard 
breast cancer therapies suggest a need for identifying novel therapeutic targets and 
continuous development of novel anticancer therapies.   
Brk is expressed in a wide range of cancer types including in hormone negative breast 
cancers which lack targetable molecular markers such as ER/PR/HER2, thus making it an 
ideal candidate for therapeutic intervention (Barker, Jackson and Crompton, 1997; Brauer 
and Tyner, 2010). At the start of my PhD, there were few studies thoroughly investigating 
Brk’s role in response to common breast cancer therapies as well as in response to novel 
Brk inhibitors.  Little was known regarding the role of the short isoform, ALT-PTK6 in breast 
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cancer and to date there have been no published studies exploring the role of this transcript 
in breast cancer cell lines or breast cancer tissues especially in relation to the full-length 
transcript and its potential prognostic value.       
Further consideration will also be needed for Brk and ALT-PTK6 localisation in the role of 
breast cancer pathogenesis as well in response to therapies as Brk has different functions in 
different tissue types and cellular compartments (discussed in Harvey and Burmi, 2011).  
Brk’s role will greatly depend on the availability of different substrates in the cytoplasm, 
plasma membrane and nucleus.  Studies have shown adding a myristoylation site to the N 
terminal of Brk, which it lacks, promotes Brk’s oncogenic role by promoting proliferation and 
migration of HEK293 cells via localisation to the membrane, whereas trapping Brk in the 
nucleus with a nuclear localisation sequence (NLS) reversed these effects (Ie Kim and Lee, 
2009).  Moreover, normally Brk is active in differentiating, non-dividing epithelial cells in the 
small intestine where it is a negative regulator of growth, however, due to an external stimulus 
such as DNA damage by irradiation, Brk has shown to promote apoptosis (Haegebarth et al., 
2009).  This shows Brk’s differing role within the same tissue but in different conditions.  In 
addition, ALT-PTK6 effects Brk’s cellular localisation as increased expression of ALT-PTK6 
resulted in decreased Brk at the membrane and an increase in nuclear Brk in transfected 
HEK293 cells (Brauer et al., 2011).  As Brk lacks an NLS and myristoylation site, it can be 
freely moving and difficult to track within the cell and the exact mechanism for Brk movement 
from one sub-cellular compartment to another is not fully understood.  It may be due to Brk’s 
interactions with its substrates which determine localisation.  However, the discovery that 
ALT-PTK6 may influence Brk’s localisation may offer an additional mechanism by which it 
changes location.    
Overall Brk has shown to be an ideal therapeutic target in breast cancer especially as it is 
involved in various hallmarks of cancer as discussed in (Hanahan and Weinberg, 2011)  
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(Figure 6.1). Furthermore, Harvey and Burmi show the number of Brk substrates and protein 
interactions (Harvey and Burmi, 2011). However, since then more substrates, regulators and 
protein interactions of Brk have been identified which indicates the involvement of Brk in 
several signalling pathways which are dysregulated in cancer.  Brk’s therapeutic potential 
could also extend to non-small cell lung cancer, prostate and colon cancer therapy (Fan et 
al., 2011; Zheng Y and Tyner AL, 2013; 2011; Gierut et al., 2011). It was recognised as one 
of the tyrosine kinases expressed in breast cancer due to the immense interest in tyrosine 









Figure 6.1 Breast tumour kinase and cancer hallmarks. Brk and cancer hallmarks. The original 
six cancer hallmarks described by Hannahan and Weinberg (2011) are illustrated along with a 
summary of Brk’s role in their regulation. Brk: Breast tumour kinase (Figure adapted from: Hussain 
and Harvey, 2014).  
 
Figure 7.2 Breast tumour kinase and cancer hallmarks. Brk and cancer hallmarks. The original 
six cancer hallmarks described by Hannahan and Weinberg (2001) are illustrated along with  a 
summary of Brk’s role in their regulation. Brk: Breast tumour kinase (Figure from: Hussain and 
Harvey, 2014).  
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summary of Brk’s role in their regulation. Brk: Breast tumour kinase (Figure from: Hussain and 
Harvey, 2014).  
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It should be noted many of Brk’s interactions require Brk’s kinase domain whereas others 
may require protein-protein interactions and some through indirect association via a third 
party (reviewed in Harvey and Burmi, 2011).   Therefore, Brk kinase-independent activity 
does need consideration when looking at tyrosine kinase inhibitors.  Interfering with Brk’s 
protein–protein interactions by disrupting its conformational activation may also be 
therapeutically effective, including disruptions in the SH2 and SH3 domains.  However, 
tyrosine kinase inhibitors have in the past proven to be well tolerated with manageable side 
effects, selective and relatively effective in a range of cancers (Zhang, Yang and Gray, 2009). 
In addition, PTK6-null mice have shown to grow relatively healthily into adulthood indicating 
potential tolerability to Brk inhibitors in breast cancer patients (Haegebarth et al., 2006).   
Many of Brk’s activities involve its kinase catalytic domain including anchorage independent 
growth, EGFR signalling, cell migration and cell death (reviewed in Harvey and Burmi, 2011; 
Irie et al., 2010).  These properties still make tyrosine kinase inhibition an attractive prospect 
despite Brk’s kinase independent functions. Furthermore, in comparison to HER2, EGFR, 
IGFR and p53, its expression is much higher in many types of breast cancer indicating 
targeting Brk may benefit a wider range of patients (Harvey and Crompton, 2004).  The 
continuous development of Brk inhibitors will offer further insight into its therapeutic potential 
especially in relation to its short isoform expression as well as within other cancers. 
6.1 Limitations  
There were some limitations for the work presented in this thesis.  Firstly, the cell line MCF10A 
although non-cancerous represented a non-tumorigenic immortalized epithelial cell and a 
normal breast cell line as a normal control was not used in my investigations.  However, it 
should be noted, there are a lack of normal breast cells due to the difficulty in obtaining tissue 
samples to generate a stable cell line, in addition, MCF10A do exhibit some of the features 
for the normal breast epithelium including anchorage independent growth and dependence 
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on growth factors for proliferation.  Further limitations included the ALT-PTK6 custom 
designed primers with the qPCR work performed by our clinical collaborators, which were 
also able to weakly detect the full length form (PTK6) due to specificity issues.  It may be that 
some levels of both PTK6 and ALT-PTK6 were detected in the cancer tissue samples and 
thus the results may not reflect the true expression of ALT-PTK6 transcript in the breast 
cancer cell lines.  It should be noted that a bigger sample size of normal and tumour breast 
tissues may offer more statistical power and validate the findings of the potential of ALT-
PTK6/PTK6 mRNA expression ratios in prognosis.  Another limitation included the lack of 
commercially available Brk inhibitors at the time of my investigations.  There are also few 
published studies investigating the role of compound 4f as well as its potency in inhibiting Brk 
in vitro.  There was limited information on the duration of effect of this compound as well as 
its stability over time.  Recently, other Brk inhibitors have been identified which may prove to 
be more potent than compound 4f, such as a novel Brk kinase inhibitor known as XMU-MP-
2 (Jiang et al., 2017).  This drug has shown to significantly inhibit proliferation in Brk 
transformed Ba/F3 and Brk overexpressing breast cancer cells (Jiang et al., 2017).  Other 
Brk inhibitors that have been identified through ELISA based in vitro kinase assay systems 
include pyrazolopyrimidines PP1 and PP2 (Shim, Kim and Lee, 2017).  These inhibitors have 
shown reduced Brk mediated proliferation of T47D breast cancer cells as well as reduction 
in STAT3 activity (Shim, Kim and Lee, 2017).  Further studies using these inhibitors will show 
the efficacy of these inhibitors as monotherapy in wide range of breast cancer cell lines as 
well as efficacy in combination with standard therapies.  Furthermore, some reports have 
suggested toxicity of MTT as the formazan crystals may puncture the cell membrane, 
however this may be dependent on the concentration of MTT reagent (Lü et al., 2012) and 
may be avoided by reducing the incubation time.  Additional limitations included the lack of 
commercially available plasmid tagged differently to Brk with green fluorescent protein tag 
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(GFP-tag) for transfection of the short isoform, ALT-PTK6 in ALT-PTK6 negative cell lines to 
determine localisation of Brk.  Localisation of Brk before and after treatment with radiotherapy 
may have shed further light on the role of Brk in radiotherapy.  There were other limitations 
which included the use of the Imagestream flow cytometry, due to the low resolution and 
accuracy of the images obtained in the Brightfield channel.  In comparison the confocal 
microscopy may have shown a greater resolution (x100 magnification) and accuracy although 
the Imagestream allowed for cells to be in suspension. Furthermore, the ‘gating’ of cells 
chosen for analysis can be subjective which may lead to a reduced sample size in addition 
to the many wash steps during the preparation of the sample.     
 
6.2 Future work 
 
It may be that a better understanding of Brk will require 3D culturing especially for 
investigating breast cancer transformation and migration/invasion as well as cell growth and 
proliferation.  3D culturing compared to 2D culturing has shown to better mimic in vivo 
conditions and maybe be more useful to further evaluate Brk’s role in normal and malignant 
breast cells.  Successful use of 3D culturing in addition to 2D culturing of breast cancer cells 
has even been used to evaluate breast cancer drug sensitivity and resistance as previously 
determined with HER2 targeted therapy neratinib and classical chemotherapy, Docetaxel (Qu 
et al., 2015; Breslin and O’Driscoll, 2016).  Future work would involve repeat of some of these 
investigations using a more stable and potent Brk inhibitor which may offer further evidence 
for the need for Brk inhibition in breast cancer.  It may be that a closer look at interrupting 
protein-protein interactions will prove to be a better method of Brk inhibition especially 
considering that Brk has kinase independent functions. This protein-protein disruption may 
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be mediated via the SH2 and SH3 domains of Brk. This is supported by studies investigating 
the SH3 binding site which showed that the SH3 domain is important for substrate recognition 
and many of Brk substrates interact via the SH3 domain including sam68 (Qiu and Miller, 
2004). It should be noted that ALT-PTK6 also contains an SH2 domain thus potential side 
effects of Brk inhibition on ALT-PTK6 will need to be considered.  Protein-protein disruptions 
have previously shown to be ideal therapeutic targets and show promise in clinical trials 
(Fischer, Rossmann and Hyvönen, 2015)(Petta et al., 2016).   
It should be noted, Brk is involved in the deregulation of cell cycle progression, as with 
increasing Brk levels, there was reduced p27 expression, a cell cycle checkpoint inhibitor 
(Chan and Nimnual, 2010).  Brk reduced cell proliferation within these cell lines suggesting 
the requirement of p27/Fox03a pathway to promote cell growth and a Brk-targeted therapy 
could be utilised to prevent cell cycle progression (Chan and Nimnual, 2010).  Seeing as 
majority of chemotherapeutic agents as well as radiotherapy are cell cycle specific, the impact 
of Brk inhibition on cell cycle progression in response to chemotherapy or radiotherapy may 
indicate whether Brk targeted therapy will be more useful before or after radiotherapy or 
chemotherapy especially considering the proliferative role of Brk in cancer cells. The effect 
on ALT-PTK6 in response to DNA damage will need further investigation in relation to Brk 
expression.  Exactly what happens to ALT-PTK6 expression in DNA damage needs further 
exploring especially if ALT-PTK6 reduces Brk proliferation and may confine Brk to the 
nucleus.  The mRNA expression ratios of ALT-PTK6 and PTK6 will need further verification 
in other cancer types as well as correlated with the breast molecular markers in patient tissue 
samples as well as with the treatment modality as these may affect the ratios and thus the 
predictive potential of the transcripts for overall patient survival.   Further in vivo studies 
evaluating Brk inhibition on normal breast cells as well as breast tumours as well as the effect 
of overexpressing ALT-PTK6 transgene in a mice model concurrently or in tumour xenografts 
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may further confirm the negative growth regulatory role of ALT-PTK6.  Further work may also 
involve investigations with other inhibitors (in combination with Brk inhibition) of signalling 
pathways that are deregulated in cancer such as mTOR inhibitors (e.g. Everolimus), 
P13K/Akt inhibitors (e.g. BKM120) as well as monoclonal antibodies (Herceptin) thus 
providing further overview and impact of Brk inhibition.  Validation of PTK6 transcript ratios 
and their potential as prognostic factors will need to be determined in other breast cancer 
patient cohorts as well as in larger tissue samples.  Further work may also involve validation 
of Brk role in response to radiotherapy through determining localisation before and after 
treatment using tagged plasmids for transfection, especially if ALT-PTK6 plays a role in 
translocation of the full length form.  This may include using genome editing technologies 
such as CRISPR-Cas9 if no suitable plasmids are available in the future in order assess the 
role of the short isoform.  CRISPR-Cas9 allows for the insertion of a small sequence that 
encodes a specific tag into genes which in turn allows for the production of a protein as 
desired by the research and which will include the tag allowing for easier monitoring of the 
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